Paragon 28 (FNA) 10-K/A 8 Aug 24 2023 FY Annual report (amended) Financial data

Document and Entity Information

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2023	Feb. 23, 2024	Jun. 30, 2023
Cover [Abstract]
Document Type	10-K/A
Document Annual Report	true
Document Period End Date	Dec. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	FY
Document Transition Report	false
Entity File Number	001-40902
Entity Registrant Name	Paragon 28, Inc.
Entity Central Index Key	0001531978
Amendment Flag	true
Current Fiscal Year End Date	--12-31
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	27-3170186
Entity Address, Address Line One	14445 Grasslands Drive
Entity Address, City or Town	Englewood
Entity Address, State or Province	CO
Entity Address, Postal Zip Code	80112
City Area Code	720
Local Phone Number	912-1332
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	FNA
Security Exchange Name	NYSE
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	true
Document Financial Statement Error Correction	true
Document Financial Statement Recovery Analysis	true
Entity Shell Company	false
Entity Public Float			$ 830.7
Entity Common Stock, Shares Outstanding		82,837,092
Documents Incorporated by Reference	DOCUMENTS INCORPORATED BY REFERENCE The Registrant intends to file a definitive proxy statement pursuant to Regulation 14A within 120 days of the end of the fiscal year ended December 31, 2023 . Portions of such definitive proxy statement are incorporated by reference into Part III of this Amended Annual Report on Form 10-K/A.
Auditor Firm ID	34
Auditor Name	Deloitte & Touche LLP
Auditor Location	Denver, Colorado
Amendment Description	GeneralAs previously announced in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on July 30, 2024, on July 30, 2024, the Audit Committee (the “Audit Committee”) of the Board of Directors and in consultation with management, concluded that its audited consolidated financial statements for the fiscal year ended December 31, 2023 and its unaudited condensed consolidated financial statements for the periods ended March 31, 2023, June 30, 2023, September 30, 2023, and March 31, 2024 could no longer be relied upon as a result of material accounting errors identified by management. Accordingly, the consolidated financial statements as of and for the fiscal year ended December 31, 2023 included in this Annual Report on Form 10-K/A have been restated to reflect the correction of identified errors in the calculation of excess and obsolete inventory, as well as its accounting for inventory variances, which impacted the valuation of inventory resulting in an overstatement of Inventories, net as of March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, and March 31, 2024 and a net understatement in Cost of goods sold for the respective interim periods ended on such dates and for the fiscal year ended December 31, 2023 (the “Restatement”). RestatementParagon 28, Inc. (collectively with its subsidiaries, “we,” “us,” “our," “P28” or the (“Company") is filing this Amendment No. 1 to our Annual Report on Form 10-K/A to amend our Annual Report on Form 10-K for the year ended December 31, 2023 (the “Amended 2023 Annual Report”), which was originally filed with the SEC on February 29, 2024 (the “Original 2023 Annual Report”). This Amended 2023 Annual Report speaks as of the date of the Original 2023 Annual Report and has not been updated to reflect events occurring subsequent to the filing of the Original 2023 Annual Report other than those associated with the Restatement of our consolidated financial statements.For the convenience of the reader, this Amended 2023 Annual Report amends and restates the Original 2023 Annual Report in its entirety. As a result, it includes both items that have been changed as a result of the Restatement and items that are unchanged from the Original 2023 Annual Report. Restatement BackgroundSubsequent to the issuance of both the Company’s consolidated financial statements as of and for the year ended December 31, 2023 and the Company’s unaudited interim condensed consolidated financial statements as of and for the fiscal quarter ended March 31, 2024, the Company identified errors in the calculation of its excess and obsolete inventory, as well as its accounting for inventory variances, which resulted in a net overstatement of Inventories, net as of March 31, 2023, June 30, 2023, September 30, 2023, December 31, 2023, and March 31, 2024 and a net understatement in Cost of goods sold for the respective interim periods ended on such dates and for the fiscal year ended December 31, 2023.In filing this Amended 2023 Annual Report, the Company is restating its previously issued audited consolidated financial statements and related notes as of and for the year ended December 31, 2023, as well as unaudited condensed consolidated financial statements included in the Company’s Quarterly Reports on Form 10-Q as of and for the quarterly and year-to-date periods ended March 31, 2023, June 30, 2023, and September 30, 2023, respectively, which have been restated to correct the errors in the calculation of its excess and obsolete inventory, as well as its accounting for inventory variances (the “Misstatements”), along with other immaterial accounting and disclosure errors that when aggregated with the Misstatements, are material in respect to the Original 2023 Annual Report (refer to Note 3. Restatement of Previously Issued Consolidated Financial Statements and Note 18. Quarterly Financial Data (Unaudited) to our financial statements included in Part II, Item 8 of this Amended 2023 Annual Report for additional information). This Amended 2023 Annual Report also contains our audited annual financial statements as of and for the year ended December 31, 2022 which have been revised to correct certain accounting errors that when aggregated are not material to those financial statements. In addition, we intend to file an amendment (such report, together with this Amendment No. 1, the “Amended Reports”) to the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2024, originally filed with the SEC on May 8, 2024 (“Original Form 10-Q” and together with the Original Form 10-K, the “Original Reports”), to account for the Misstatements during the periods presented therein and to restate our unaudited condensed consolidated financial statements for the quarterly period ended March 31, 2024. All material restatement information that relates to the Misstatements will be included in the Amended Reports, and we do not intend to separately amend other filings that the Company has previously filed with the SEC. As a result, such prior reports should no longer be relied upon. Control ConsiderationsIn connection with the restatement, management has reassessed its conclusions regarding the effectiveness of our internal control over financial reporting as of December 31, 2023 and has determined that material weaknesses in our internal control over financial reporting existed as of that date. As a result of the material weaknesses, our disclosure controls and procedures were not effective at a reasonable assurance level as of December 31, 2023. Management will be implementing changes to strengthen our internal controls and remediate the material weaknesses. See Item 9A, Controls and Procedures, for additional information related to the material weaknesses in internal control over financial reporting and our related remediation activities.  Items Amended in this FilingThis Amended 2023 Annual Report sets forth our Original 2023 Annual Report, as amended, in its entirety. Except as required to reflect the restated amounts, related disclosures, and updates to our assessment of internal control over financial reporting and disclosure controls and procedures, there were no changes to any other parts of the Original 2023 Annual Report, and this Amended 2023 Annual Report does not reflect events occurring after the date of the Original 2023 Annual Report.The following sections have been amended in this Amended 2023 Annual Report:•Special Note Regarding Forward-Looking Statements•Risk Factors Summary•Part I, Item 1A, Risk Factors•Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations•Part II, Item 8, Financial Statements and Supplementary Data•Part II, Item 9A, Controls and Procedures•Part IV, Item 15, Exhibit and Financial Statement SchedulesThe exhibit list included in Item 15, “Exhibit and Financial Statement Schedules” herein has been amended to contain currently dated certifications from the Company’s Chief Executive Officer (as Principal Executive Officer) and Chief Financial Officer (as Principal Financial Officer), as required by Sections 302 and 906 of the Sarbanes-Oxley Act of 2002 and filed as Exhibits 31.1/31.2 and 32.1/32.2, respectively, as well as an updated Consent of Independent Registered Public Accounting Firm filed as Exhibit 23.In accordance with applicable SEC rules, this Form 10-K/A also includes an updated signature page and Report of Independent Registered Public Accounting Firm.Except as relating to the identified errors and the Restatement described above, discussions within Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and other forward-looking statements made in our Original 2023 Annual Report have not been revised in this Amended 2023 Annual Report to reflect events that occurred at a later date or facts that subsequently became known to the Company and should be read in their historical context.Refer to Note 3. Restatement of Previously Issued Consolidated Financial Statements and Note 18. Quarterly Financial Data (Unaudited) in the Notes to Consolidated Financial Statements on this Form 10-K/A for additional information

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 75,639	$ 34,949	$ 56,747	$ 85,883	$ 38,468
Trade receivables, net of allowance for doubtful accounts	37,323	33,615	34,331	37,262	37,687	$ 35,960	$ 32,598	$ 27,653
Inventories, net	90,046	89,128	81,501	68,191	61,288	54,861	51,502	43,185
Income taxes receivable	794	1,022	870	596	615	705	660	622
Other current assets	3,997	4,826	3,257	4,167	4,658	1,947	3,129	3,448
Total current assets	207,799	163,540	176,706	196,099	142,716	149,798	160,891	168,555
Property and equipment, net	74,122	73,530	70,936	66,810	61,938	58,591	56,066	51,850
Intangible assets, net	21,674	21,802	21,921	22,137	22,387	20,850	20,352	21,350
Goodwill	25,465	25,465	25,465	25,465	25,465	26,975	26,975	26,672
Deferred income taxes	705	132	319	354	148	841	563	303
Other assets	2,918	3,634	3,057	2,597	3,132	1,303	414
Total assets	332,683	288,103	298,404	313,462	255,786	258,358	265,261	268,730
Current liabilities:
Accounts payable	21,696	27,395	29,681	20,538	14,939	13,979	14,564	11,877
Accrued expenses	27,781	24,966	24,390	25,446	26,807	19,507	21,407	17,827
Accrued legal settlement				13,000	22,000
Other current liabilities	883	1,893	1,700	3,772	3,844	6,889	6,926	7,433
Current maturities of long-term debt	640	640	652	690	728	735	757	781
Income taxes payable	243		20	208	184	497	305	492
Total current liabilities	51,243	54,894	56,443	63,654	68,502	41,607	43,959	38,410
Long-term liabilities:
Long-term debt net, less current maturities	109,799	42,288	42,259	42,204	42,182	42,492	42,519	42,471
Other long-term liabilities	1,048	1,467	1,842	1,523	1,628	907	905	3,123
Deferred income taxes	233	327	620	377	342	59	197	302
Income taxes payable	635	635	635	635	527	527	527	527
Total liabilities	162,958	99,611	101,799	108,393	113,181	85,592	88,107	84,833
Commitments and contingencies (Note 15)
Stockholders' equity:
Common stock, $0.01 par value, 300,000,000 shares authorized; 83,738,974 and 78,684,107 shares issued, and 82,825,455 and 77,770,588 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	827	824	824	821	776	769	764	763
Additional paid in capital	298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736
Accumulated deficit	(123,646)	(101,323)	(90,172)	(76,924)	(66,112)	(27,633)	(19,086)	(10,304)
Accumulated other comprehensive income (loss)	132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)
Treasury stock, at cost; 913,519 shares as of December 31, 2023 and December 31, 2022	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
Total stockholders' equity	169,725	188,492	196,605	205,069	142,605	172,766	177,154	183,897	$ 192,194	$ 30,393
Total liabilities & stockholders' equity	$ 332,683	$ 288,103	$ 298,404	$ 313,462	$ 255,786	$ 258,358	$ 265,261	$ 268,730

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Oct. 08, 2021
Allowance for doubtful accounts	$ 1,339	$ 934	$ 1,706	$ 1,816	$ 1,688	$ 1,990	$ 1,234	$ 1,310	$ 1,032
Common stock par value	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01
Common stock share authorized	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000		300,000,000
Common stock share issued	83,738,974	83,469,426	83,449,565	83,220,392	78,684,107	77,990,290	77,451,087	77,362,681
Common stock shares, outstanding	82,825,455	82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162
Treasury stock share issued	913,519	913,519	913,519	913,519	913,519	913,519	913,519	913,519

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE (LOSS) INCOME - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net revenue	$ 60,561	$ 52,783	$ 51,009	$ 52,036	$ 51,508	$ 46,006	$ 42,498	$ 41,371	$ 103,045	$ 83,869	$ 155,828	$ 129,875	$ 216,389	$ 181,383	$ 147,464
Cost of goods sold		11,922	11,599	10,229		8,203	7,836	6,791	21,828	14,627	33,750	22,830	51,954	32,117	28,024
Gross profit	42,357	40,861	39,410	41,807	42,221	37,803	34,662	34,580	81,217	69,242	122,078	107,045	164,435	149,266	119,440
Operating expenses:
Research and development costs		7,244	7,683	7,049		6,337	5,990	5,773	14,732	11,763	21,976	18,100	30,078	24,650	16,128
Selling, general, and administrative		44,126	43,827	43,820		39,667	37,948	37,242	87,647	75,190	131,773	114,857	180,022	159,323	114,087
Legal settlement														27,000
Total operating expenses		51,370	51,510	50,869		46,004	43,938	43,015	102,379	86,953	153,749	132,957	210,100	210,973	130,215
Operating loss	(13,994)	(10,509)	(12,100)	(9,062)	(35,795)	(8,201)	(9,276)	(8,435)	(21,162)	(17,711)	(31,671)	(25,912)	(45,665)	(61,707)	(10,775)
Other income (expense):
Other income (expense), net		369	(76)	(616)		948	1,671	(706)	(692)	965	(323)	1,913	(1,183)	123	(486)
Loss on early extinguishment of debt													(5,308)
Interest expense, net		(1,119)	(803)	(1,205)		(1,093)	(1,104)	(668)	(2,008)	(1,772)	(3,127)	(2,865)	(5,165)	(4,129)	(1,719)
Total other income (expense)		(750)	(879)	(1,821)		(145)	567	(1,374)	(2,700)	(807)	(3,450)	(952)	(11,656)	(4,006)	(2,205)
Loss before income taxes		(11,259)	(12,979)	(10,883)		(8,346)	(8,709)	(9,809)	(23,862)	(18,518)	(35,121)	(26,864)	(57,321)	(65,713)	(12,980)
Income tax expense (benefit)		(108)	269	(71)		201	73	32	198	105	90	306	213	(64)	713
Net loss	$ (22,323)	(11,151)	(13,248)	(10,812)	$ (38,479)	(8,547)	(8,782)	(9,841)	(24,060)	(18,623)	(35,211)	(27,170)	(57,534)	(65,649)	(13,693)
Foreign currency translation adjustment		(630)	(283)	(99)		(588)	(593)	(324)	(382)	(917)	(1,012)	(1,505)	165	(41)	(815)
Comprehensive loss		$ (11,781)	$ (13,531)	$ (10,911)		$ (9,135)	$ (9,375)	$ (10,165)	$ (24,442)	$ (19,540)	$ (36,223)	$ (28,675)	$ (57,369)	$ (65,690)	$ (14,508)
Weighted average number of shares of common stock outstanding:
Basic		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100	52,916,711
Diluted		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100	52,916,711
Net loss per share attributable to common stockholders:
Basic	$ (0.27)	$ (0.14)	$ (0.16)	$ (0.13)	$ (0.5)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.3)	$ (0.24)	$ (0.43)	$ (0.35)	$ (0.7)	$ (0.86)	$ (0.26)
Diluted	$ (0.27)	$ (0.14)	$ (0.16)	$ (0.13)	$ (0.5)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.3)	$ (0.24)	$ (0.43)	$ (0.35)	$ (0.7)	$ (0.86)	$ (0.26)

CONSOLIDATED STATEMENTS OF CONV

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SERIES EQUITY & STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Initial Public Offering	Common Stock	Common Stock Initial Public Offering	Preferred Stock Series A Convertible Preferred Stock	Preferred Stock Series B Convertible Preferred Stock	Additional Paid-in-Capital	Additional Paid-in-Capital Initial Public Offering	Accumulated Deficit	Accumulated Other Comprehensive Income (Loss)	Treasury stock
Temporary equity, beginning balance, shares at Dec. 31, 2020					13,812,500	6,608,700
Temporary equity, beginning balance at Dec. 31, 2020					$ 4,250	$ 36,842
Beginning balance, shares at Dec. 31, 2020			46,738,540
Beginning balance at Dec. 31, 2020	$ 30,393		$ 467				$ 22,107		$ 12,418	$ 823	$ (5,422)
Net loss	(13,693)								(13,693)
Issuance of common stock, shares			151,515	8,984,375
Issuance of common stock	1,001	$ 129,384	$ 1	$ 90			1,000	$ 129,294
Common stock repurchase, shares			(85,049)
Common stock repurchase	(561)		$ (1)								(560)
Temporary equity, Conversion of Series A and Series B preferred stock to common stock, Shares					(13,812,500)	(6,608,700)
Temporary equity, Conversion of Series A and Series B preferred stock to common stock, Value					$ (4,250)	$ (36,842)
Conversion of Series A and Series B preferred stock to common stock, Shares			20,421,200
Conversion of Series A and Series B preferred stock to common stock, Value	41,092		$ 204				40,076		812
Options exercised, shares			236,706
Options exercised	445		$ 2				443
Foreign currency translation	(815)									(815)
Stock-based compensation	4,948						4,948
Ending balance, shares at Dec. 31, 2021			76,447,287
Ending balance at Dec. 31, 2021	192,194		$ 763				197,868		(463)	8	(5,982)
Net loss	(9,841)								(9,841)
Options exercised, shares			1,875
Options exercised	12						12
Foreign currency translation	(324)									(324)
Stock-based compensation	2,122						2,122
Ending balance, shares at Mar. 31, 2022			76,449,162
Ending balance at Mar. 31, 2022	183,897		$ 763				199,736		(10,304)	(316)	(5,982)
Beginning balance, shares at Dec. 31, 2021			76,447,287
Beginning balance at Dec. 31, 2021	192,194		$ 763				197,868		(463)	8	(5,982)
Net loss	(18,623)
Ending balance, shares at Jun. 30, 2022			76,537,568
Ending balance at Jun. 30, 2022	177,154		$ 764				202,367		(19,086)	(909)	(5,982)
Beginning balance, shares at Dec. 31, 2021			76,447,287
Beginning balance at Dec. 31, 2021	192,194		$ 763				197,868		(463)	8	(5,982)
Net loss	(27,170)
Ending balance, shares at Sep. 30, 2022			77,076,771
Ending balance at Sep. 30, 2022	172,766		$ 769				207,109		(27,633)	(1,497)	(5,982)
Beginning balance, shares at Dec. 31, 2021			76,447,287
Beginning balance at Dec. 31, 2021	192,194		$ 763				197,868		(463)	8	(5,982)
Net loss	(65,649)								(65,649)
Issuance of common stock, shares			0
Offering costs associated with initial public offering	(266)						(266)
Options exercised, shares			1,284,333
Options exercised	5,271		$ 13				5,258
Foreign currency translation	(41)									(41)
Employee stock purchase plan	731						731
Employee stock purchase plan,Shares			38,968
Stock-based compensation	10,365						10,365
Ending balance, shares at Dec. 31, 2022			77,770,588
Ending balance at Dec. 31, 2022	142,605		$ 776				213,956		(66,112)	(33)	(5,982)
Beginning balance, shares at Mar. 31, 2022			76,449,162
Beginning balance at Mar. 31, 2022	183,897		$ 763				199,736		(10,304)	(316)	(5,982)
Net loss	(8,782)								(8,782)
Options exercised, shares			88,406
Options exercised	289		$ 1				288
Foreign currency translation	(593)									(593)
Stock-based compensation	2,343						2,343
Ending balance, shares at Jun. 30, 2022			76,537,568
Ending balance at Jun. 30, 2022	177,154		$ 764				202,367		(19,086)	(909)	(5,982)
Net loss	(8,547)								(8,547)
Options exercised, shares			539,203
Options exercised	2,060		$ 5				2,055
Foreign currency translation	(588)									(588)
Employee stock purchase plan	100						100
Stock-based compensation	2,587						2,587
Ending balance, shares at Sep. 30, 2022			77,076,771
Ending balance at Sep. 30, 2022	172,766		$ 769				207,109		(27,633)	(1,497)	(5,982)
Net loss	(38,479)
Ending balance, shares at Dec. 31, 2022			77,770,588
Ending balance at Dec. 31, 2022	142,605		$ 776				213,956		(66,112)	(33)	(5,982)
Net loss	(10,812)								(10,812)
Issuance of common stock, shares			4,312,500
Issuance of common stock	68,449		$ 43				68,406
Options exercised, shares			223,785
Options exercised	1,622		$ 2				1,620
Foreign currency translation	(99)									(99)
Employee stock purchase plan	122						122
Stock-based compensation	3,182						3,182
Ending balance, shares at Mar. 31, 2023			82,306,873
Ending balance at Mar. 31, 2023	205,069		$ 821				287,286		(76,924)	(132)	(5,982)
Beginning balance, shares at Dec. 31, 2022			77,770,588
Beginning balance at Dec. 31, 2022	142,605		$ 776				213,956		(66,112)	(33)	(5,982)
Net loss	(24,060)
Ending balance, shares at Jun. 30, 2023			82,536,046
Ending balance at Jun. 30, 2023	196,605		$ 824				292,350		(90,172)	(415)	(5,982)
Beginning balance, shares at Dec. 31, 2022			77,770,588
Beginning balance at Dec. 31, 2022	142,605		$ 776				213,956		(66,112)	(33)	(5,982)
Net loss	(35,211)
Ending balance, shares at Sep. 30, 2023			82,555,907
Ending balance at Sep. 30, 2023	188,492		$ 824				296,018		(101,323)	(1,045)	(5,982)
Beginning balance, shares at Dec. 31, 2022			77,770,588
Beginning balance at Dec. 31, 2022	142,605		$ 776				213,956		(66,112)	(33)	(5,982)
Net loss	(57,534)								(57,534)
Issuance of common stock, shares			4,312,500
Issuance of common stock	68,453		$ 43				68,410
Options exercised, shares			668,925
Options exercised	2,406		$ 7				2,399
Foreign currency translation	165									165
Employee stock purchase plan	1,266		$ 1				1,265
Employee stock purchase plan,Shares			73,442
Stock-based compensation	12,364						12,364
Ending balance, shares at Dec. 31, 2023			82,825,455
Ending balance at Dec. 31, 2023	169,725		$ 827				298,394		(123,646)	132	(5,982)
Beginning balance, shares at Mar. 31, 2023			82,306,873
Beginning balance at Mar. 31, 2023	205,069		$ 821				287,286		(76,924)	(132)	(5,982)
Net loss	(13,248)								(13,248)
Options exercised, shares			192,027
Options exercised	843		$ 3				840
Foreign currency translation	(283)									(283)
Employee stock purchase plan	620						620
Employee stock purchase plan,Shares			37,146
Stock-based compensation	3,600						3,600
Ending balance, shares at Jun. 30, 2023			82,536,046
Ending balance at Jun. 30, 2023	196,605		$ 824				292,350		(90,172)	(415)	(5,982)
Net loss	(11,151)								(11,151)
Options exercised, shares			19,861
Options exercised	70						70
Foreign currency translation	(630)									(630)
Employee stock purchase plan	86						86
Stock-based compensation	3,512						3,512
Ending balance, shares at Sep. 30, 2023			82,555,907
Ending balance at Sep. 30, 2023	188,492		$ 824				296,018		(101,323)	(1,045)	(5,982)
Net loss	(22,323)
Ending balance, shares at Dec. 31, 2023			82,825,455
Ending balance at Dec. 31, 2023	$ 169,725		$ 827				$ 298,394		$ (123,646)	$ 132	$ (5,982)

CONSOLIDATED STATEMENTS OF CO_2

CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SERIES EQUITY & STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jul. 31, 2020	Dec. 31, 2023	Dec. 31, 2021
Issuance costs		$ 827
IPO
Issuance costs			$ 4,304
Series B Convertible Preferred Stock
Issuance costs	$ 1,970

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss	$ (10,812)	$ (9,841)	$ (24,060)	$ (18,623)	$ (35,211)	$ (27,170)	$ (57,534)	$ (65,649)	$ (13,693)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	3,117	3,030	6,414	6,566	10,602	9,624	15,542	13,728	8,961
Allowance for doubtful accounts		600	147		147		614	155	1,022
Provision for excess and obsolete inventories	293	(643)	923	(446)	3,204	(91)	4,037	485	2,821
Loss on early extinguishment of debt							1,881
Stock-based compensation	3,182	2,122	6,782	4,465	10,294	7,052	12,364	10,365	4,948
Change in fair value of financial instruments	517	605	366	(414)	(57)	(1,303)	546	(57)	440
Other	100	387	394	(1,514)	(34)	(1,295)	984	704	1,014
Changes in other assets and liabilities, net of acquisitions:
Accounts receivable	(441)	(2,240)	(3,138)	(6,825)	(3,706)	(10,227)	(161)	(12,013)	(6,461)
Inventories	(7,112)	(2,329)	(20,959)	(11,320)	(31,117)	(15,406)	(32,628)	(21,852)	(11,098)
Accounts payable	5,592	(1,178)	14,745	1,537	12,468	951	6,742	1,895	3,431
Accrued expenses	(877)		1,845	1,992	3,718	176	6,428	2,317	7,095
Accrued legal settlement	(9,000)		(22,000)		(22,000)		(22,000)	22,000
Income tax receivable/payable	132	669	(359)	454	(533)	297	(50)	391	671
Other assets and liabilities	(367)		(779)	289	(2,704)	1,442	(655)	(1,650)	(2,468)
Net cash used in operating activities	(14,060)	(9,503)	(33,403)	(23,839)	(47,517)	(35,950)	(63,890)	(49,181)	(3,317)
Cash flows from investing activities
Purchase of office building						(18,300)		(18,300)
Purchases of property and equipment	(7,521)	(23,036)	(15,354)	(29,204)	(21,893)	(15,637)	(26,716)	(22,813)	(18,296)
Proceeds from sale of property and equipment	223	305	635	519	795	642	1,043	897	799
Purchases of intangible assets	(254)	(704)	(544)	(783)	(933)	(1,720)	(1,314)	(1,973)	(2,993)
Acquisition, net of cash received		(18,201)		(18,504)		(18,504)		(18,504)	(15,000)
Net cash used in investing activities	(7,552)	(41,636)	(15,263)	(47,972)	(22,031)	(53,519)	(26,987)	(60,693)	(35,490)
Cash flows from financing activities
Proceeds from draw on term loan		20,000		20,000		20,000		20,000
Proceeds from issuance of long-term debt		16,000		16,000		16,000	100,000	16,000	10,000
Payments on long-term debt	(197)	(37)	(396)	(178)	(568)	(367)	(30,727)	(570)	(6,034)
Payments of debt issuance costs	(7)	(405)		(405)		(420)	(4,423)	(732)	(3,139)
Proceeds from issuance of common stock, net of issuance costs	68,449		68,453		68,453		68,453		1,001
Proceeds from IPO, net of issuance costs									129,384
Payments on treasury stock repurchased									(561)
Proceeds from exercise of stock options	1,622	12	2,464	300	2,535	2,224	2,406	5,271	445
Proceeds from employee stock purchase plan			560		560		944	518
Payments on earnout liability	(500)		(4,250)		(5,500)	(500)	(8,000)	(1,000)
Net cash provided by financing activities	69,367	35,570	66,831	35,717	65,480	36,937	128,653	39,487	131,096
Effect of exchange rate changes on cash and cash equivalents	(340)	(136)	114	(256)	549	(495)	(605)	(497)	(438)
Net increase (decrease) in cash and cash equivalents	47,415	(15,705)	18,279	(36,350)	(3,519)	(53,027)	37,171	(70,884)	91,851
Cash and cash equivalents at beginning of period	38,468	109,352	38,468	109,352	38,468	109,352	38,468	109,352	17,501
Cash and cash equivalents at end of period	85,883	93,647	56,747	73,002	34,949	56,325	75,639	38,468	109,352
Supplemental disclosures of cash flow information:
Restricted cash (Note 8)			2,250		1,000		1,000
Cash paid for income taxes			456	386	610	788	908	1,103	678
Cash paid for interest	601	273	2,068	1,520	3,342	2,111	4,271	3,073	1,086
Purchase of property and equipment included in accounts payable	$ 4,026	$ 1,804	$ 5,617	$ 3,088	$ 4,842	$ 2,363	$ 3,402	$ 3,402	$ 881

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pay vs Performance Disclosure
Net Income (Loss)	$ (22,323)	$ (11,151)	$ (13,248)	$ (10,812)	$ (38,479)	$ (8,547)	$ (8,782)	$ (9,841)	$ (24,060)	$ (18,623)	$ (35,211)	$ (27,170)	$ (57,534)	$ (65,649)	$ (13,693)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2023
Trading Arrangements, by Individual
Material Terms of Trading Arrangement		During the three months ended December 31, 2023, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Business and Basis of Presentat

Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Business and Basis of Presentation	NOTE 1. BUSINESS AND BASIS OF PRESENTATION Business Paragon 28, Inc. (collectively with its subsidiaries, “we,” “us,” “our,” “P28” or the “Company”) develops, distributes, and sells medical devices in the foot and ankle segment of the orthopedic implant marketplace. Our approach to product development is procedurally focused, resulting in a full range of procedure-specific foot and ankle products designed specifically for foot and ankle anatomy. Our products and product families include plates and plating systems, screws, staples, and nails aimed to address all major foot and ankle procedures including fracture fixation, forefoot, ankle, flatfoot or progressive collapsing foot deformity (“PCDF”), charcot foot and orthobiologics. P28 is a United States (“U.S.”) based company incorporated in the State of Delaware, with headquarters in Englewood, Colorado. Our sales representatives and distributors are located globally with the majority concentrated in the U.S., Australia, South Africa, and the United Kingdom. Initial Public Offering In October 2021, the Company completed its initial public offering (“IPO”), in which it issued and sold 8,984,375 shares of its common stock at the public offering price of $ 16.00 per share, including 1,171,875 shares of its common stock upon the exercise of the underwriters’ option to purchase additional shares. The Company received net proceeds after deducting underwriting discounts and commissions o f $ 133,688 . The Company incurred $ 4,304 of offering expenses that were offset against proceeds for the year ended December 31, 2021. In connection with the IPO, all of the shares of the Company’s outstanding convertible preferred stock automatically converted into an aggregate of 20,421,200 shares of the common stock. Secondary Public Offering On January 30, 2023, the Company completed an underwritten public offering (“the Offering”) of 6,500,000 shares of its common stock at an offering price of $ 17.00 per share, which consisted of 3,750,000 shares of common stock issued and sold by the Company and 2,750,000 shares of common stock sold by certain selling securityholders. On February 17, 2023, the underwriters exercised in full their option to purchase an additional 562,500 shares and 412,500 shares of common stock from the Company and the selling securityholders, respectively.‌ The Company received aggregate net proceeds from the Offering of approximately $ 68,453 after deducting underwriting discounts and commissions and offering expenses payable by the Company. The selling securityholders received aggregate net proceeds from the Offering of approximately $ 50,700 after deducting underwriting discounts and commissions. The Company did not receive any of the proceeds from the sale of shares of Common Stock by the selling securityholders. Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the accounts of Paragon 28, Inc. and its subsidiaries, all of which are wholly-owned. All intercompany balances and transactions have been eliminated in consolidation. The accompanying Consolidated Financial Statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”).

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the Company’s Consolidated Financial Statements. Significant items subject to such estimates and assumptions include the determination of the credit loss reserves for trade receivables, inventory obsolescence, impairment of long-lived assets, recoverability of goodwill and intangible assets, contingent earn-out liability, interest rate swap valuation, income taxes and stock-based compensation. Foreign Currency Translation The Consolidated Financial Statements are presented in U.S. dollars. The Company’s non-U.S. subsidiaries have a functional currency (i.e., the currency in which operational activities are primarily conducted) that is other than the U.S. dollar, generally the currency of the country in which such subsidiaries are domiciled. Such subsidiaries’ assets and liabilities are translated into U.S. dollars at year-end exchange rates, while revenue and expenses are translated at average exchange rates during the year based on the daily closing exchange rates. Adjustments that result from translating amounts from a subsidiary’s functional currency to U.S. dollars are reported in Accumulated other comprehensive loss, net of tax, a separate component of stockholders' equity. Transactions made in a currency other than the functional currency are remeasured to the functional currency at the exchange rates on the dates of the transaction. Foreign exchange gains and losses are recorded within Other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss. Business Combinations We allocate the purchase consideration to the identifiable net assets acquired, including intangible assets and liabilities assumed, based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, is recorded as goodwill. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires significant judgment, including the selection of valuation methodologies including the income approach, the cost approach, and the market approach. Significant assumptions used in those methodologies include, but are not limited to, the expected values of the underlying metric, the systematic risk embedded in the underlying metric, the volatility of the underlying metric, the risk-free rate, and the counterparty risk. The use of different valuation methodologies and assumptions is highly subjective and inherently uncertain and, as a result, actual results may differ materially from estimates. Cash Cash and cash equivalents include cash, money market funds, and highly liquid investments with an original maturity of three months or less. As of December 31, 2023, $ 1,000 related to the achievement of an Additive Orthopaedics acquisition milestone was included as restricted cash within the Consolidated Balance Sheets and Consolidated Statement of Cash Flows. For additional information regarding the Additive Orthopaedics acquisition refer to Note 4 to our Consolidated Financial Statements. There were no contractual or other restrictions as to the use of cash for the years ended December 31, 2022 or 2021. Trade Receivables, Less Allowance for Doubtful Accounts Trade receivables due from customers are uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date and are stated at the amount billed to the customer. Trade receivables also include unbilled receivables due from customers that represent completed surgical cases that are pending customer-issued purchase orders. These unbilled receivables are covered by agreements with customers, the products have typically been used in a surgery, and collection is determined to be probable. The Company estimates an allowance for doubtful accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. The following table presents the activity in the allowance for doubtful accounts for the years ended December 31, 2023 and 2022. December 31, 2023 2022 Allowance for doubtful accounts, beginning of year $ 1,688 $ 1,032 Additions charged against revenue or to expense 223 1,853 Write-offs ( 572 ) ( 1,197 ) Allowance for doubtful accounts, end of year $ 1,339 $ 1,688 Inventories, Net Inventories are considered finished goods and are purchased from third party contract manufacturers. These inventories consist of implants, hardware, and consumables and are held in our warehouse, with third-party independent sales representatives or distributors, or consigned directly with hospitals. Inventories are stated at the lower of cost or net realizable value, with the US inventory cost determined on a first-in first out basis or and International inventory cost determined on weighed average cost basis. When sold, inventory is relieved at weighted average cost. We evaluate the carrying value of our inventories in relation to historical sales, current inventory levels, and consideration of the life cycle of the product. A significant decrease in demand or development of products could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory. The Company estimates a reserve for obsolete and slow-moving inventory based on current inventory levels and historical sales. E xpense for excess and obsolete inventory is included in Cost of goods sold. The inventory reserve was $ 20,921 and $ 16,804 as of December 31, 2023 and 2022, respectively. The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs related to the patient’s anatomical size. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle. Property and Equipment, Net Property and equipment are recorded at cost less accumulated depreciation. Expenditures for renewals and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized and included in Property and equipment, net in the Consolidated Balance Sheets. Expenditures for maintenance and repairs are charged to expense as incurred and are included in Selling, general, and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. When equipment is retired or sold, the cost and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is included in included in Selling, general and administrative in the Consolidated Statements of Operations and Comprehensive Loss. Depreciation is provided using the straight-line method based on useful lives of the assets which range from three to twenty-five years , which best reflects the pattern of use. The Company depreciates surgical instrumentation, once available for use, over a five-year period and in certain cases, once available for use, over a three-year period. Depreciation for surgical instrumentation used in surgery is included in Selling, general, and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. Leasehold improvements are amortized using the straight-line method over the shorter of the asset’s useful life or the lease term. Property and equipment are assessed for impairment upon triggering events that indicate that the carrying value of an asset group may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows of the asset group expected to be generated from its use and eventual disposition. If the asset group’s carrying value is determined to not be recoverable, the impairment to be recognized is measured by which the carrying amount exceeds the fair value of the asset group. No impairment charges related to property and equipment were recorded in any of the periods presented. Intangibles The costs associated with applying for patents and trademarks are capitalized. Patents are amortized on a straight-line basis over the lesser of the patent’s economic or legal life, which is seventeen years . Costs associated with capitalized patents include third-party attorney fees and other third-party fees as well as costs related to the following: the preparation of patent applications, government filings and registration fees, drawings, computer searches, and translations related to specific patents. Trademarks that are anticipated to be renewed every ten years have an indefinite life and are not amortized but tested for impairment annually. Once it is determined a trademark will no longer be renewed, the trademark is amortized over the remainder of the trademark’s registration period. Customer relationships are amortized over an estimated useful life of three to seven years on a straight-line basis. Other intangibles, which mainly consist of noncompete arrangements, are amortized over an estimated useful life of three years on a straight-line basis. Developed technology is amortized over an estimated useful life of twelve years on a straight-line basis. Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If the asset’s carrying value is determined to not be recoverable, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. No impairment charges related to amortizable assets were recorded for the years ended December 31, 2023, 2022 and 2021. Indefinite-lived trademark assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company can elect to first apply the optional qualitative impairment assessment to determine whether the indefinite-lived intangible asset is more-likely-than-not impaired. If, on the basis of the qualitative impairment assessment, an entity asserts that it is more likely than not that the indefinite-lived intangible asset is impaired, the Company would be required to calculate the fair value of the asset for an impairment test. Impairment loss is recognized if the carrying amount of the asset exceeds its fair value. A qualitative assessment considers macroeconomic and other industry-specific factors, such as trends in short-term and long-term interest rates and the ability to access capital, and company specific factors such as trends in revenue generating activities, and merger or acquisition activity. If the Company elects to bypass qualitatively assessing its indefinite-lived intangible assets, or it is not more likely than not that the fair value of the intangible asset exceeds its carrying value, management estimates the fair value of the intangible asset and compares it to the carrying value. The estimated fair value of the intangible asset is established using an income approach based on a discounted cash flow model that includes significant assumptions about the future operating results and cash flows of the intangible asset or assets. The Company elected to perform a qualitative analysis for its indefinite-lived intangible assets as of October 1, 2023, the annual test date. The Company determined, after performing the qualitative analysis that there was no evidence that it is more likely than not that the fair value of its intangible assets was less than the carrying amount. Therefore, it was not necessary to perform a quantitative impairment test. Goodwill Goodwill represents the excess of the purchase price as compared to the fair value of net assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment annually or when indications of impairment exist. Goodwill is tested at the reporting unit level as defined in ASC 350. Per this definition, a reporting unit is an operating segment or one level below an operating segment. The Company has determined one reporting unit for the purpose of goodwill impairment. We can elect to qualitatively assess goodwill for impairment if it is more likely than not that the fair value of a reporting unit exceeds its carrying value. Impairment exists when the carrying amount, including goodwill, of the reporting unit exceeds its fair value, resulting in an impairment charge for this excess (not t o exceed the carrying amount of the goodwill). The impairment, if determined, is recorded within Operating expenses in the Consolidated Statements of Operations and Comprehensive Loss in the period the determination is made. Fair Value of Financial Instruments Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There is a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, such as quoted market prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3 - Unobservable inputs which are supported by little or no market activity. Financial instruments (principally cash and cash equivalents , trade receivables, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. The majority of our debt is carried at cost, which approximates fair value due to the variable interest rate associated with our debt. However, we are the fixed rate payor on an interest rate swap contract associated with the Company’s Zions Facility, which is classified as Level 2. We reassess the fair value of our interest rate swap on a quarterly basis. The change in fair value is recorded in Other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss. The Company does not have any assets or liabilities presented in the Level 1 category as of December 31, 2023, and 2022, and there were no changes in level hierarchies during the years ended December 31, 2023, 2022 and 2021. See “ Contingent Earn-out Consideration” below for a discussion on our Level 3 inputs. Contingent Earn-out Consideration Business combinations may include contingent earn-out consideration as part of the purchase price under which the Company will make future payments to the seller upon the achievement of certain milestones. The fair value of the contingent earn-out consideration is estimated as of the acquisition date at the present value of the expected contingent payments and is subsequently remeasured at each balance sheet date. Two methodologies may be considered in the valuation: the scenario-based model (“SBM”) and Monte Carlo simulation. The SBM relies on multiple outcomes to estimate the likelihood of future payoff of the contingent consideration. The resulting earnout payoff is then probability-weighted and discounted at an appropriate risk adjusted rate in order to arrive at the present value of the expected earnout payment. The Monte Carlo simulation is used to value the non-linear contingent considerations based on projected financial metrics. Each trial of the Monte Carlo simulation draws a value from the assumed distribution for the underlying metric. The earnout payoff for each simulation trial is calculated based on that particular simulated path for the underlying metrics and then discounted to present value using the risk-free rate, adjusted for counterparty credit risk. The value of the earnout is estimated as the average value from all simulation trials. The fair value estimates use unobservable inputs that reflect our own assumptions as to the ability of the acquired business to meet the targeted benchmarks and discount rates used in the calculations. The unobservable inputs are defined in ASC Topic 820, Fair Value Measurements and Disclosures, as Level 3 inputs. We review the probabilities of achievement of the earnout milestones to determine impact on the fair value of the earnout consideration on a quarterly basis over the earn-out period. Actual results are compared to the estimates and probabilities of achievement used in our forecasts. Should actual results of the acquired business increase or decrease as compared to our estimates and assumptions, the estimated fair value of the contingent earn-out consideration liability will increase or decrease, up to the contractual limit, as applicable. Changes in the estimated fair value of the contingent earn-out consideration are recorded in Other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss and are reflected in the period in which they are identified. Changes in the estimated fair value of the contingent earn-out consideration may materially impact or cause volatility in our operating results. Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and establishes a valuation allowance if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The determination as to whether a deferred tax asset will be realized is made on a jurisdictional basis and is based on both positive and negative evidence. This evidence includes historic taxable income, projected future taxable income, the expected timing of the reversal of existing temporary differences and the implementation of tax planning strategies. The Company records uncertain tax positions in accordance with Accounting Standards Codification (“ASC”) Topic 740 on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company evaluates its tax positions that have been taken or are expected to be taken on income tax returns to determine if an accrual is necessary for uncertain tax positions. The Company will recognize interest and penalties as a component of income tax expense if incurred. Revenue Recognition We account for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is generated primarily from the sale of our implants and disposables and, to a much lesser extent, from the sale of our surgical instrumentation. We sell our products through employee sales personnel and independent sales representatives in the U.S. Outside the U.S., sales are through independent sales representatives and to stocking distributors. We have consignment agreements with certain distributors and hospitals. Our customers are primarily hospitals and surgery centers. Revenue is recorded, net of estimated discounts and other price concessions, when our performance obligation is satisfied which is when our customers take title of the product, and typically when the product is used in surgery. We generally have written contracts with our customers which incorporate pricing and our standard terms and conditions. Any discounts we offer are outlined in our customer agreements. As the discounts are known at the time of purchase, no estimates are required at the time of revenue recognition. Shipping and handling costs are recorded as cost of goods sold and amounts billed to customers for shipping and handling costs are recorded in revenue. We record as revenue any amounts billed to customers for shipping and handling costs and record as cost of goods sold the actual shipping costs incurred. We have elected to exclude from the measurement of the transaction price all taxes (e.g., sales, use, value-added) assessed by government authorities and collected from a customer. Therefore, revenue is recognized net of such taxes. We have elected to use the practical expedient allowed under ASC 606 to account for shipping and handling activities that occur after the customer has obtained control of a promised good as fulfillment costs rather than as an additional promised service and, therefore, we do not allocate a portion of the transaction price to a shipping service obligation. Commissions to sales agents for the sales exceeding their quotas are classified as incremental costs of obtaining a contract as such costs would not have been incurred if the contract was not signed. We have elected to use the practical expedient to expense such costs that should be capitalized as the amortization period of the costs would be less than one year . Due to the nature of our products, returns are minimal and an estimate for returns is not material. The timing of revenue recognition may differ from the timing of invoicing to our customers . We recorded unbilled revenue of $ 5,598 and $ 4,511 as of December 31, 2023, and December 31, 2022 , respectively. Determining unbilled revenue involves management judgment. Cost of Goods Sold Cost of goods sold consists primarily of products purchased from third-party suppliers, freight, shipping, excess and obsolete inventory charges and royalties. Implants are manufactured to our specifications by third-party suppliers. Most implants are produced in the U.S. Cost of goods sold is recognized for consigned implants at the time the implant is used in surgery and the related revenue is recognized. Prior to their use in surgery, the cost of consigned implants is recorded as Inventories, net in our Consolidated Balance Sheets. Stock-Based Compensation All stock-based awards to employees and nonemployee contractors, including any grants of stock, stock options, restricted stock units (“RSU”), performance stock units (“PSU”) and the option to purchase common stock under the Employee Stock Purchase Plan (“ESPP”), are measured at fair value at the grant date and recognized over the relevant vesting period in accordance with the ASC Topic 718, Compensation - Stock Compensation (“ASC 718”). Stock-based awards to nonemployees are recognized as a selling, general and administrative expense over the period of performance. Such awards are measured at fair value at the date of grant. In addition, for awards that vest immediately, the awards are measured at fair value and recognized in full at the grant date. The Company estimates the fair value of each stock-option award containing service and/or performance conditions on the grant date using the Black-Scholes option valuation model which incorporates assumptions as to stock price volatility, the expected life of the options, risk-free interest rate and dividend yield. The Company relies on its historical volatility as an input to the option pricing model as management believes that this rate will be representative of future volatility over the expected term of the options. The expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. The Company estimates forfeitures of share-based awards at the time of grant and revises such estimates in subsequent periods if actual forfeitures differ from original estimates. Option awards are generally granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Subsequent to the IPO, the fair value of the Company’s common stock underlying its equity awards is based on the quoted market price of the Company’s common stock on the grant date. Prior to the IPO, because there was no public market for the Company’s common stock, the fair value of the common stock underlying the stock awards has historically been determined at the time of grant of the stock option by considering a number of objective and subjective factors, including sales of shares of common stock, third-party valuations performed, important developments in the Company’s operations, actual operating results and financial performance, the conditions in the medical device industry and the economy in general, and the stock price performance, volatility of comparable public companies, and an assumption for a discount for lack of marketability, among other factors. Research and Development Research and development expense is comprised of in-house research and development of new products and technologies, clinical studies and trials, regulatory expenses, and employee related compensation and expenses. We maintain a procedurally focused approach to product development and have projects underway to add new products to our existing systems and to add new systems across multiple foot and ankle indications. Leases At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease. The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets within Other assets. Contingencies A liability is contingent if the amount is not presently known but may become known in the future as a result of the occurrence of some uncertain future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. We expense legal costs, including those legal costs incurred in connection with a loss contingency, as incurred. Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which is part of the FASB’s overall simplification initiative to reduce the costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. ASU 2019-12 simplifies accounting guidance for intra-period a llocations, deferred tax liabilities, year-to-date losses in interim periods, franchise taxes, step-up in tax basis of goodwill, separate entity financial statements, and interim recognition of tax laws or rate changes. The Company adopted ASU 2019-12 effective January 1, 2023 . The adoption of this guidance did not have a significant impact on the Company ’s Consolidated Financial Statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. The Company adopted ASU 2016-13 effective January 1, 2023 . The adoption of this guidance did not have a significant impact on the Company ’s Consolidated Financial Statements and related disclosures. Recently Issued Accounting Pronouncements In October 2023, the FASB issued Accounting Standards Update ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”). The amendments in ASU 2023-06 modify the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. ASU 2023-06 is applicable to all entities subject to the SEC’s existing disclosure requirements. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the amendments in ASU 2023-06 and does not expect the adoption to have a significant impact on the Company’s related disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides amendments to improve reportable segment disclosures requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the amendments in ASU 2023-07 to determine the impact it will have on the Company's Consolidated Financial Statements and related notes for the year ended December 31, 2024, upon adoption. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740):

Restatement Of Previously Issue

Restatement Of Previously Issued Consolidated Financial Statements	12 Months Ended
	Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Restatement Of Previously Issued Consolidated Financial Statements	NOTE 3. RESTATEMENT OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS Subsequent to the issuance of the Company’s consolidated financial statements as of and for the year ended December 31, 2023 and the Company’s unaudited condensed consolidated financial statements as of and for the fiscal quarter ended March 31, 2024, the Company identified errors in the calculation of its excess and obsolete inventory reserves, as well as its accounting for inventory variances, which resulted in a net overstatement of Inventories, net as of December 31, 2023 and a net understatement in Cost of goods sold for the fiscal year ended December 31, 2023. The consolidated financial statements (as restated) reflect the correction of this error and include adjustments to correct certain other previously identified misstatements relating to prior periods, including the fiscal year ended December 31, 2022, that the Company had determined to be immaterial both individually and in aggregate. A description of the errors and their impacts on the previously issued financial statements are included below. Description of Misstatement Adjustments (a) Inventory Treatment The Company recorded adjustments to correct the calculation of its excess and obsolete inventory reserve and valuation of purchase price variances. The corrections resulted in a decrease in Inventories, net of $ 8,016 , an increase in the Cost of goods sold of $ 8,356 , and a decrease in the beginning balance of Accumulated deficit of $ 340 , respectively, as of and for the fiscal year ended December 31, 2023. (b) Interest Rate Swap The Company recorded adjustments to correct certain misstatements related to its interest rate swap previously corrected out of period in Q3 2023. The adjustments recognize the correction to prior periods. The following tables reflect the impact of the Restatement of the Company’s previously reported consolidated financial statements: PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET Year ended December 31, 2023 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash and cash equivalents $ 75,639 $ — $ 75,639 Trade receivables, net of allowance for doubtful accounts of $ 1,339 37,323 — 37,323 Inventories, net 98,062 ( 8,016 ) (a) 90,046 Income taxes receivable 794 — 794 Other current assets 3,997 — 3,997 Total current assets 215,815 ( 8,016 ) 207,799 Property and equipment, net 74,122 — 74,122 Intangible assets, net 21,674 — 21,674 Goodwill 25,465 — 25,465 Deferred income taxes 705 — 705 Other assets 2,918 — 2,918 Total assets $ 340,699 $ ( 8,016 ) $ 332,683 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 21,696 $ — $ 21,696 Accrued expenses 27,781 — 27,781 Other current liabilities 883 — 883 Current maturities of long-term debt 640 — 640 Income taxes payable 243 — 243 Total current liabilities 51,243 — 51,243 Long-term liabilities: Long-term debt net, less current maturities 109,799 — 109,799 Other long-term liabilities 1,048 — 1,048 Deferred income taxes 233 — 233 Income taxes payable 635 — 635 Total liabilities 162,958 — 162,958 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 83,738,974 shares issued, and 82,825,455 shares outstanding as of December 31, 2023 827 — 827 Additional paid in capital 298,394 — 298,394 Accumulated deficit ( 115,630 ) ( 8,016 ) (a) ( 123,646 ) Accumulated other comprehensive income 132 — 132 Treasury stock, at cost; 913,519 shares as of December 31, 2023 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 177,741 ( 8,016 ) 169,725 Total liabilities & stockholders’ equity $ 340,699 $ ( 8,016 ) $ 332,683 The description of the error is in the Description of Misstatement Adjustments provided herein this Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 8,016 , including a decrease to the beginning balance of Accumulated deficit of $ 340 as of December 31, 2023. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS Year Ended December 31, 2023 As Previously Reported Adjustments Ref As Restated Net revenue $ 216,389 $ — $ 216,389 Cost of goods sold 43,598 8,356 (a) 51,954 Gross profit 172,791 ( 8,356 ) 164,435 Operating expenses: Research and development costs 30,078 — 30,078 Selling, general, and administrative 180,022 — 180,022 Total operating expenses 210,100 — 210,100 Operating loss ( 37,309 ) ( 8,356 ) ( 45,665 ) Other income (expense): Other income (expense), net 154 ( 1,337 ) (b) ( 1,183 ) Loss on early extinguishment of debt ( 5,308 ) — ( 5,308 ) Interest expense, net ( 5,165 ) — ( 5,165 ) Total other expense ( 10,319 ) ( 1,337 ) ( 11,656 ) Loss before income taxes ( 47,628 ) ( 9,693 ) ( 57,321 ) Income tax expense 213 — 213 Net loss $ ( 47,841 ) $ ( 9,693 ) $ ( 57,534 ) Foreign currency translation adjustment 165 — 165 Comprehensive loss $ ( 47,676 ) $ ( 9,693 ) $ ( 57,369 ) Weighted average number of shares of common stock outstanding: Basic 82,087,329 — 82,087,329 Diluted 82,087,329 — 82,087,329 Net loss per share attributable to common stockholders: Basic $ ( 0.58 ) $ ( 0.12 ) $ ( 0.70 ) Diluted $ ( 0.58 ) $ ( 0.12 ) $ ( 0.70 ) The description of each error is in the Description of Misstatement Adjustments provided herein this Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $ 8,356 for the period ended December 31, 2023. (b) Interest Rate Swap - The correction of the misstatement resulted in a decrease to Other income (expense), net of $ 1,337 for the period ended December 31, 2023, and an equal impact to the beginning balance of Accumulated deficit. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SERIES EQUITY & STOCKHOLDERS’ EQUITY Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Income (Loss) Stock Equity Balance, December 31, 2022 77,770,588 $ 776 $ 213,956 $ ( 67,789 ) $ ( 33 ) $ ( 5,982 ) $ 140,928 Net loss — — — ( 47,841 ) — — ( 47,841 ) Issuance of common stock net of issuance costs of $ 827 4,312,500 43 68,410 — — — 68,453 Options exercised 668,925 7 2,399 — — — 2,406 Foreign currency translation — — — — 165 — 165 Employee stock purchase plan 73,442 1 1,265 — — — 1,266 Stock-based compensation — — 12,364 — — — 12,364 Balance, December 31, 2023 82,825,455 827 298,394 ( 115,630 ) 132 ( 5,982 ) 177,741 Adjustments Balance, December 31, 2022 — — — 1,677 — — 1,677 Net loss (a)(b) — — — ( 9,693 ) — — ( 9,693 ) Issuance of common stock net of issuance costs of $ 827 — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, December 31, 2023 — — — ( 8,016 ) — — ( 8,016 ) As Restated Balance, December 31, 2022 77,770,588 776 213,956 ( 66,112 ) ( 33 ) ( 5,982 ) 142,605 Net loss — — — ( 57,534 ) — — ( 57,534 ) Issuance of common stock net of issuance costs of $ 827 4,312,500 43 68,410 — — — 68,453 Options exercised 668,925 7 2,399 — — — 2,406 Foreign currency translation — — — — 165 — 165 Employee stock purchase plan 73,442 1 1,265 — — — 1,266 Stock-based compensation — — 12,364 — — — 12,364 Balance, December 31, 2023 82,825,455 $ 827 $ 298,394 $ ( 123,646 ) $ 132 $ ( 5,982 ) $ 169,725 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS Year Ended December 31, 2023 As Previously Reported Adjustments Ref As Restated Cash flows from operating activities Net loss $ ( 47,841 ) $ ( 9,693 ) (a)(b) $ ( 57,534 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 15,542 — 15,542 Allowance for doubtful accounts 614 — 614 Provision for excess and obsolete inventories ( 352 ) 4,389 (a) 4,037 Loss on early extinguishment of debt 1,881 — 1,881 Stock-based compensation 12,364 — 12,364 Change in fair value of financial instruments ( 791 ) 1,337 (b) 546 Other 984 — 984 Changes in other assets and liabilities, net of acquisitions: Accounts receivable ( 161 ) — ( 161 ) Inventories ( 36,595 ) 3,967 (a) ( 32,628 ) Accounts payable 6,742 — 6,742 Accrued expenses 6,428 — 6,428 Accrued legal settlement ( 22,000 ) — ( 22,000 ) Income tax receivable ( 50 ) — ( 50 ) Other assets and liabilities ( 655 ) — ( 655 ) Net cash used in operating activities ( 63,890 ) — ( 63,890 ) Cash flows from investing activities Purchases of property and equipment ( 26,716 ) — ( 26,716 ) Proceeds from sale of property and equipment 1,043 — 1,043 Purchases of intangible assets ( 1,314 ) — ( 1,314 ) Net cash used in investing activities ( 26,987 ) — ( 26,987 ) Cash flows from financing activities Proceeds from issuance of long-term debt 100,000 — 100,000 Payments on long-term debt ( 30,727 ) — ( 30,727 ) Payments of debt issuance costs ( 4,423 ) — ( 4,423 ) Proceeds from issuance of common stock, net of issuance costs 68,453 — 68,453 Proceeds from exercise of stock options 2,406 — 2,406 Proceeds from employee stock purchase plan 944 — 944 Payments on earnout liability ( 8,000 ) — ( 8,000 ) Net cash provided by financing activities 128,653 — 128,653 Effect of exchange rate changes on cash and cash equivalents ( 605 ) — ( 605 ) Net increase in cash and cash equivalents 37,171 — 37,171 Cash and cash equivalents at beginning of period 38,468 — 38,468 Cash and cash equivalents at end of period $ 75,639 $ — $ 75,639 Supplemental disclosures of cash flow information: Restricted cash $ 1,000 $ — $ 1,000 Cash paid for income taxes 908 — 908 Cash paid for interest 4,271 — 4,271 Purchase of property and equipment included in accounts payable 3,402 — 3,402 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Year ended December 31, 2022 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash $ 38,468 $ — $ 38,468 Trade receivables, net of allowance for doubtful accounts of $ 1,688 37,687 — 37,687 Inventories, net 60,948 340 (a) 61,288 Income taxes receivable 615 — 615 Other current assets 4,658 — 4,658 Total current assets 142,376 340 142,716 Property and equipment, net 61,938 — 61,938 Intangible assets, net 22,387 — 22,387 Goodwill 25,465 — 25,465 Deferred income taxes 148 — 148 Other assets 1,795 1,337 (b) 3,132 Total assets $ 254,109 $ 1,677 $ 255,786 LIABILITIES & STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 14,939 $ — $ 14,939 Accrued expenses 26,807 — 26,807 Accrued legal settlement 22,000 — 22,000 Other current liabilities 3,844 — 3,844 Current maturities of long-term debt 728 — 728 Income taxes payable 184 — 184 Total current liabilities 68,502 — 68,502 Long-term liabilities: Long-term debt net, less current maturities 42,182 — 42,182 Other long-term liabilities 1,628 — 1,628 Deferred income taxes 342 — 342 Income taxes payable 527 — 527 Total liabilities 113,181 — 113,181 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 78,684,107 shares issued, and 77,770,588 shares outstanding as of December 31, 2022 776 — 776 Additional paid in capital 213,956 — 213,956 Accumulated deficit ( 67,789 ) 1,677 (a)(b) ( 66,112 ) Accumulated other comprehensive loss ( 33 ) — ( 33 ) Treasury stock, at cost; 913,519 shares as of December 31, 2022 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 140,928 1,677 142,605 Total liabilities & stockholders’ equity $ 254,109 $ 1,677 $ 255,786 PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Year Ended December 31, 2022 As Previously Reported Adjustments Ref As Restated Net revenue $ 181,383 $ — $ 181,383 Cost of goods sold 32,457 ( 340 ) (a) 32,117 Gross profit 148,926 340 149,266 Operating expenses: Research and development costs 24,650 — 24,650 Selling, general, and administrative 159,323 — 159,323 Legal settlement 27,000 — 27,000 Total operating expenses 210,973 — 210,973 Operating loss ( 62,047 ) 340 ( 61,707 ) Other income (expense): Other income (expense), net ( 1,214 ) 1,337 (b) 123 Interest expense, net ( 4,129 ) — ( 4,129 ) Total other expense ( 5,343 ) 1,337 ( 4,006 ) Loss before income taxes ( 67,390 ) 1,677 ( 65,713 ) Income tax benefit ( 64 ) — ( 64 ) Net loss $ ( 67,326 ) $ 1,677 $ ( 65,649 ) Foreign currency translation adjustment ( 41 ) — ( 41 ) Comprehensive loss $ ( 67,367 ) $ 1,677 $ ( 65,690 ) Weighted average number of shares of common stock outstanding: Basic 76,766,100 — 76,766,100 Diluted 76,766,100 — 76,766,100 Net loss per share attributable to common stockholders: Basic $ ( 0.88 ) $ 0.02 $ ( 0.86 ) Diluted $ ( 0.88 ) $ 0.02 $ ( 0.86 ) The description of each error is in the Description of Misstatement Adjustments provided herein this Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Cost of Sales of $ 340 for the period ended December 31, 2022. (b) Interest Rate Swap - The correction of the out of period misstatement resulted in an increase to Other income (expense), net of $ 1,337 , and impacted opening accumulated deficit, for the period ended December 31, 2022. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SERIES EQUITY & STOCKHOLDERS’ EQUITY Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Income (Loss) Stock Equity Balance, December 31, 2021 76,447,287 $ 763 $ 197,868 $ ( 463 ) $ 8 $ ( 5,982 ) $ 192,194 Net loss — — — ( 67,326 ) — — ( 67,326 ) Offering costs associated with initial public offering — — ( 266 ) — — — ( 266 ) Options exercised 1,284,333 13 5,258 — — — 5,271 Foreign currency translation — — — — ( 41 ) — ( 41 ) Employee stock purchase plan 38,968 — 731 — — — 731 Stock-based compensation — — 10,365 — — — 10,365 Balance, December 31, 2022 77,770,588 776 213,956 ( 67,789 ) ( 33 ) ( 5,982 ) 140,928 Adjustments Balance, December 31, 2021 — — — — — — — Net loss (a)(b) — — — 1,677 — — 1,677 Offering costs associated with initial public offering — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, December 31, 2022 — — — 1,677 — — 1,677 As Restated Balance, December 31, 2021 76,447,287 763 197,868 ( 463 ) 8 ( 5,982 ) 192,194 Net loss — — — ( 65,649 ) — — ( 65,649 ) Offering costs associated with initial public offering — — ( 266 ) — — — ( 266 ) Options exercised 1,284,333 13 5,258 — — — 5,271 Foreign currency translation — — — — ( 41 ) — ( 41 ) Employee stock purchase plan 38,968 — 731 — — — 731 Stock-based compensation — — 10,365 — — — 10,365 Balance, December 31, 2022 77,770,588 $ 776 $ 213,956 $ ( 66,112 ) $ ( 33 ) $ ( 5,982 ) $ 142,605 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS Year Ended December 31, 2022 As Previously Reported Adjustments Ref As Restated Cash flows from operating activities Net loss $ ( 67,326 ) $ 1,677 (a)(b) $ ( 65,649 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 13,728 — 13,728 Allowance for doubtful accounts 155 — 155 Provision for excess and obsolete inventories 485 — 485 Stock-based compensation 10,365 — 10,365 Change in fair value of financial instruments 1,280 ( 1,337 ) (b) ( 57 ) Other 704 — 704 Changes in other assets and liabilities, net of acquisitions: Accounts receivable ( 12,013 ) — ( 12,013 ) Inventories ( 21,512 ) ( 340 ) (a) ( 21,852 ) Accounts payable 1,895 — 1,895 Accrued expenses 2,317 — 2,317 Accrued legal settlement 22,000 — 22,000 Income tax receivable/payable 391 — 391 Other assets and liabilities ( 1,650 ) — ( 1,650 ) Net cash used in operating activities ( 49,181 ) — ( 49,181 ) Cash flows from investing activities Purchase of office building ( 18,300 ) — ( 18,300 ) Purchases of property and equipment ( 22,813 ) — ( 22,813 ) Proceeds from sale of property and equipment 897 — 897 Purchases of intangible assets ( 1,973 ) — ( 1,973 ) Acquisitions, net of cash received ( 18,504 ) — ( 18,504 ) Net cash used in investing activities ( 60,693 ) — ( 60,693 ) Cash flows from financing activities Proceeds from draw on term loan 20,000 — 20,000 Proceeds from issuance of long-term debt 16,000 — 16,000 Payments on long-term debt ( 570 ) — ( 570 ) Payments of debt issuance costs ( 732 ) — ( 732 ) Proceeds from exercise of stock options 5,271 — 5,271 Proceeds from employee stock purchase plan 518 — 518 Payments on earnout liability ( 1,000 ) — ( 1,000 ) Net cash provided by financing activities 39,487 — 39,487 Effect of exchange rate changes on cash ( 497 ) — ( 497 ) Net decrease in cash ( 70,884 ) — ( 70,884 ) Cash at beginning of period 109,352 — 109,352 Cash at end of period $ 38,468 $ — $ 38,468 Supplemental disclosures of cash flow information: Cash paid for income taxes $ 1,103 $ — $ 1,103 Cash paid for interest 3,073 — 3,073 Purchase of property and equipment included in accounts payable 3,402 — 3,402

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
Business Combinations	NOTE 4. BUSINESS COMBINATIONS Disior On January 10, 2022 (“Disior Acquisition Date”), the Company entered into a Securities Purchase Agreement (“SPA”) with Disior LTD. (“Disior”) and acquired 100 % of the outstanding equity of Disior (the “Disior Acquisition”). The aggregate purchase price of the Disior Acquisition was approximately $ 26,246 inclusive of an earn-out provision with a fair value of $ 6,550 and certain net working capital adjustments and deferred payments totaling a net payable of $ 222 . The SPA provided for potential earn-out consideration to the seller in connection with the achievement of certain milestones with various expiration dates through the second anniversary of the Disior Acquisition Date. The earn-out has a maximum payment not to exceed $ 8,000 in the aggregate. If an individual milestone is not met by the specified milestone expiration date, the earn-out related to that specific milestone will not be paid. The acquisition was primarily funded by a $ 20,000 draw on the Company’s term loan from Midcap. Acquisition related costs were $ 761 during the year ended December 31, 2022, and are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. No acquisition related costs were incurred during the year ended December 31, 2023. The Company has accounted for the acquisition of Disior under ASC Topic 805, Business Combinations (“ASC 805”). Disior’s results of operations are included in the Consolidated Financial Statements beginning after January 10, 2022, the Disior Acquisition Date. The following table summarizes the purchase price: Consideration paid: Cash consideration $ 19,696 Contingent consideration 6,550 Total consideration $ 26,246 The following table summarizes the fair values of the assets acquired and liabilities assumed as of the Disior Acquisition Date: Assets acquired: Cash and cash equivalents $ 1,192 Other current assets 410 Intangible assets 6,800 Goodwill 19,136 Total assets acquired 27,538 Liabilities assumed: Accruals and other current liabilities 615 Deferred tax liabilities, net 677 Total liabilities assumed 1,292 Net assets acquired $ 26,246 Identified intangible assets consist of tradenames and developed technology. The fair value of each were determined with the assistance of an external valuation specialist using a combination of the income, market, cost approach, and relief from royalty rate method, in accordance with ASC 805. The purchase consideration was allocated to the identifiable net assets acquired based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, was recorded as goodwill. The goodwill is attributable to the expected synergies with the Company’s existing operations. The useful life on intangible assets was determined by management to be in line with the Company’s policy on intangible assets. Both determinations are outlined in the table below: Fair Value Estimated Useful Life Developed technology $ 6,400 12 Tradenames 400 Indefinite Total intangible assets $ 6,800 The entire amount of the purchase price allocated to goodwill will not be deductible for income tax purposes under the Finnish Income Tax Act. There is no supplemental proforma presentation of operating results of the acquisition of Disior due to the immaterial impact on the Company’s Consolidated operations for the years ended December 31, 2022 and 2021. Additive Orthopaedics On May 28, 2021 (“Closing Date”), the Company entered into an Asset Purchase Agreement (“APA”) with Additive Orthopaedics, LLC (“Additive”) and completed an acquisition of substantially all of the operating and intangible assets of Additive, for total cash consideration of $ 15,000 at closing. The APA also provided for potential earn-out consideration to Additive in connection with the achievement of certain milestones, including both project-based and revenue-based milestones, with various expiration dates through the fourth anniversary of the Closing Date. The earn-out has a maximum payment not to exceed $ 9,500 , in the aggregate. If an individual milestone is not met by the specified milestone expiration date, no earn-out related to that specific milestone is due. The contingent earn-out consideration had an estimated fair value of $ 2,870 as of the Closing Date. Acquisition related costs were approximately $ 822 during the year ended December 31, 2021, and are included in Selling, general, and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. No acquisition related costs were incurred during the years ended December 31, 2023 and 2022. The Company has accounted for the acquisition of Additive under ASC 805. Additive’s results of operations are included in the Consolidated Financial Statements beginning after May 28, 2021, the acquisition date. The following table summarizes the purchase consideration transferred in connection with the acquisition of Additive and consists of the following: Consideration Paid Cash consideration $ 15,000 Contingent consideration 2,870 Total consideration $ 17,870 The following table summarizes the fair values of the assets acquired and liabilities assumed as of the Closing Date: Assets acquired: Accounts receivable $ 761 Inventory 113 Intangible assets 11,560 Goodwill 6,329 Total assets acquired 18,763 Liabilities assumed: Accounts payable 796 Accrued expenses 97 Total liabilities assumed 893 Net assets acquired $ 17,870 Identified intangible assets consist of noncompete arrangements, customer relationships, and developed technology. The fair value of each were determined with the assistance of an external valuation specialist using a combination of the income, market, and asset approach valuation methodologies, in accordance with ASC 805. The purchase consideration was allocated to the identifiable net assets acquired based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, was recorded as goodwill. The goodwill is attributable to the expected synergies with the Company’s existing operations. The entire amount of the purchase price allocated to goodwill will be deductible for income tax purposes pursuant to Internal Revenue Code Section 197 over a 15-year period. The useful life determination was made by management in line with the Company’s policy on assets. Both determinations are outlined in the table below: Fair Value Estimated Useful Life Noncompete arrangements $ 30 3 Customer relationships 240 3 Developed technology 11,290 12 $ 11,560 There is no supplemental proforma presentation of operating results of the acquisition of Additive due to the immaterial impact on the Company’s Consolidated operations for the years ended December 31, 2022 and 2021.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 5. PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2023 and 2022 consist of the following: Estimated Life December 31, (in years) 2023 2022 Surgical instrumentation 3 - 5 $ 60,100 $ 44,625 Land 3,625 3,625 Buildings 25 20,190 14,178 Leasehold improvements Various 8,307 7,961 Computer and software 3 - 5 16,546 11,562 Machinery and equipment 5 3,843 2,815 Office equipment and furniture 5 - 7 2,267 2,049 Construction in progress Various 288 5,817 Other 5 - 15 2,785 1,046 117,951 93,678 Less: accumulated depreciation ( 43,829 ) ( 31,740 ) Property and equipment, net $ 74,122 $ 61,938 Depreciation expense is included in Selling, general, and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss and was $ 13,515 , $ 10,824 and $ 7,615 for the years ended December 31, 2023, 2022 and 2021 respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	NOTE 6. GOODWILL AND INTANGIBLE ASSETS Goodwill Our annual impairment testing date is October 1. The Company determined, after performing the qualitative analysis that there was no evidence that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. Therefore, it was not necessary to perform a quantitative impairment test. As of December 31, 2023 and 2022 , goodwill was $ 25,465 . Intangibles Intangible assets as of December 31, 2023 are as follows: Estimated Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trademarks and tradenames, indefinite-lived Indefinite $ 987 $ — $ 987 Patents, definite-lived 17.6 7,900 2,649 5,251 Customer relationships 3 - 7 1,733 567 1,166 Developed technology 12 17,690 3,424 14,266 Other intangibles 3 30 26 4 Total intangible assets, net $ 28,340 $ 6,666 $ 21,674 Intangible assets as of December 31, 2022, are as follows: Estimated Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trademarks, indefinite-lived Indefinite $ 901 $ — $ 901 Patents, definite-lived 16.5 6,671 2,370 4,301 Customer relationships 3 - 7 1,733 279 1,454 Developed technology 12 17,690 1,973 15,717 Other intangibles 3 30 16 14 Total intangible assets, net $ 27,025 $ 4,638 $ 22,387 Amortization expense is included in Selling, general, and administrative expenses, which is included on the consolidated statements of operations and comprehensive loss, and was $ 2,027 , $ 2,904 and $ 1,372 for the years ended December 31, 2023, 2022 and 2021, respectively. Expected future amortization expense is as follows: 2024 $ 1,981 2025 1,940 2026 1,940 2027 1,940 2028 1,929 No impairment charges related to intangible assets and goodwill were recorded for the years ended December 31, 2 0 23, 2022 and 2021 .

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Accrued Expenses	NOTE 7. ACCRUED EXPENSES Accrued expenses consist of the following as of December 31, 2023 and 2022, respectively: December 31, 2023 2022 Accrued commissions $ 6,126 $ 6,026 Accrued compensation 10,213 8,569 Accrued purchases 1,883 204 Accrued earnout payment 2,000 6,500 Accrued interest 2,006 450 Other accrued expenses 5,553 5,058 Total accrued expenses $ 27,781 $ 26,807

Fair Value of Financial Instrum

Fair Value of Financial Instruments	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Fair Value of Financial Instruments	NOTE 8. FAIR VALUE OF FINANCIAL INSTRUMENTS The Company measures certain financial assets and liabilities at fair value. There is a fair value hierarchy which prioritizes inputs used in measuring fair value into three broad levels: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, such as quoted market prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3 - Unobservable inputs which are supported by little or no market activity. The level in the fair value hierarchy within which a fair value measurement in its entirety falls is based on the lowest-level input that is significant to the fair value measurement in its entirety. The Company ’s significant financial assets and liabilities measured at fair value as of December 31, 2023, were as follows: Level 1 Level 2 Level 3 Total Financial Assets: Interest rate swap $ — 991 — $ 991 Financial Liabilities: Contingent consideration — — 340 $ 340 The Company's significant financial assets and liabilities measured at fair value as of December 31, 2022, were as follows: Level 1 Level 2 Level 3 Total Financial Assets: Interest rate swap (As Restated) $ — 1,337 — $ 1,337 Financial Liabilities: Contingent consideration — — 3,640 $ 3,640 The Company’s Level 2 asset pertains to an interest rate swap associated with the Company’s Zions Facility, used to manage interest rate risk related to variable rate borrowings and manage exposure to the variability of cash flows. The interest rate swap is not designated for hedge accounting and is measured utilizing inputs observable in active markets. For the year ended December 31, 2023, we reassessed the fair value of our interest rate swap which resulted in a decrease of $ 0.3 million. The ch ange in fair value is recorded in Other assets on the Consolidated Balance Sheet, Other income (expense), net within the Consolidated Statement of Operations and Comprehensive Loss. The Company’ s Level 3 instruments consist of contingent consideration. The following table provides a reconciliation of the Level 3 earn-out liabilities for the years ended December 31, 2023 and 2022: December 31, 2023 Fair value measurement, beginning of year $ 3,640 Achieved milestones paid ( 2,500 ) Achieved milestones reclassified to accrued expenses ( 1,000 ) Change in fair value of earn-out liabilities 200 Fair value measurement, end of year $ 340 As of December 31, 2023, the contingent earn-out liabilities are included in Other current liabilities on the Consolidated Balance Sheet. During the year ended December 31, 2023, we reassessed the estimate of the earn-out liabilities which resulted in a net increase o f $ 200 recorded in Other (expense) income within the Consolidated Statement of Operations and Comprehensive Loss for the year ended December 31, 2023. As of December 31, 2022, three project milestones associated with the Disior acquisition and two project milestones associated with the Additive Orthopaedics acquisition were included in Accrued expenses on the Consolidated Balance Sheet totaling $ 5,000 and $ 1,500 , respectively. During the year ended December 31, 2023, $ 500 was paid in cash for one of the Additive Orthopaedics milestones and $ 5,000 was paid in cash for the Disior milestones. As of December 31, 2023, the remaining $ 1,000 related to the Additive Orthopaedics milestone was included in Accrued expenses on the Condensed Consolidated Balance Sheet and is included as restricted cash within the Consolidated Statement of Cash Flows for the year ended December 31, 2023. In addition, we completed two project milestones associated with the Disior acquisition and one project milestone associated with the Additive acquisition as of December 31, 2023. The Additive milestone and one of the Disior milestones were paid in cash during the year ended December 31, 2023, and the remaining Disior milestone totaling $ 1,000 is included in Accrued expenses on the Consolidated Balance Sheet as of December 31, 2023. For additional information on the Disior and Additive Orthopaedics acquisitions refer to Note 4 to our Consolidated Financial Statements.

Debt

Debt	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Debt	NOTE 9. DEBT Long-term debt as of December 31, 2023, and December 31, 2022, consists of the following: December 31, 2023 December 31, 2022 Ares Revolving Loan $ 25,000 $ — Ares Term Loan 75,000 — MidCap Term Loan — 30,000 Zions Term Loan 14,933 15,573 Bank of Ireland Note Payable — 86 114,933 45,659 Less: deferred issuance costs ( 4,494 ) ( 2,749 ) Total debt, net of issuance costs 110,439 42,910 Less: current portion ( 640 ) ( 728 ) Long-term debt, net, less current maturities $ 109,799 $ 42,182 Ares Credit Agreement On November 2, 2023, the Company entered into a new credit agreement with Ares Capital Corporation to provide a total of $ 150,000 , inclusive of a revolving credit facility of up to $ 50,000 (the “Ares Revolving Loan”) and a term loan facility of up to $ 100,000 (the “Ares Term Loan”). The obligations under the Ares Credit Agreement are guaranteed by each of the Borrowers’ current and future domestic subsidiaries and secured by liens on substantially all of the Borrowers’ and guarantors’ present and after-acquired assets, in each case, subject to certain customary exceptions. In connection with the closing of the Ares Credit Agreement, the Company drew down $ 25,000 and $ 75,000 on the Ares Revolving Loan and Ares Term Loan, respectively. The Ares Revolving Loan and Ares Term Loan bear interest at variable rates of Term SOFR plus 4 % and Term SOFR plus 6.75 %, respectively, subject in the case of the Ares Term Loan to certain step-downs and adjustments as set forth in the Ares Credit Agreement, and mature on the earlier of (i) November 2, 2028 , and (ii) with respect to the Ares Revolving Loan, 6 months prior to the maturity date of any other indebtedness in a principal or stated amount in excess of $ 12,500 . The Ares Credit Agreement contains a financial covenant requiring the Company to maintain certain minimum revenue levels. As of December 31, 2023, the Company was in compliance with all financial covenants under the Ares Credit Agreement. Total debt issuance costs associated with the Ares Credit Agreement were $ 4,275 . Amortization expense associated with such debt issuance costs totaled $ 147 , $ 0 and $ 0 for the years ended December 31, 2023, 2022 and 2021, respectively and is included in Interest expense, net on the Consolidated Statements of Operations and Comprehensive Loss. MidCap Credit Agreements On May 6, 2021, the Company entered into a new credit agreement with MidCap Financial Trust to provide a total of $ 70,000 including up to a $ 30,000 revolving loan (“MidCap Revolving Loan”) and up to a $ 40,000 term loan (“MidCap Term Loan”), secured by substantially all the Company’s assets (“MidCap Credit Agreements”). The MidCap Term Loan was comprised of two tranches, the first of which provided a commitment amount of $ 10,000 , and the second a commitment of $ 30,000 . The MidCap Term Loan and Midcap Revolving Loan bore a variable interest rate of LIBOR plus 6 % and LIBOR plus 3 %, respectively, and matured on the earlier of May 1, 2026 , or a change in control event (the “Termination Date”). The entire principal balances of the MidCap Revolving Loan and MidCap Term Loan were due on the Termination Date. Interest payments were payable monthly, with optional principal prepayments allowed under the MidCap Credit Agreements. The Midcap Credit Agreements required us to maintain minimum net product sales and minimum consolidated EBITDA, (each term as defined in the Midcap Credit Agreements), for the preceding twelve-month period. On November 9, 2022, the Company entered into an amendment to the MidCap Credit Agreements. The amendment to the Midcap Revolving Loa n provided up to $ 50,000 in total borrowing capacity. The MidCap amendments modified the MidCap Credit Agreements to include provisions related to the transition from the LIBOR Interest Rate plus Applicable Margin to the SOFR Interest Rate plus Applicable Margin, maintaining the Applicable Margin of 6 % under the MidCap Term Loan and increasing the Applicable Margin from 3 % to 3.75 % under the Midcap Revolving Loan. In addition, the MidCap amendments amended certain covenants, terms and provisions in the Midcap Credit Agreements to, among other things, modify the covenant levels for the Minimum Net Product Sales financial covenant and to remove the Minimum Consolidated EBITDA financial covenant. On November 2, 2023, in connection with the entry into the Ares Credit Agreement, the Company terminated the commitments and satisfied all outstanding obligations under the MidCap Credit Agreements. During the year ended December 31, 2023, the Company recorded a loss on early extinguishment of debt of $ 5,308 , inclusive of the write-off of remaining unamortized debt issuance costs of $ 1,881 and fees incurred to exit the MidCap Credit Agreements early of $ 3,427 . Amortization expense associated with debt issuance costs prior to write-off totaled $ 613 , $ 586 and $ 576 for the years ended December 31, 2023, 2022 and 2021, respectively, and is included in Interest expense, net on the Consolidated Statements of Operations and Comprehensive Loss. Vectra Bank Colorado Loan Agreements On March 24, 2022, the Company entered into a secured term loan facility (the “Zions Facility”) with Zions Bancorporation, N.A. dba Vectra Bank Colorado in the principal amount of $ 16,000 . The loans under the Zions Facility (i) bear interest at a variable rate per annum equal to the sum of (a) a one-month Term SOFR based rate, plus (b) 1.75 %, adjusted on a monthly basis and (ii) mature on March 24, 2037 . Principal and interest payments are payable monthly , with optional prepayments allowed without premium or penalty. Effective as of November 10, 2022, the Company entered into the First Amendment to the Zions Facility. The amendment to the Zions Facility amends the financial covenants to require the Company to maintain (i) the Liquidity Ratio, if the Cash Flow as of the last day of any quarter measured on a trailing three month basis is less than or equal to $ 0 , and (ii) th e Fixed Charge Coverage Ratio which will be calculated as of the last day of each quarter on a trailing four quarter basis, as well as a certain level of Liquidity, if the Cash Flow is greater than $ 0 . In addition, a Net Revenue Growth covenant was added which will be calculated as of the last day of each quarter on a year-over-year basis. Effective as of November 2, 2023, the Company entered into the Second Amendment to the Zions Facility (the “Second Amendment”). The Second Amendment replaces references to MidCap Financial Trust and MidCap Credit Agreements with references to Ares and the Ares Credit Agreement. As of December 31, 2023, the Company was in compliance with all financial covenants under the Second Amendment. Total debt issuance costs associated with the Zions Facility were $ 219 . Amortization expense associated with such debt issuance costs totaled $ 16 , $ 13 and $ 0 for the years ended December 31, 2023, 2022 and 2021, respectively, and is included in Interest expense, net on the Consolidated Statements of Operations and Comprehensive Loss. Bank of Ireland Note Payable On June 12, 2020, the Company entered a term loan with Bank of Ireland in a principal amount of $ 474 (the “Bank of Ireland Note Payable”). The Bank of Ireland Note Payable bore an annual interest rate of 4 % and was due in equal monthly installments over a 36 -month period, including interest. The Company repaid the Bank of Ireland Note Payable in 2023. Debt Maturities Schedule The required principal payments for the Ares Revolving Loan, Ares Term Loan and the Zions Facility following the Consolidated Balance Sheet dates are as follows: 2024 $ 640 2025 640 2026 640 2027 640 2028 100,640 Thereafter 11,733 Total $ 114,933

Convertible Preferred Series Eq

Convertible Preferred Series Equity and Stockholders' Equity	12 Months Ended
	Dec. 31, 2023
Stockholders' Equity Note [Abstract]
Convertible Preferred Series Equity And Stockholders' Equity	NOTE 10. CONVERTIBLE PREFERRED SERIES EQUITY AND STOCKHOLDERS’ EQUITY Under its Amended and Restated Certificate of Incorporation, the Company has a total of 310,000,000 shares of capital stock authorized for issuance, consisting of 300,000,000 shares of common stock, par value of $ 0.01 per share, and 10,000,000 shares of convertible preferred stock, par value of $ 0.01 per share. Common Stock On January 30, 2023, the Company completed an underwritten public offering (“the Offering”) of 6,500,000 shares of its common stock at an offering price of $ 17.00 per share, which consisted of 3,750,000 shares of common stock issued and sold by the Company and 2,750,000 shares of common stock sold by certain selling securityholders. On February 17, 2023, the underwriters exercised in full their option to purchase an additional 562,500 shares and 412,500 shares of common stock from the Company and the selling securityholders, respectively.‌ The Company received aggregate net proceeds from the Offering of approximately $ 68,453 after deducting underwriting discounts and commissions and offering expenses payable by the Company. The selling securityholders received aggregate net proceeds from the Offering of approximately $ 50,700 after deducting underwriting discounts and commissions. The Company did not receive any of the proceeds from the sale of shares of Common Stock by the selling securityholders. The Company did no t issue any common stock during the year ended December 31, 2022. Each holder of common stock is entitled to one vote for each share owned on all matters voted upon by the stockholders, and a majority vote is required for all actions taken by stockholders. Common stock has no preemptive rights, no cumulative voting rights and no redemption or conversion provisions. Holders of common stock are entitled to receive dividends when and if, declared by the Board of Directors. Series A Convertible Preferred Stock In December 2011, the Company issued an aggregate of 3,250,005 shares of its Series A convertible preferred stock at a price of $ 0.30769 per share, resulting in total proceeds of approximately $ 1,000 . In February and November 2012, the Company issued an aggregate of 10,562,495 shares of its Series A convertible preferred stock at a price of $ 0.30769 per share, resulting in total proceeds of approximately $ 3,250 . In October 2021, in connection with the IPO, all of the shares of the Company’s outstanding Series A convertible preferred stock automatically converted into an aggregate of 13,812,500 shares of common stock. Series B Convertible Preferred Stock In July 2020, the Company issued an aggregate of 6,608,700 shares of its Series B convertible preferred stock at a price of $ 5.75 per share, resulting in total net proceeds of approximately $ 36,030 , net of issuance costs of $ 1,970 . In connection with the IPO, all of the shares of the Company’s outstanding Series B convertible preferred stock automatically converted into an aggregate of 6,608,700 shares of the common stock. Pursuant to the terms of the Series B convertible preferred stock offering, the $ 2,328 of cash dividends accrued as of October 19, 2021, were cancelled upon conversion of the Series B preferred stock into common stock. Treasury Stock The Company did no t purchase any shares of its common stock during the years ended December 31, 2023 and 2022. The Company purchased a total of 85,049 shares of its common stock during the year ended December 31, 2021 for $ 561 . Shares purchased during the year ended December 31, 2021, were at an average of $ 6.60 per share. All repurchased shares were recorded in Treasury stock at cost.

Loss Per Share

Loss Per Share	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Loss Per Share	NOTE 11. LOSS PER SHARE Basic net loss per share is computed by dividing net loss attributable to common stockholders (the numerator) by the weighted average number of common stock outstanding for the period (the denominator). Diluted net loss per common stock attributable to common stockholders is computed by dividing net income by the weighted average number of shares of common stock outstanding during the period adjusted for the dilutive effects of common stock equivalents using the treasury stock method or the if-converted method based on the nature of such securities. In periods when losses from continuing operations are reported, the weighted-average number of common stock outstanding excludes common stock equivalents because their inclusion would be anti-dilutive. The computation of net loss per share for the years ended December 31, 2023, 2022 and 2021, respectively was as follows: Year Ended December 31, 2023 2022 2021 (As Restated) (As Restated) Net loss $ ( 57,534 ) $ ( 65,649 ) $ ( 13,693 ) Weighted-average common stock outstanding: Basic 82,087,329 76,766,100 52,916,711 Diluted 82,087,329 76,766,100 52,916,711 Loss per share: Basic $ ( 0.70 ) $ ( 0.86 ) $ ( 0.26 ) Diluted $ ( 0.70 ) $ ( 0.86 ) $ ( 0.26 ) The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact would have been antidilutive for the period presented: December 31, 2023 2022 2021 Stock options 5,943,898 6,538,536 7,953,018 Restricted stock units 1,317,402 964,054 79,886

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-Based Compensation	NOTE 12. STOCK-BASED COMPENSATION The Company’s Employee Stock Purchase Plan (“ESPP”) and 2021 Incentive Award Plan (“2021 Plan”) were adopted by the Company’s Board of Directors on October 8, 2021. The ESPP and 2021 Plan were both adopted by the Company’s stockholders on October 19, 2021, and became effective on the date prior to the first date of the effectiveness of the registration statement on Form S-1 filed by the Company. Employee Stock Purchase Plan The ESPP initially provided participating employees with the opportunity to purchase up to an aggregate of 1,329,040 shares of the Company’s common stock at 85 % of the market price at the lesser of the date the purchase right is granted or exercisable. The ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2022, and ending on January 1, 2031, by the lesser of 1 % of all classes of the Company’s common stock outstanding on the immediately preceding December 31, or such smaller number of shares as determined by the Company’s Board or the committee. As of December 31, 2023, 2,758,808 shares remained available for issuance. Eligible employees can contribute up to 15 % of their gross base earnings for purchases under the ESPP through regular payroll deductions, limited to $ 25,000 worth of the Company’s shares of common stock for each calendar year in which the purchase right is outstanding. The Company currently holds offerings consisting of six-month periods commencing on January 1st and July 1st of each calendar year, with a single purchase date at the end of the purchase period on June 30th and December 31st of each calendar year. During the years ended December 31, 2023 and 2022, the Company issued 73,442 and 38,968 shares, respectively, upon exercise of purchase rights. The Company recognizes compensation expense on a straight-line basis over the service period. During the years ended December 31, 2023 and 2022, the Company recognized $ 322 and $ 213 of compensation expense, respectively, related to the ESPP. There were no shares issued and no compensation expense was recognized related to the ESPP during 2021. Below are the assumptions used for the years ended December 31, 2023 and 2022 in determining the fair value of shares under the ESPP. Year Ended December 31, 2023 2022 Expected volatility 54.64 % 70.27 % Expected dividends — — Expected term (in years) 0.50 0.50 Discount rate 15.00 % 15.00 % Risk-free rate 5.26 % 2.79 % 2021 Incentive Award Plan The 2021 Plan authorized the Company to issue an initial aggregate maximum number of shares of common stock equal to (i) 7,641,979 shares plus (ii) a number of shares that are available for issuance under the 2011 Plan plus (iii) any shares that are subject to 2011 Plan that become available for issuance (via expiration, forfeitures, etc.) plus (iv) an increase commencing on January 1, 2022, and continuing annually on the anniversary thereof through January 1, 2031, equal to the lesser of (a) 5 % of the shares of all classes of the Company’s common stock outstanding on the last day of the immediately preceding calendar year or (b) such smaller number of shares as determined by the Company’s Board or the committee. As of December 31, 2023, the Company had reserved 13,510,971 shares of common stock for future grant. Stock Options The following table summarizes the Company’s stock option plan and the activity for the year ended December 31, 2023. Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Outstanding, December 31, 2022 6,538,536 $ 10.02 7.36 Granted 225,000 18.33 Exercised or released ( 458,005 ) 6.56 Forfeited or expired ( 361,633 ) 15.29 Outstanding, December 31, 2023 5,943,898 $ 10.28 6.53 Exercisable, December 31, 2023 4,292,558 $ 8.51 6.02 Vested and expected to vest at December 31, 2023 5,938,438 $ 10.27 6.53 There were 225,000 , 359,054 and 3,467,069 options granted during the years ended December 31, 2023, 2022 and 2021, at a weighted average strike price of $ 18.33 , $ 16.08 and $ 14.63 , respectively. The Company received cash in the amount of $ 2,406 , $ 5,271 and $ 445 from the exercise of stock options for the years ended December 31, 2023, 2022 and 2021, respectively. The tax benefit from equity options exercised were $ 560 , $ 1,223 and $ 93 for the years ended December 31, 2023, 2022 and 2021, respectively. The aggregate intrinsic value of options outstanding at December 31, 2023 , is $ 22,900 . The aggregate intrinsic value of vested and exercisable options at December 31, 2023 is $ 21,530 . The aggregate intrinsic value of options exercised during the years ended December 31, 2023, 2022 and 2021 is $ 4,742 , $ 18,764 and $ 3,743 , respectively. As of December 31, 2023 , there was approximately $ 5,634 total unrecognized compensation cost related to non-vested stock option compensation arrangements, which is expected to be recognized over a weighted average period of 1.78 years. Below are the assumptions used for the years ended December 31, 2023, 2022 and 2021 in determining the fair value of each option award: Year Ended December 31, 2023 2022 2021 Expected volatility 66.20 % 55 % - 70 % 52 % - 55 % Expected dividends — — — Expected term (in years) 6.25 6.00 5.75 - 6.25 Risk-free rate 4.11 % 1.69 - 2.79 % 0.47 % - 1.20 % Restricted Stock Units RSUs granted under the 2021 Plan have a ten-year contractual term and typically vest over a three or four-year period, contingent upon continued service with the Company. The following table summarizes the Company’s restricted stock units' activity for the years ended December 31, 2023. Year Ended December 31, 2023 Restricted Stock Units Weighted-Average Fair Value Outstanding, beginning of period 964,054 $ 17.74 Granted 776,359 16.56 Vested ( 273,618 ) 17.65 Forfeited or expired ( 149,393 ) 17.81 Outstanding, end of period 1,317,402 $ 17.06 Vested and expected to vest at end of period 1,305,827 $ 17.05 During the years ended December 31, 2023, 2022 and 2021, the Company granted 776,359 , 929,090 and 79,886 RSU’s, respectively. The grant date fair value for RSUs is the thirty-day trailing average market price of the common stock on the date of grant. As of December 31, 2023 , there was approximately $ 18,689 total unrecognized compensation cost related to non-vested RSUs, which is expected to be recognized over a weighted average period of 2.88 years. Stock-Based Compensation Expense Stock-based compensation expenses are recorded in Selling, general and administrative expenses in the Consolidated Statements of Operations and Comprehensive Loss. During the years ended December 31, 2023, 2022 and 2021 , the Company recognized $ 5,542 , $ 8,500 , and $ 4,863 respectively, of compensation expense related to stock options. During the years ended December 31, 2023, 2022 and 2021 , the Company recognized $ 6,822 , $ 1,865 and $ 85 , respectively, of compensation expense related to RSUs.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2023
Retirement Benefits [Abstract]
Employee Benefit Plan	NOTE 13. EMPLOYEE BENEFIT PLAN The Company sponsors a defined contribution plan for eligible employees who are 21 years of age with three months of service can voluntarily contribute up to 100 % of their eligible compensation. The Company has elected a Safe Harbor plan in which the Company must contribute 3 % of eligible compensation. In addition, the Company may make discretionary contributions which are determined and authorized by the Board of Directors each plan year. The Company made contributions to its employee benefit plan of $ 1,190 , $ 992 and $ 633 for the years ended December 31, 2023, 2022 and 2021, respectively.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income Taxes	NOTE 14. INCOME TAXES Total provision (benefit) for income taxes for the years ended December 31, 2023, 2022 and 2021: December 31, 2023 2022 2021 (As Restated) (As Restated) (Loss) income before taxes Domestic $ ( 56,342 ) $ ( 64,071 ) $ ( 17,030 ) Foreign ( 979 ) ( 1,642 ) 4,050 Total loss before taxes ( 57,321 ) ( 65,713 ) ( 12,980 ) Current tax expense (benefit): Federal 105 — ( 165 ) State 58 96 ( 36 ) Foreign 730 315 744 Total current tax expense 893 411 543 Deferred tax expense (benefit): Federal ( 11,309 ) ( 15,900 ) ( 3,506 ) State ( 1,402 ) ( 1,939 ) ( 464 ) Foreign ( 1,099 ) ( 909 ) 170 Change in valuation allowance 13,129 18,273 3,970 Total deferred tax (benefit) expense ( 681 ) ( 475 ) 170 Total tax (benefit) expense: Federal ( 11,204 ) ( 15,900 ) ( 3,671 ) State ( 1,344 ) ( 1,843 ) ( 500 ) Foreign ( 368 ) ( 594 ) 914 Change in valuation allowance 13,129 18,273 3,970 Total income tax expense (benefit) $ 213 $ ( 64 ) $ 713 We account for income taxes under the asset and liability method, which required the recognition of deferred tax assets and liabilities for the expected future consequences of events that have been included in the financial statements. Under this method, we determine deferred tax assets and liabilities on the basis of differences between the financial statement and tax bases of the assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. We file income tax returns in the U.S. federal jurisdiction, various state jurisdictions and applicable foreign jurisdictions. We are no longer subject to U.S. federal or state tax examinations for the years prior to 2020. The 2018 year is open in a limited scope as a result of the 2020 NOL carryback. Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred taxes as of December 31, 2023 and 2022 were: December 31, 2023 2022 (As Restated) (As Restated) Deferred tax assets: Receivable allowances $ 253 $ 356 Accrued expenses 1,262 5,351 S263A capitalizable costs 2,923 461 Inventory reserves 4,635 3,436 Research and development credits 3,974 3,615 Net operating losses 25,176 13,505 Interest expense 2,407 906 Stock-based compensation 4,496 3,324 Lease liability 356 384 R&D IRC 174(b) capitalized costs 5,161 3,433 Other 764 651 Total deferred tax assets 51,407 35,422 Valuation allowance ( 41,671 ) ( 28,543 ) Net deferred tax assets 9,736 6,879 Deferred tax liabilities: Property and equipment ( 6,808 ) ( 5,391 ) Section 481 adjustment ( 821 ) — Patents and trademarks ( 1,343 ) ( 1,304 ) Right of use asset ( 292 ) ( 378 ) Total deferred tax liabilities ( 9,264 ) ( 7,073 ) Total net deferred tax asset (liability) $ 472 $ ( 194 ) A valuation allowance is established when it is “more likely than not” that all, or a portion, of net deferred tax assets will not be realized. As a result, the Company has concluded based on all available evidence and determined that valuation allowances of $ 41,671 and $ 28,543 should be provided for certain deferred tax assets at December 31, 2023, and 2022, respectively. As of December 31, 2023 and 2022 we had federal US net operating loss carryforwards of $ 97,490 and $ 52,009 respectively which have an indefinite carryforward period and $ 52,211 of combined U.S state net operating loss carryforwards in various states that will begin to expire in 2033 . Additionally, the Company has foreign net operating loss carryforwards of $ 10,368 that will begin to expire in 2034 . A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: 2023 2022 Gross unrecognized tax benefits - beginning of period $ 1,431 $ 1,337 Increases related to current year tax positions 92 92 Increases related to prior year tax positions — 2 Gross unrecognized tax benefits - end of period $ 1,523 $ 1,431 The unrecognized tax benefits of $ 1,523 , if recognized, will impact the Company’s effective tax rate. In accordance with the Company’s accounting policy, accrued interest and penalties are recognized related to unrecognized tax benefits as a component of tax expense. As of December 31, 2023 , the Company recorded $ 106 of interest or penalties associated with unrecognized tax benefits. The Company expects the total amount of tax contingencies will not decrease in 2024 based on statute of limitation expiration. A reconciliation of the provision for income taxes at the federal statutory rate compared to the effective tax rate for the years ended December 31, 2023, 2022 and 2021 is: 2023 2022 2021 (As Restated) (As Restated) Statutory U.S. federal tax rate $ ( 12,037 ) $ ( 13,800 ) $ ( 2,726 ) State taxes net of federal benefit ( 1,356 ) ( 1,863 ) ( 492 ) Non-U.S. earnings taxed at rates different than the U.S. statutory rate 5 ( 80 ) ( 150 ) Foreign source earnings, net of associated foreign tax credits 628 486 601 Benefit of tax credits ( 501 ) ( 458 ) ( 1,569 ) Stock based compensation 27 ( 2,852 ) ( 212 ) Change in valuation allowance 13,129 18,273 3,970 Change in unrecognized tax benefits 175 92 710 Other 143 138 581 Total provision (benefit) for income taxes $ 213 $ ( 64 ) $ 713 As of December 31, 2023 , our foreign operations held cash totaling $ 10,293 . We have not provided for a U.S. deferred tax liability or foreign withholding tax on the undistributed earnings from our non-U.S. subsidiaries that are considered to be indefinitely reinvested. If such earnings were to be distributed, any U.S. deferred tax liability or foreign withholding tax would not be significant.

Commitments And Contingencies

Commitments And Contingencies	12 Months Ended
	Dec. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	NOTE 15. COMMITMENTS AND CONTIGENCIES Leases The Company determines if an arrangement is a lease at inception by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company determines the initial classification and measurement of its right-of-use (“ROU”) asset and lease liabilities at the lease commencement date and thereafter, if modified. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. The Company leases certain office space and equipment under operating leases. The Company adopted ASC 842 as of January 1, 2022, and as of December 31, 2022, recorded a lease liability of $ 1,821 and corresponding right-of-use asset of $ 1,795 on its Consolidated Balance Sheet. The lease liability of $ 1,821 consisted of $ 447 of short-term lease liabilities and $ 1,374 of long-term lease liabilities, included in Other current liabilities and Other long-term liabilities, respectively. As of December 31, 2023, right-of-use assets of $ 1,533 are included in Other assets and operating lease liabilities are included within the current and long-term portions of other liabilities of $543 and $ 1,048 , respectively on the Consolidated Balance Sheet. During the years ended December 31, 2023 and 2022, the Company recorded lease expense of $ 574 and $ 408 , respectively, as a component of Operating income (expense) in the Consolidated Statement of Operations and Comprehensive Loss Income. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. In order to apply the incremental borrowing rate, a portfolio approach with a collateralized rate was utilized wherein assets were grouped based on similar terms and economic environments in a manner whereby the Company reasonably expects that the application does not differ materially from a lease-by-lease approach. Disclosures Related to Periods Prior to Adoption of ASC 842 Rent expense under operating leases totaled $ 1,369 for the year ended December 31, 2021, and is included in Selling, general, and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. In January 2022, the Company purchased its corporate headquarters which was previously leased through 2029 . Lease expense for the years ended December 31, 2023 and 2022 do not include expense associated with this lease while rent expense for the year ended December 31, 2021, does. Legal Proceedings The Company is involved in various lawsuits, claims, inquiries, and other regulatory and compliance matters, most of which are routine to the nature of our business. When it is probable that a loss will be incurred and where a range of the loss can be reasonably estimated, the best estimate within the range is accrued. When the best estimate within the range cannot be determined, the low end of the range is accrued. The ultimate resolution of these claims could affect future results of operations should the exposure be materially different from the estimates or should liabilities be incurred that were not previously accrued. Potential insurance reimbursements are not offset against potential liabilities. On November 28, 2022, the Company entered into a settlement agreement with Stryker Corp. to settle two complaints filed against the Company and any Company counter claims for a total amount of $ 26,000 paid by the Company to Stryker Corp (the “Settlement Amount”). In addition, the Company incurred $ 1,000 in legal fees associated with the settlement. The Settlement Amount was scheduled to be paid by the Company in three separate installments consisting of: (i) $ 5,000 on or by December 16, 2022, (ii) $ 8,000 at any time between January 1, 2023, and January 16, 2023, and (iii) $ 13,000 at any time between April 1, 2023, and April 17, 2023. The Company remitted all three payments in accordance with the installment schedule. The settlement agreement did not impact the Company’s ability to continue operating its business and did not require any changes to the Company’s existing product lines. The Settlement Amount was the only consideration paid, and the Company is not required to make any future payments to Stryker Corp. The Company entered into the settlement agreement solely to eliminate the burden, expense, distraction, and uncertainties of litigation. The settlement agreement is not, and shall not be construed as, an admission of liability or that the Company engaged in any wrongful, tortious, or unlawful activity. As of December 31, 2023, the Company is not involved in any legal proceedings that could have a material adverse effect on its consolidated financial position.

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2023
Related Party Transactions [Abstract]
Related Party Transactions	NOTE 16. RELATED PARTY TRANSACTIONS The Company has a license agreement dated July 1, 2017, for certain intellectual property with an entity that is affiliated with one of the directors of the Company, under which the Company pays a royalty of four percent ( 4 %) of net revenue related to the licensed intellectual property for the 15 years following the date of first sale, including a minimum annual payment of $ 250 . The term of the agreement is 20 years , and automatically renews for five-year periods thereafter. Payments to the entity under this license agreement totaled $ 269 , $ 249 and $ 87 for the years ended December 31, 2023, 2022 and 2021, respectively. Amounts payable to this entity as of December 31, 2023 and 2022 were $ 155 and $ 164 , respectively. The Company paid professional services fees to a related party totaling $ 327 , $ 405 and $ 542 for the years ended December 31, 2023, 2022 and 2021, respectively, and are included in Selling, general, and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. Amounts payable as of December 31, 2023 and 2022 to this related party were $ 16 and $ 0 , respectively.

Segment and Geographic Informat

Segment and Geographic Information	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Segment and Geographic Information	NOTE 17. SEGMENT AND GEOGRAPHIC INFORMATION Operating segments are defined as components of an enterprise for which separate financial information is available and evaluated regularly by the chief operating decision maker, which is our Chief Executive Officer, in deciding how to allocate resources and in assessing performance. We manage our business globally within one operating segment in accordance with ASC Topic 280, Segment Reporting (“ASC 280”). Segment information is consistent with how management reviews the business, makes investing and resource allocation decisions and assesses operating performance. Product sales attributed to a country or region includes product sales to hospitals, physicians and distributors. No individual customer accounted for more than 10% of total product sales for any of the periods presented. No customer accounted for more than 10% of consolidated accounts receivable as of December 31, 2023 and 2022. The following table represents total net revenue by geographic area, based on the location of the customer for the years ended December 31, 2023, 2022 and 2021, respectively. Year Ended December 31, 2023 2022 2021 United States $ 183,505 $ 158,105 $ 130,112 International 32,884 23,278 17,352 Total net revenue $ 216,389 $ 181,383 $ 147,464 No individual country with net revenue originating outside of the United States accounted for more than 10% of consolidated net revenue for the years ended December 31, 2023, 2022 and 2021. The following table represents total non-current assets, excluding deferred taxes, by geographic area for the years ended December 31, 2023 and 2022, respectively. December 31, 2023 December 31, 2022 As Restated As Restated United States $ 89,531 $ 80,795 Finland 25,032 25,581 Other International 9,616 6,546 Total assets $ 124,179 $ 112,922

Quarterly Financial Data

Quarterly Financial Data	12 Months Ended
	Dec. 31, 2023
Quarterly Financial Information Disclosure [Abstract]
Quarterly FInancial Data	NOTE 18. QUARTERLY FINANCIAL DATA (Unaudited) Subsequent to the issuance of the Company's consolidated financial statements as of and for the year ended December 31, 2023, the Company identified errors in the calculation of its excess and obsolete inventory reserves, as well as its accounting for inventory variances. The following tables present the net impact of the Restatement described in Note 3. Restatement of Previously Issued Consolidated Financial Statements on our previously reported unaudited condensed consolidated financial statements for each interim period ended September 30, 2023, June 30, 2023, March 31, 2023, respectively, which have been restated for the Misstatements, along with other immaterial accounting and disclosure errors. The following tables also present the unaudited condensed consolidated financial statements as of and for the quarterly and year-to-date periods ended September 30, 2022, June 30, 2022, and March 31, 2022, respectively, which have been revised to correct certain accounting errors that, individually, and when aggregated, are not material to those financial statements. The previously reported amounts presented in the tables below have been derived from our Quarterly Reports on Form 10-Q filed on November 8, 2023, August 2, 2023, May 4, 2023, November 10, 2022, August 3, 2022, and May 9, 2022, respectively. See Note 3. Restatement of Previously Issued Consolidated Financial Statements for a description of the misstatements in each category of restatements referenced by (a) through (b). Reclassification of Prior Year Presentation In addition to the correction of errors described in Note 3. Restatement of Previously Issued Consolidated Financial Statements, certain prior period amounts have been reclassified for consistency with the current year presentation within this Note 18. 2022 Quarterly Financial Data (Unaudited). These reclassifications had no effect on the reported results of operations. Supplementary Financial Information The net impact of the Restatement on the Consolidated Statements of Operations and Comprehensive Loss for the three-months ended December 31, 2023 and 2022 is summarized as follows: Quarter Ended December 31, 2023 2022 As Previously Reported As Restated As Previously Reported As Restated (in thousands, except per share data) Net revenue $ 60,561 $ 60,561 $ 51,508 $ 51,508 Gross profit 45,121 42,357 41,971 42,221 Operating loss ( 11,230 ) ( 13,994 ) ( 36,045 ) ( 35,795 ) Net loss $ ( 19,559 ) $ ( 22,323 ) $ ( 38,763 ) $ ( 38,479 ) Net loss per share attributable to common stockholders: Basic $ ( 0.24 ) $ ( 0.27 ) $ ( 0.50 ) $ ( 0.50 ) Diluted $ ( 0.24 ) $ ( 0.27 ) $ ( 0.50 ) $ ( 0.50 ) As of and for the Three and Nine Months Ended September 30, 2023: The effects of the restatement on the condensed consolidated balance sheet as of September 30, 2023 are summarized in the following table (in thousands, except share and per share data): September 30, 2023 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash and cash equivalents $ 34,949 $ — $ 34,949 Trade receivables, net of allowance for doubtful accounts of $ 934 33,615 — 33,615 Inventories, net 94,380 ( 5,252 ) (a) 89,128 Income taxes receivable 1,022 — 1,022 Other current assets 4,826 — 4,826 Total current assets 168,792 ( 5,252 ) 163,540 Property and equipment, net 73,530 — 73,530 Intangible assets, net 21,802 — 21,802 Goodwill 25,465 — 25,465 Deferred income taxes 132 — 132 Other assets 3,634 — 3,634 Total assets $ 293,355 $ ( 5,252 ) $ 288,103 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 27,395 $ — $ 27,395 Accrued expenses 24,966 — 24,966 Other current liabilities 1,893 — 1,893 Current maturities of long-term debt 640 — 640 Total current liabilities 54,894 — 54,894 Long-term liabilities: Long-term debt net, less current maturities 42,288 — 42,288 Other long-term liabilities 1,467 — 1,467 Deferred income taxes 327 — 327 Income taxes payable 635 — 635 Total liabilities 99,611 — 99,611 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 83,469,426 shares issued, and 82,555,907 shares outstanding as of September 30, 2023 824 — 824 Additional paid in capital 296,018 — 296,018 Accumulated deficit ( 96,071 ) ( 5,252 ) (a) ( 101,323 ) Accumulated other comprehensive loss ( 1,045 ) — ( 1,045 ) Treasury stock, at cost; 913,519 shares as of September 30, 2023 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 193,744 ( 5,252 ) 188,492 Total liabilities & stockholders’ equity $ 293,355 $ ( 5,252 ) $ 288,103 The description of the error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 5,252 , including an increase to the beginning balance of Accumulated deficit of $ 3,724 for the three months ended and a decrease to the beginning balance of Accumulated deficit of $ 340 for the nine months ended September 30, 2023. The effects of the restatement on the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2023 are summarized in the following table (in thousands except share and per share data): Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Ref As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Net revenue $ 52,783 $ — $ 52,783 $ 155,828 $ — $ 155,828 Cost of goods sold (a) 10,394 1,528 11,922 28,158 5,592 33,750 Gross profit 42,389 ( 1,528 ) 40,861 127,670 ( 5,592 ) 122,078 Operating expenses: Research and development costs 7,244 — 7,244 21,976 — 21,976 Selling, general, and administrative 44,126 — 44,126 131,773 — 131,773 Total operating expenses 51,370 — 51,370 153,749 — 153,749 Operating loss ( 8,981 ) ( 1,528 ) ( 10,509 ) ( 26,079 ) ( 5,592 ) ( 31,671 ) Other income (expense): Other income (expenses), net (b) 1,660 ( 1,291 ) 369 1,014 ( 1,337 ) ( 323 ) Interest expense, net ( 1,119 ) — ( 1,119 ) ( 3,127 ) — ( 3,127 ) Total other income (expense) 541 ( 1,291 ) ( 750 ) ( 2,113 ) ( 1,337 ) ( 3,450 ) Loss before income taxes ( 8,440 ) ( 2,819 ) ( 11,259 ) ( 28,192 ) ( 6,929 ) ( 35,121 ) Income tax (benefit) expense ( 108 ) — ( 108 ) 90 — 90 Net loss $ ( 8,332 ) $ ( 2,819 ) $ ( 11,151 ) $ ( 28,282 ) $ ( 6,929 ) $ ( 35,211 ) Foreign currency translation adjustment ( 630 ) — ( 630 ) ( 1,012 ) — ( 1,012 ) Comprehensive loss $ ( 8,962 ) $ ( 2,819 ) $ ( 11,781 ) $ ( 29,294 ) $ ( 6,929 ) $ ( 36,223 ) Weighted average number of shares of common stock outstanding: Basic 82,548,892 — 82,548,892 81,878,814 — 81,878,814 Diluted 82,548,892 — 82,548,892 81,878,814 — 81,878,814 Net loss per share attributable to common stockholders: Basic $ ( 0.10 ) $ ( 0.04 ) $ ( 0.14 ) $ ( 0.35 ) $ ( 0.08 ) $ ( 0.43 ) Diluted $ ( 0.10 ) $ ( 0.04 ) $ ( 0.14 ) $ ( 0.35 ) $ ( 0.08 ) $ ( 0.43 ) The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $ 1,528 and $ 5,592 for the three and nine months ended September 30, 2023, respectively. (b) Interest Rate Swap - The correction of the misstatement resulted in a decrease to Other income (expense), net of $ 1,291 and $ 1,337 for the three and nine months ended September 30, 2023, respectively. The effects of the restatement on the condensed consolidated statement of cash flow for the nine months ended September 30, 2023 are summarized in the following table (in thousands): Nine Months Ended September 30, 2023 As Previously Reported Adjustments Ref Effect of Reclassification As Restated Cash flows from operating activities Net loss $ ( 28,282 ) $ ( 6,929 ) (a)(b) $ — $ ( 35,211 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 10,602 — — 10,602 Allowance for doubtful accounts 147 — — 147 Provision for excess and obsolete inventories 2,053 1,151 (a) — 3,204 Stock-based compensation 10,294 — — 10,294 Change in fair value of financial instruments — 1,337 (b) ( 1,394 ) ( 57 ) Other ( 1,428 ) — 1,394 ( 34 ) Changes in other assets and liabilities, net of acquisitions: Accounts receivable 3,706 — — 3,706 Inventories ( 35,558 ) 4,441 (a) — ( 31,117 ) Accounts payable 12,468 — — 12,468 Accrued expenses 3,718 — — 3,718 Accrued legal settlement ( 22,000 ) — — ( 22,000 ) Income tax receivable/payable ( 533 ) — — ( 533 ) Other assets and liabilities ( 2,704 ) — — ( 2,704 ) Net cash used in operating activities ( 47,517 ) — — ( 47,517 ) Cash flows from investing activities Purchases of property and equipment ( 21,893 ) — — ( 21,893 ) Proceeds from sale of property and equipment 795 — — 795 Purchases of intangible assets ( 933 ) — — ( 933 ) Net cash used in investing activities ( 22,031 ) — — ( 22,031 ) Cash flows from financing activities Payments on long-term debt ( 568 ) — — ( 568 ) Proceeds from issuance of common stock, net of issuance costs 68,453 — — 68,453 Proceeds from exercise of stock options 2,535 — — 2,535 Proceeds from employee stock purchase plan 560 — — 560 Payments on earnout liability ( 5,500 ) — — ( 5,500 ) Net cash provided by financing activities 65,480 — — 65,480 Effect of exchange rate changes on cash and cash equivalents 549 — — 549 Net decrease in cash and cash equivalents ( 3,519 ) — — ( 3,519 ) Cash and cash equivalents at beginning of period 38,468 — — 38,468 Cash and cash equivalents at end of period $ 34,949 $ — $ — $ 34,949 Supplemental disclosures of cash flow information: Restricted cash $ 1,000 $ — $ — $ 1,000 Cash paid for income taxes 610 — — 610 Cash paid for interest 3,342 — — 3,342 Purchase of property and equipment included in accounts payable 4,842 — — 4,842 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. As of and for the Three and Six Months Ended June 30, 2023: The effects of the restatement on the condensed consolidated balance sheet as of June 30, 2023 are summarized in the following table (in thousands, except share and per share data): June 30, 2023 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash and cash equivalents $ 56,747 $ — $ 56,747 Trade receivables, net of allowance for doubtful accounts of $ 1,706 34,331 — 34,331 Inventories, net 85,225 ( 3,724 ) (a) 81,501 Income taxes receivable 870 — 870 Other current assets 3,257 — 3,257 Total current assets 180,430 ( 3,724 ) 176,706 Property and equipment, net 70,936 — 70,936 Intangible assets, net 21,921 — 21,921 Goodwill 25,465 — 25,465 Deferred income taxes 319 — 319 Other assets 1,766 1,291 (b) 3,057 Total assets $ 300,837 $ ( 2,433 ) $ 298,404 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 29,681 $ — $ 29,681 Accrued expenses 24,390 — 24,390 Other current liabilities 1,700 — 1,700 Current maturities of long-term debt 652 — 652 Income taxes payable 20 — 20 Total current liabilities 56,443 — 56,443 Long-term liabilities: Long-term debt net, less current maturities 42,259 — 42,259 Other long-term liabilities 1,842 — 1,842 Deferred income taxes 620 — 620 Income taxes payable 635 — 635 Total liabilities 101,799 — 101,799 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 83,449,565 shares issued, and 82,536,046 shares outstanding as of June 30, 2023 824 — 824 Additional paid in capital 292,350 — 292,350 Accumulated deficit ( 87,739 ) ( 2,433 ) (a)(b) ( 90,172 ) Accumulated other comprehensive loss ( 415 ) — ( 415 ) Treasury stock, at cost; 913,519 shares as of June 30, 2023 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 199,038 ( 2,433 ) 196,605 Total liabilities & stockholders’ equity $ 300,837 $ ( 2,433 ) $ 298,404 The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 3,724 , including an increase to the beginning balance of Accumulated deficit of $ 983 for the three-months ended and a decrease to the beginning balance of Accumulated deficit of $ 340 for the six-months ended June 30, 2023. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other assets and a decrease to Accumulated deficit of $ 1,291 , including a decrease to the beginning balance of Accumulated deficit of $ 900 and $ 1,337 for the three- and six-months ended June 30, 2023, respectively. The effects of the restatement on the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2023 are summarized in the following table (in thousands except share and per share data): Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Ref As Previously Reported Adjustments As As Previously Reported Adjustments As Net revenue $ 51,009 $ — $ 51,009 $ 103,045 $ — $ 103,045 Cost of goods sold (a) 8,858 2,741 11,599 17,764 4,064 21,828 Gross profit 42,151 ( 2,741 ) 39,410 85,281 ( 4,064 ) 81,217 Operating expenses: Research and development costs 7,683 — 7,683 14,732 — 14,732 Selling, general, and administrative 43,827 — 43,827 87,647 — 87,647 Total operating expenses 51,510 — 51,510 102,379 — 102,379 Operating loss ( 9,359 ) ( 2,741 ) ( 12,100 ) ( 17,098 ) ( 4,064 ) ( 21,162 ) Other (expense) income: Other (expense) income, net (b) ( 467 ) 391 ( 76 ) ( 646 ) ( 46 ) ( 692 ) Interest expense, net ( 803 ) — ( 803 ) ( 2,008 ) — ( 2,008 ) Total other expense, net ( 1,270 ) 391 ( 879 ) ( 2,654 ) ( 46 ) ( 2,700 ) Loss before income taxes ( 10,629 ) ( 2,350 ) ( 12,979 ) ( 19,752 ) ( 4,110 ) ( 23,862 ) Income tax expense 269 — 269 198 — 198 Net loss $ ( 10,898 ) $ ( 2,350 ) $ ( 13,248 ) $ ( 19,950 ) $ ( 4,110 ) $ ( 24,060 ) Foreign currency translation adjustment ( 283 ) — ( 283 ) ( 382 ) — ( 382 ) Comprehensive loss $ ( 11,181 ) $ ( 2,350 ) $ ( 13,531 ) $ ( 20,332 ) $ ( 4,110 ) $ ( 24,442 ) Weighted average number of shares of common stock outstanding: Basic 82,373,441 — 82,373,441 81,536,607 — 81,536,607 Diluted 82,373,441 — 82,373,441 81,536,607 — 81,536,607 Net loss per share attributable to common stockholders: Basic $ ( 0.13 ) $ ( 0.03 ) $ ( 0.16 ) $ ( 0.24 ) $ ( 0.06 ) $ ( 0.30 ) Diluted $ ( 0.13 ) $ ( 0.03 ) $ ( 0.16 ) $ ( 0.24 ) $ ( 0.06 ) $ ( 0.30 ) The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $ 2,741 and $ 4,064 for the three and six months ended June 30, 2023, respectively. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other (expense) income, net of $ 391 and a decrease to Other (expense) income of $ 46 for the three and six months ended June 30, 2023, respectively. The effects of the restatement on the condensed consolidated statement of cash flow for the six months ended June 30, 2023 are summarized in the following table (in thousands): Six Months Ended June 30, 2023 As Previously Reported Adjustments Ref Effect of Reclassification As Restated Cash flows from operating activities Net loss $ ( 19,950 ) $ ( 4,110 ) (a)(b) $ — $ ( 24,060 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 6,414 — — 6,414 Allowance for doubtful accounts 147 — — 147 Provision for (reversal of) excess and obsolete inventories ( 205 ) 1,128 (a) — 923 Stock-based compensation 6,782 — — 6,782 Change in fair value of financial instruments — 46 (b) 320 366 Other 714 — ( 320 ) 394 Changes in other assets and liabilities, net of acquisitions: Accounts receivable 3,138 — — 3,138 Inventories ( 23,895 ) 2,936 (a) — ( 20,959 ) Accounts payable 14,745 — — 14,745 Accrued expenses 1,845 — — 1,845 Accrued legal settlement ( 22,000 ) — — ( 22,000 ) Income tax receivable/payable ( 359 ) — — ( 359 ) Other assets and liabilities ( 779 ) — — ( 779 ) Net cash used in operating activities ( 33,403 ) — — ( 33,403 ) Cash flows from investing activities Purchases of property and equipment ( 15,354 ) — — ( 15,354 ) Proceeds from sale of property and equipment 635 — — 635 Purchases of intangible assets ( 544 ) — — ( 544 ) Net cash used in investing activities ( 15,263 ) — — ( 15,263 ) Cash flows from financing activities Payments on long-term debt ( 396 ) — — ( 396 ) Proceeds from issuance of common stock, net of issuance costs 68,453 — — 68,453 Proceeds from exercise of stock options 2,464 — — 2,464 Proceeds from employee stock purchase plan 560 — — 560 Payments on earnout liability ( 4,250 ) — — ( 4,250 ) Net cash provided by financing activities 66,831 — — 66,831 Effect of exchange rate changes on cash and cash equivalents 114 — — 114 Net increase in cash and cash equivalents 18,279 — — 18,279 Cash and cash equivalents at beginning of period 38,468 — — 38,468 Cash and cash equivalents at end of period $ 56,747 $ — $ — $ 56,747 Supplemental disclosures of cash flow information: Restricted cash $ 2,250 $ — $ — $ 2,250 Cash paid for taxes 456 — — 456 Cash paid for interest 2,068 — — 2,068 Purchase of property and equipment included in accounts payable 5,617 — — 5,617 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. As of and for the Three Months Ended March 31, 2023: The effects of the restatement on the condensed consolidated balance sheet as of March 31, 2023 are summarized in the following table (in thousands, except share and per share data): March 31, 2023 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash and cash equivalents $ 85,883 $ — $ 85,883 Trade receivables, net of allowance for doubtful accounts of $ 1,816 37,262 — 37,262 Inventories, net 69,174 ( 983 ) (a) 68,191 Income taxes receivable 596 — 596 Other current assets 4,167 — 4,167 Total current assets 197,082 ( 983 ) 196,099 Property and equipment, net 66,810 — 66,810 Intangible assets, net 22,137 — 22,137 Goodwill 25,465 — 25,465 Deferred income taxes 354 — 354 Other assets 1,697 900 (b) 2,597 Total assets $ 313,545 $ ( 83 ) $ 313,462 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 20,538 $ — $ 20,538 Accrued expenses 25,446 — 25,446 Accrued legal settlement 13,000 — 13,000 Other current liabilities 3,772 — 3,772 Current maturities of long-term debt 690 — 690 Income taxes payable 208 — 208 Total current liabilities 63,654 — 63,654 Long-term liabilities: Long-term debt net, less current maturities 42,204 — 42,204 Other long-term liabilities 1,523 — 1,523 Deferred income taxes 377 — 377 Income taxes payable 635 — 635 Total liabilities 108,393 — 108,393 Commitments and contingencies Stockholders' equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 83,220,392 shares issued, and 82,306,873 shares outstanding as of March 31, 2023 821 — 821 Additional paid in capital 287,286 — 287,286 Accumulated deficit ( 76,841 ) ( 83 ) (a)(b) ( 76,924 ) Accumulated other comprehensive loss ( 132 ) — ( 132 ) Treasury stock, at cost; 913,519 shares as of June 30, 2023 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 205,152 ( 83 ) 205,069 Total liabilities & stockholders’ equity $ 313,545 $ ( 83 ) $ 313,462 The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 983 , including a decrease to the beginning balance of Accumulated deficit of $ 340 for the three months ended March 31, 2023. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other assets and an decrease to Accumulated deficit of $ 900 , including a decrease to the beginning balance of Accumulated deficit of $ 1,337 for the three months ended March 31, 2023. The effects of the restatement on the condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2023 are summarized in the following table (in thousands, except share and per share data): Three Months Ended March 31, 2023 As Previously Reported Adjustments Ref As Restated Net revenue $ 52,036 $ — $ 52,036 Cost of goods sold 8,906 1,323 (a) 10,229 Gross profit 43,130 ( 1,323 ) 41,807 Operating expenses: Research and development costs 7,049 — 7,049 Selling, general, and administrative 43,820 — 43,820 Total operating expenses 50,869 — 50,869 Operating loss ( 7,739 ) ( 1,323 ) ( 9,062 ) Other expense: Other expense ( 179 ) ( 437 ) (b) ( 616 ) Interest expense, net ( 1,205 ) — ( 1,205 ) Total other expense ( 1,384 ) ( 437 ) ( 1,821 ) Loss before income taxes ( 9,123 ) ( 1,760 ) ( 10,883 ) Income tax benefit ( 71 ) — ( 71 ) Net loss $ ( 9,052 ) $ ( 1,760 ) $ ( 10,812 ) Foreign currency translation adjustment ( 99 ) — ( 99 ) Comprehensive loss $ ( 9,151 ) $ ( 1,760 ) $ ( 10,911 ) Weighted average number of shares of common stock outstanding: Basic 80,681,715 — 80,681,715 Diluted 80,681,715 — 80,681,715 Net loss per share attributable to common stockholders: Basic $ ( 0.11 ) $ ( 0.02 ) $ ( 0.13 ) Diluted $ ( 0.11 ) $ ( 0.02 ) $ ( 0.13 ) The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $ 1,323 for the three months ended March 31, 2023. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other expense of $ 437 for the three months ended March 31, 2023. The effects of the restatement on the condensed consolidated statement of cash flow for the three months ended March 31, 2023 are summarized in the following table (in thousands): Three Months Ended March 31, 2023 As Previously Reported Adjustments Ref As Restated Cash flows from operating activities Net loss $ ( 9,052 ) $ ( 1,760 ) (a)(b) $ ( 10,812 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 3,117 — 3,117 Provision for excess and obsolete inventories 293 — 293 Stock-based compensation 3,182 — 3,182 Change in fair value of financial instruments 80 437 (b) 517 Other 100 — 100 Changes in other assets and liabilities, net of acquisitions: Accounts receivable 441 — 441 Inventories ( 8,435 ) 1,323 (a) ( 7,112 ) Accounts payable 5,592 — 5,592 Accrued expenses ( 877 ) — ( 877 ) Accrued legal settlement ( 9,000 ) — ( 9,000 ) Income tax payable 132 — 132 Other assets and liabilities 367 — 367 Net cash used in operating activities ( 14,060 ) — ( 14,060 ) Cash flows from investing activities Purchases of property and equipment ( 7,521 ) — ( 7,521 ) Proceeds from sale of property and equipment 223 — 223 Purchases of intangible assets ( 254 ) — ( 254 ) Net cash used in investing activities ( 7,552 ) — ( 7,552 ) Cash flows from financing activities Payments on long-term debt ( 197 ) — ( 197 ) Payments of debt issuance costs ( 7 ) — ( 7 ) Proceeds from issuance of common stock, net of issuance costs 68,449 — 68,449 Proceeds from exercise of stock options 1,622 — 1,622 Payments on earnout liability ( 500 ) — ( 500 ) Net cash provided by financing activities 69,367 — 69,367 Effect of exchange rate changes on cash ( 340 ) — ( 340 ) Net increase in cash 47,415 — 47,415 Cash at beginning of period 38,468 — 38,468 Cash at end of period $ 85,883 $ — $ 85,883 Supplemental disclosures of cash flow information: Cash paid for taxes $ — $ — $ — Cash paid for interest 601 — 601 Purchase of property and equipment included in accounts payable 4,026 — 4,026 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. 2023 Effect of Restatement on the Condensed Consolidated Statement of Stockholders' Equity: The effects of the restatement on the condensed consolidated statements of stockholders' equity for each of the three periods ended March 31, 2023, June 30, 2023, and September 30, 2023, are summarized in the following table, respectively: Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, January 1, 2023 77,770,588 $ 776 $ 213,956 $ ( 67,789 ) $ ( 33 ) $ ( 5,982 ) $ 140,928 Net loss — — — ( 9,052 ) — — ( 9,052 ) Issuance of common stock 4,312,500 43 68,406 — — — 68,449 Options exercised 223,785 2 1,620 — — — 1,622 Foreign currency translation — — — — ( 99 ) — ( 99 ) Employee stock purchase plan — — 122 — — — 122 Stock-based compensation — — 3,182 — — — 3,182 Balance, March 31, 2023 82,306,873 821 287,286 ( 76,841 ) ( 132 ) ( 5,982 ) 205,152 Adjustments Balance, January 1, 2023 — — — 1,677 — — 1,677 Net loss (a)(b) — — — ( 1,760 ) — — ( 1,760 ) Issuance of common stock — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, March 31, 2023 — — — ( 83 ) — — ( 83 ) As Restated Balance, January 1, 2023 77,770,588 776 213,956 ( 66,112 ) ( 33 ) ( 5,982 ) 142,605 Net loss — — — ( 10,812 ) — — ( 10,812 ) Issuance of common stock 4,312,500 43 68,406 — — — 68,449 Options exercised 223,785 2 1,620 — — — 1,622 Foreign currency translation — — — — ( 99 ) — ( 99 ) Employee stock purchase plan — — 122 — — — 122 Stock-based compensation — — 3,182 — — — 3,182 Balance, March 31, 2023 82,306,873 $ 821 $ 287,286 $ ( 76,924 ) $ ( 132 ) $ ( 5,982 ) $ 205,069 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, March 31, 2023 82,306,873 $ 821 $ 287,286 $ ( 76,841 ) $ ( 132 ) $ ( 5,982 ) $ 205,152 Net loss — — — ( 10,898 ) — — ( 10,898 ) Offering costs associated with public offering — — 4 — — — 4 Options exercised 192,027 3 840 — — — 843 Foreign currency translation — — — — ( 283 ) — ( 283 ) Employee stock purchase plan 37,146 — 620 — — — 620 Stock-based compensation — — 3,600 — — — 3,600 Balance, June 30, 2023 82,536,046 824 292,350 ( 87,739 ) ( 415 ) ( 5,982 ) 199,038 Adjustments Balance, March 31, 2023 — — — ( 83 ) — — ( 83 ) Net loss (a)(b) — — — ( 2,350 ) — — ( 2,350 ) Offering costs associated with public offering — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, June 30, 2023 — — — ( 2,433 ) — — ( 2,433 ) As Restated Balance, March 31, 2023 82,306,873 821 287,286 ( 76,924 ) ( 132 ) ( 5,982 ) 205,069 Net loss — — — ( 13,248 ) — — ( 13,248 ) Offering costs associated with public offering — — 4 — — — 4 Options exercised 192,027 3 840 — — — 843 Foreign currency translation — — — — ( 283 ) — ( 283 ) Employee stock purchase plan 37,146 — 620 — — — 620 Stock-based compensation — — 3,600 — — — 3,600 Balance, June 30, 2023 82,536,046 $ 824 $ 292,350 $ ( 90,172 ) $ ( 415 ) $ ( 5,982 ) $ 196,605 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, June 30, 2023 82,536,046 $ 824 $ 292,350 $ ( 87,739 ) $ ( 415 ) $ ( 5,982 ) $ 199,038 Net loss — — — ( 8,332 ) — — ( 8,332 ) Options exercised 19,861 — 70 — — — 70 Foreign currency translation — — — — ( 630 ) — ( 630 ) Employee stock purchase plan — — 86 — — — 86 Stock-based compensation — — 3,512 — — — 3,512 Balance, September 30, 2023 82,555,907 824 296,018 ( 96,071 ) ( 1,045 ) ( 5,982 ) 193,744 Adjustments Balance, June 30, 2023 — — — ( 2,433 ) — — ( 2,433 ) Net loss (a)(b) — — — ( 2,819 ) — — ( 2,819 ) Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, September 30, 2023 — — — ( 5,252 ) — — ( 5,252 ) As Restated Balance, June 30, 2023 82,536,046 824 292,350 ( 90,172 ) ( 415 ) ( 5,982 ) 196,605 Net loss — — — ( 11,151 ) — — ( 11,151 ) Options exercised 19,861 — 70 — — — 70 Foreign currency translation — — — — ( 630 ) — ( 630 ) Employee stock purchase plan — — 86 — — — 86 Stock-based compensation — — 3,512 — — — 3,512 Balance, September 30, 2023 82,555,907 $ 824 $ 296,018 $ ( 101,323 ) $ ( 1,045 ) $ ( 5,982 ) $ 188,492 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. As of and for the Three and Nine Months Ended September 30, 2022: The effects of the revision on the condensed consolidated balance sheet as of September 30, 2022 are summarized in the following table (in thousands, except share and per share data): September 30, 2022 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash $ 56,325 $ — $ 56,325 Trade receivables, net of allowance for doubtful accounts of $ 1,990 35,960 — 35,960 Inventories, net 54,771 90 (a) 54,861 Income taxes receivable 705 — 705 Other current assets 1,947 — 1,947 Total current assets 149,708 90 149,798 Property and equipment, net 58,591 — 58,591 Intangible assets, net 20,850 — 20,850 Goodwill 26,975 — 26,975 Deferred income taxes 841 — 841 Other assets — 1,303 (b) 1,303 Total assets $ 256,965 $ 1,393 $ 258,358 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 13,979 $ — $ 13,979 Accrued expenses 19,507 — 19,507 Other current liabilities 6,889 — 6,889 Current maturities of long-term debt 735 — 735 Income taxes payable 497 — 497 Total current liabilities 41,607 — 41,607 Long-term liabilities: Long-term debt net, less current maturities 42,492 — 42,492 Other long-term liabilities 907 — 907 Deferred income taxes 59 — 59 Income taxes payable 527 — 527 Total liabilities 85,592 — 85,592 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 77,990,290 shares issued, and 77,076,771 shares outstanding as of September 30, 2022 769 — 769 Additional paid in capital 207,109 — 207,109 Accumulated deficit ( 29,026 ) 1,393 (a)(b) ( 27,633 ) Accumulated other comprehensive loss ( 1,497 ) — ( 1,497 ) Treasury stock, at cost; 913,519 shares as of September 30, 2022 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 171,373 1,393 172,766 Total liabilities & stockholders’ equity $ 256,965 $ 1,393 $ 258,358 The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Inventories, net and a decrease to Accumulated deficit of $ 90 , including an increase to the beginning balance of Accumulated deficit of $ 198 for the three months ended September 30, 2022. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other assets and a decrease to Accumulated deficit of $ 1,303 , including a decrease to the beginning balance of Accumulated deficit of $ 414 for the three months ended September 30, 2022. The effects of the revision on the condensed consolidated statement of oper

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2023
Accounting Policies [Abstract]
Basis of Presentation and Consolidation	Basis of Presentation and Consolidation The accompanying Consolidated Financial Statements include the accounts of Paragon 28, Inc. and its subsidiaries, all of which are wholly-owned. All intercompany balances and transactions have been eliminated in consolidation. The accompanying Consolidated Financial Statements have been prepared in conformity with accounting principles generally accepted in the U.S. (“U.S. GAAP”).
Use of Estimates	Use of Estimates The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Because future events and their effects cannot be determined with precision, actual results could differ significantly from these estimates. Any changes in these estimates will be reflected in the Company’s Consolidated Financial Statements. Significant items subject to such estimates and assumptions include the determination of the credit loss reserves for trade receivables, inventory obsolescence, impairment of long-lived assets, recoverability of goodwill and intangible assets, contingent earn-out liability, interest rate swap valuation, income taxes and stock-based compensation.
Foreign Currency Translation	Foreign Currency Translation The Consolidated Financial Statements are presented in U.S. dollars. The Company’s non-U.S. subsidiaries have a functional currency (i.e., the currency in which operational activities are primarily conducted) that is other than the U.S. dollar, generally the currency of the country in which such subsidiaries are domiciled. Such subsidiaries’ assets and liabilities are translated into U.S. dollars at year-end exchange rates, while revenue and expenses are translated at average exchange rates during the year based on the daily closing exchange rates. Adjustments that result from translating amounts from a subsidiary’s functional currency to U.S. dollars are reported in Accumulated other comprehensive loss, net of tax, a separate component of stockholders' equity. Transactions made in a currency other than the functional currency are remeasured to the functional currency at the exchange rates on the dates of the transaction. Foreign exchange gains and losses are recorded within Other income (expense), net on the Consolidated Statements of Operations and Comprehensive Loss.
Business Combinations	Business Combinations We allocate the purchase consideration to the identifiable net assets acquired, including intangible assets and liabilities assumed, based on estimated fair values at the date of the acquisition. The excess of the fair value of the purchase consideration over the fair value of the identifiable assets and liabilities, if any, is recorded as goodwill. During the measurement period, which is up to one year from the acquisition date, we may adjust provisional amounts that were recognized at the acquisition date to reflect new information obtained about facts and circumstances that existed as of the acquisition date. Determining the fair value of assets acquired and liabilities assumed requires significant judgment, including the selection of valuation methodologies including the income approach, the cost approach, and the market approach. Significant assumptions used in those methodologies include, but are not limited to, the expected values of the underlying metric, the systematic risk embedded in the underlying metric, the volatility of the underlying metric, the risk-free rate, and the counterparty risk. The use of different valuation methodologies and assumptions is highly subjective and inherently uncertain and, as a result, actual results may differ materially from estimates.
Cash	Cash Cash and cash equivalents include cash, money market funds, and highly liquid investments with an original maturity of three months or less. As of December 31, 2023, $ 1,000 related to the achievement of an Additive Orthopaedics acquisition milestone was included as restricted cash within the Consolidated Balance Sheets and Consolidated Statement of Cash Flows. For additional information regarding the Additive Orthopaedics acquisition refer to Note 4 to our Consolidated Financial Statements. There were no contractual or other restrictions as to the use of cash for the years ended December 31, 2022 or 2021.
Trade Receivables, Less Allowance for Doubtful Accounts	Trade Receivables, Less Allowance for Doubtful Accounts Trade receivables due from customers are uncollateralized customer obligations due under normal trade terms requiring payment within 30 days from the invoice date and are stated at the amount billed to the customer. Trade receivables also include unbilled receivables due from customers that represent completed surgical cases that are pending customer-issued purchase orders. These unbilled receivables are covered by agreements with customers, the products have typically been used in a surgery, and collection is determined to be probable. The Company estimates an allowance for doubtful accounts based upon an evaluation of the current status of receivables, historical experience, and other factors as necessary. It is reasonably possible that the Company’s estimate of the allowance for doubtful accounts will change. The following table presents the activity in the allowance for doubtful accounts for the years ended December 31, 2023 and 2022. December 31, 2023 2022 Allowance for doubtful accounts, beginning of year $ 1,688 $ 1,032 Additions charged against revenue or to expense 223 1,853 Write-offs ( 572 ) ( 1,197 ) Allowance for doubtful accounts, end of year $ 1,339 $ 1,688
Inventories, Net	Inventories, Net Inventories are considered finished goods and are purchased from third party contract manufacturers. These inventories consist of implants, hardware, and consumables and are held in our warehouse, with third-party independent sales representatives or distributors, or consigned directly with hospitals. Inventories are stated at the lower of cost or net realizable value, with the US inventory cost determined on a first-in first out basis or and International inventory cost determined on weighed average cost basis. When sold, inventory is relieved at weighted average cost. We evaluate the carrying value of our inventories in relation to historical sales, current inventory levels, and consideration of the life cycle of the product. A significant decrease in demand or development of products could result in an increase in the amount of excess inventory on hand, which could lead to additional charges for excess and obsolete inventory. The Company estimates a reserve for obsolete and slow-moving inventory based on current inventory levels and historical sales. E xpense for excess and obsolete inventory is included in Cost of goods sold. The inventory reserve was $ 20,921 and $ 16,804 as of December 31, 2023 and 2022, respectively. The need to maintain substantial levels of inventory impacts our estimates for excess and obsolete inventory. Each of our implant systems are designed to include implantable products that come in different sizes and shapes to accommodate the surgeon’s needs related to the patient’s anatomical size. Typically, a small number of the set components are used in each surgical procedure. Certain components within each set may become obsolete before other components based on the usage patterns. We adjust inventory values, as needed, to reflect these usage patterns and life cycle.
Property and Equipment, Net	Property and Equipment, Net Property and equipment are recorded at cost less accumulated depreciation. Expenditures for renewals and improvements that significantly add to the productive capacity or extend the useful life of an asset are capitalized and included in Property and equipment, net in the Consolidated Balance Sheets. Expenditures for maintenance and repairs are charged to expense as incurred and are included in Selling, general, and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. When equipment is retired or sold, the cost and related accumulated depreciation are eliminated from the accounts and the resulting gain or loss is included in included in Selling, general and administrative in the Consolidated Statements of Operations and Comprehensive Loss. Depreciation is provided using the straight-line method based on useful lives of the assets which range from three to twenty-five years , which best reflects the pattern of use. The Company depreciates surgical instrumentation, once available for use, over a five-year period and in certain cases, once available for use, over a three-year period. Depreciation for surgical instrumentation used in surgery is included in Selling, general, and administrative expense in the Consolidated Statements of Operations and Comprehensive Loss. Leasehold improvements are amortized using the straight-line method over the shorter of the asset’s useful life or the lease term. Property and equipment are assessed for impairment upon triggering events that indicate that the carrying value of an asset group may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows of the asset group expected to be generated from its use and eventual disposition. If the asset group’s carrying value is determined to not be recoverable, the impairment to be recognized is measured by which the carrying amount exceeds the fair value of the asset group. No impairment charges related to property and equipment were recorded in any of the periods presented.
Intangibles	Intangibles The costs associated with applying for patents and trademarks are capitalized. Patents are amortized on a straight-line basis over the lesser of the patent’s economic or legal life, which is seventeen years . Costs associated with capitalized patents include third-party attorney fees and other third-party fees as well as costs related to the following: the preparation of patent applications, government filings and registration fees, drawings, computer searches, and translations related to specific patents. Trademarks that are anticipated to be renewed every ten years have an indefinite life and are not amortized but tested for impairment annually. Once it is determined a trademark will no longer be renewed, the trademark is amortized over the remainder of the trademark’s registration period. Customer relationships are amortized over an estimated useful life of three to seven years on a straight-line basis. Other intangibles, which mainly consist of noncompete arrangements, are amortized over an estimated useful life of three years on a straight-line basis. Developed technology is amortized over an estimated useful life of twelve years on a straight-line basis. Amortizable intangible assets are assessed for impairment upon triggering events that indicate that the carrying value of an asset may not be recoverable. Recoverability is measured by a comparison of the carrying amount to future net undiscounted cash flows expected to be generated by the associated asset. If the asset’s carrying value is determined to not be recoverable, the impairment to be recognized is measured by the amount by which the carrying amount exceeds the fair market value of the intangible assets. No impairment charges related to amortizable assets were recorded for the years ended December 31, 2023, 2022 and 2021. Indefinite-lived trademark assets are reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying value of an asset may not be recoverable. The Company can elect to first apply the optional qualitative impairment assessment to determine whether the indefinite-lived intangible asset is more-likely-than-not impaired. If, on the basis of the qualitative impairment assessment, an entity asserts that it is more likely than not that the indefinite-lived intangible asset is impaired, the Company would be required to calculate the fair value of the asset for an impairment test. Impairment loss is recognized if the carrying amount of the asset exceeds its fair value. A qualitative assessment considers macroeconomic and other industry-specific factors, such as trends in short-term and long-term interest rates and the ability to access capital, and company specific factors such as trends in revenue generating activities, and merger or acquisition activity. If the Company elects to bypass qualitatively assessing its indefinite-lived intangible assets, or it is not more likely than not that the fair value of the intangible asset exceeds its carrying value, management estimates the fair value of the intangible asset and compares it to the carrying value. The estimated fair value of the intangible asset is established using an income approach based on a discounted cash flow model that includes significant assumptions about the future operating results and cash flows of the intangible asset or assets. The Company elected to perform a qualitative analysis for its indefinite-lived intangible assets as of October 1, 2023, the annual test date. The Company determined, after performing the qualitative analysis that there was no evidence that it is more likely than not that the fair value of its intangible assets was less than the carrying amount. Therefore, it was not necessary to perform a quantitative impairment test.
Goodwill	Goodwill Goodwill represents the excess of the purchase price as compared to the fair value of net assets acquired and liabilities assumed. Goodwill is not amortized but is tested for impairment annually or when indications of impairment exist. Goodwill is tested at the reporting unit level as defined in ASC 350. Per this definition, a reporting unit is an operating segment or one level below an operating segment. The Company has determined one reporting unit for the purpose of goodwill impairment. We can elect to qualitatively assess goodwill for impairment if it is more likely than not that the fair value of a reporting unit exceeds its carrying value. Impairment exists when the carrying amount, including goodwill, of the reporting unit exceeds its fair value, resulting in an impairment charge for this excess (not t o exceed the carrying amount of the goodwill). The impairment, if determined, is recorded within Operating expenses in the Consolidated Statements of Operations and Comprehensive Loss in the period the determination is made.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value is an exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. There is a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies in measuring fair value: Level 1 - Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets. Level 2 - Includes other inputs that are directly or indirectly observable in the marketplace, such as quoted market prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3 - Unobservable inputs which are supported by little or no market activity. Financial instruments (principally cash and cash equivalents , trade receivables, accounts payable and accrued expenses) are carried at cost, which approximates fair value due to the short-term maturity of these instruments. The majority of our debt is carried at cost, which approximates fair value due to the variable interest rate associated with our debt. However, we are the fixed rate payor on an interest rate swap contract associated with the Company’s Zions Facility, which is classified as Level 2. We reassess the fair value of our interest rate swap on a quarterly basis. The change in fair value is recorded in Other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss. The Company does not have any assets or liabilities presented in the Level 1 category as of December 31, 2023, and 2022, and there were no changes in level hierarchies during the years ended December 31, 2023, 2022 and 2021. See “ Contingent Earn-out Consideration” below for a discussion on our Level 3 inputs.
Contingent Earn-Out Consideration	Contingent Earn-out Consideration Business combinations may include contingent earn-out consideration as part of the purchase price under which the Company will make future payments to the seller upon the achievement of certain milestones. The fair value of the contingent earn-out consideration is estimated as of the acquisition date at the present value of the expected contingent payments and is subsequently remeasured at each balance sheet date. Two methodologies may be considered in the valuation: the scenario-based model (“SBM”) and Monte Carlo simulation. The SBM relies on multiple outcomes to estimate the likelihood of future payoff of the contingent consideration. The resulting earnout payoff is then probability-weighted and discounted at an appropriate risk adjusted rate in order to arrive at the present value of the expected earnout payment. The Monte Carlo simulation is used to value the non-linear contingent considerations based on projected financial metrics. Each trial of the Monte Carlo simulation draws a value from the assumed distribution for the underlying metric. The earnout payoff for each simulation trial is calculated based on that particular simulated path for the underlying metrics and then discounted to present value using the risk-free rate, adjusted for counterparty credit risk. The value of the earnout is estimated as the average value from all simulation trials. The fair value estimates use unobservable inputs that reflect our own assumptions as to the ability of the acquired business to meet the targeted benchmarks and discount rates used in the calculations. The unobservable inputs are defined in ASC Topic 820, Fair Value Measurements and Disclosures, as Level 3 inputs. We review the probabilities of achievement of the earnout milestones to determine impact on the fair value of the earnout consideration on a quarterly basis over the earn-out period. Actual results are compared to the estimates and probabilities of achievement used in our forecasts. Should actual results of the acquired business increase or decrease as compared to our estimates and assumptions, the estimated fair value of the contingent earn-out consideration liability will increase or decrease, up to the contractual limit, as applicable. Changes in the estimated fair value of the contingent earn-out consideration are recorded in Other income (expense), net in the Consolidated Statements of Operations and Comprehensive Loss and are reflected in the period in which they are identified. Changes in the estimated fair value of the contingent earn-out consideration may materially impact or cause volatility in our operating results.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date. The Company regularly reviews its deferred tax assets for recoverability and establishes a valuation allowance if it is more likely than not that some portion, or all, of a deferred tax asset will not be realized. The determination as to whether a deferred tax asset will be realized is made on a jurisdictional basis and is based on both positive and negative evidence. This evidence includes historic taxable income, projected future taxable income, the expected timing of the reversal of existing temporary differences and the implementation of tax planning strategies. The Company records uncertain tax positions in accordance with Accounting Standards Codification (“ASC”) Topic 740 on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company evaluates its tax positions that have been taken or are expected to be taken on income tax returns to determine if an accrual is necessary for uncertain tax positions. The Company will recognize interest and penalties as a component of income tax expense if incurred.
Revenue Recognition	Revenue Recognition We account for revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers (“ASC 606”). Revenue is generated primarily from the sale of our implants and disposables and, to a much lesser extent, from the sale of our surgical instrumentation. We sell our products through employee sales personnel and independent sales representatives in the U.S. Outside the U.S., sales are through independent sales representatives and to stocking distributors. We have consignment agreements with certain distributors and hospitals. Our customers are primarily hospitals and surgery centers. Revenue is recorded, net of estimated discounts and other price concessions, when our performance obligation is satisfied which is when our customers take title of the product, and typically when the product is used in surgery. We generally have written contracts with our customers which incorporate pricing and our standard terms and conditions. Any discounts we offer are outlined in our customer agreements. As the discounts are known at the time of purchase, no estimates are required at the time of revenue recognition. Shipping and handling costs are recorded as cost of goods sold and amounts billed to customers for shipping and handling costs are recorded in revenue. We record as revenue any amounts billed to customers for shipping and handling costs and record as cost of goods sold the actual shipping costs incurred. We have elected to exclude from the measurement of the transaction price all taxes (e.g., sales, use, value-added) assessed by government authorities and collected from a customer. Therefore, revenue is recognized net of such taxes. We have elected to use the practical expedient allowed under ASC 606 to account for shipping and handling activities that occur after the customer has obtained control of a promised good as fulfillment costs rather than as an additional promised service and, therefore, we do not allocate a portion of the transaction price to a shipping service obligation. Commissions to sales agents for the sales exceeding their quotas are classified as incremental costs of obtaining a contract as such costs would not have been incurred if the contract was not signed. We have elected to use the practical expedient to expense such costs that should be capitalized as the amortization period of the costs would be less than one year . Due to the nature of our products, returns are minimal and an estimate for returns is not material. The timing of revenue recognition may differ from the timing of invoicing to our customers . We recorded unbilled revenue of $ 5,598 and $ 4,511 as of December 31, 2023, and December 31, 2022 , respectively. Determining unbilled revenue involves management judgment.
Cost of Goods Sold	Cost of Goods Sold Cost of goods sold consists primarily of products purchased from third-party suppliers, freight, shipping, excess and obsolete inventory charges and royalties. Implants are manufactured to our specifications by third-party suppliers. Most implants are produced in the U.S. Cost of goods sold is recognized for consigned implants at the time the implant is used in surgery and the related revenue is recognized. Prior to their use in surgery, the cost of consigned implants is recorded as Inventories, net in our Consolidated Balance Sheets.
Stock-Based Compensation	Stock-Based Compensation All stock-based awards to employees and nonemployee contractors, including any grants of stock, stock options, restricted stock units (“RSU”), performance stock units (“PSU”) and the option to purchase common stock under the Employee Stock Purchase Plan (“ESPP”), are measured at fair value at the grant date and recognized over the relevant vesting period in accordance with the ASC Topic 718, Compensation - Stock Compensation (“ASC 718”). Stock-based awards to nonemployees are recognized as a selling, general and administrative expense over the period of performance. Such awards are measured at fair value at the date of grant. In addition, for awards that vest immediately, the awards are measured at fair value and recognized in full at the grant date. The Company estimates the fair value of each stock-option award containing service and/or performance conditions on the grant date using the Black-Scholes option valuation model which incorporates assumptions as to stock price volatility, the expected life of the options, risk-free interest rate and dividend yield. The Company relies on its historical volatility as an input to the option pricing model as management believes that this rate will be representative of future volatility over the expected term of the options. The expected term until exercise represents the weighted-average period of time that options granted are expected to be outstanding giving consideration to vesting schedules and the Company’s historical exercise patterns. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant. The Company has not paid any dividends since its inception and does not anticipate paying any dividends for the foreseeable future, so the dividend yield is assumed to be zero. The Company estimates forfeitures of share-based awards at the time of grant and revises such estimates in subsequent periods if actual forfeitures differ from original estimates. Option awards are generally granted with an exercise price equal to the fair value of the Company’s common stock at the date of grant. Subsequent to the IPO, the fair value of the Company’s common stock underlying its equity awards is based on the quoted market price of the Company’s common stock on the grant date. Prior to the IPO, because there was no public market for the Company’s common stock, the fair value of the common stock underlying the stock awards has historically been determined at the time of grant of the stock option by considering a number of objective and subjective factors, including sales of shares of common stock, third-party valuations performed, important developments in the Company’s operations, actual operating results and financial performance, the conditions in the medical device industry and the economy in general, and the stock price performance, volatility of comparable public companies, and an assumption for a discount for lack of marketability, among other factors.
Research and Development	Research and Development Research and development expense is comprised of in-house research and development of new products and technologies, clinical studies and trials, regulatory expenses, and employee related compensation and expenses. We maintain a procedurally focused approach to product development and have projects underway to add new products to our existing systems and to add new systems across multiple foot and ankle indications.
Leases	At the inception of a contractual arrangement, the Company determines whether the contract contains a lease by assessing whether there is an identified asset and whether the contract conveys the right to control the use of the identified asset in exchange for consideration over a period of time. If both criteria are met, the Company calculates the associated lease liability and corresponding right-of-use asset upon lease commencement using a discount rate based on a borrowing rate commensurate with the term of the lease. The Company records lease liabilities within current liabilities or long-term liabilities based upon the length of time associated with the lease payments. The Company records its operating lease right-of-use assets within Other assets.
Contingencies	Contingencies A liability is contingent if the amount is not presently known but may become known in the future as a result of the occurrence of some uncertain future event. We accrue a liability for an estimated loss if we determine that the potential loss is probable of occurring and the amount can be reasonably estimated. Significant judgment is required in both the determination of probability and the determination as to whether the amount of an exposure is reasonably estimable, and accruals are based only on the information available to our management at the time the judgment is made. We expense legal costs, including those legal costs incurred in connection with a loss contingency, as incurred.
Recently Adopted and Issued Accounting Pronouncements	Recently Adopted Accounting Pronouncements In December 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2019-12, Income Taxes (Topic 740) (“ASU 2019-12”), which is part of the FASB’s overall simplification initiative to reduce the costs and complexity of applying accounting standards while maintaining or improving the usefulness of the information provided to users of financial statements. ASU 2019-12 simplifies accounting guidance for intra-period a llocations, deferred tax liabilities, year-to-date losses in interim periods, franchise taxes, step-up in tax basis of goodwill, separate entity financial statements, and interim recognition of tax laws or rate changes. The Company adopted ASU 2019-12 effective January 1, 2023 . The adoption of this guidance did not have a significant impact on the Company ’s Consolidated Financial Statements and related disclosures. In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”), which requires entities to estimate all expected credit losses for certain types of financial instruments, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The updated guidance also expands the disclosure requirements to enable users of financial statements to understand the entity’s assumptions, models and methods for estimating expected credit losses over the entire contractual term of the instrument from the date of initial recognition of that instrument. The Company adopted ASU 2016-13 effective January 1, 2023 . The adoption of this guidance did not have a significant impact on the Company ’s Consolidated Financial Statements and related disclosures. Recently Issued Accounting Pronouncements In October 2023, the FASB issued Accounting Standards Update ASU 2023-06, Disclosure Improvements: Codification Amendments in Response to the SEC’s Disclosure Update and Simplification Initiative (“ASU 2023-06”). The amendments in ASU 2023-06 modify the disclosure or presentation requirements of a variety of Topics in the Codification. Certain of the amendments represent clarifications to or technical corrections of the current requirements. ASU 2023-06 is applicable to all entities subject to the SEC’s existing disclosure requirements. The effective date for each amendment will be the date on which the SEC’s removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The Company is currently evaluating the amendments in ASU 2023-06 and does not expect the adoption to have a significant impact on the Company’s related disclosures. In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which provides amendments to improve reportable segment disclosures requirements. The amendments in ASU 2023-07 are effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The Company is currently evaluating the amendments in ASU 2023-07 to determine the impact it will have on the Company's Consolidated Financial Statements and related notes for the year ended December 31, 2024, upon adoption. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), to enhance the transparency and decision usefulness of income tax disclosures. The main provisions in ASU 2023-09 enhance the disclosure requirements of rate reconciliations and income taxes paid. For public business entities, the amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The amendments in this update should be applied on a prospective basis, retrospective application is permitted. The Company is currently evaluating the amendments in this guidance to determine the impact it will have on the Company’ s Consolidated Financial Statements and related disclosures.
Reclassification of Prior Year Presentation	Reclassification of Prior Year Presentation In addition to the correction of errors described in Note 3. Restatement of Previously Issued Consolidated Financial Statements, certain prior period amounts have been reclassified for consistency with the current year presentation within this Note 18. 2022 Quarterly Financial Data (Unaudited). These reclassifications had no effect on the reported results of operations.

Restatement Of Previously Iss_2

Restatement Of Previously Issued Consolidated Financial Statements (Tables)	12 Months Ended
	Dec. 31, 2023
Accounting Changes and Error Corrections [Abstract]
Schedule of Restatement of Previously Issued Condensed Consolidated FInancial Statements	The following tables reflect the impact of the Restatement of the Company’s previously reported consolidated financial statements: PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEET Year ended December 31, 2023 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash and cash equivalents $ 75,639 $ — $ 75,639 Trade receivables, net of allowance for doubtful accounts of $ 1,339 37,323 — 37,323 Inventories, net 98,062 ( 8,016 ) (a) 90,046 Income taxes receivable 794 — 794 Other current assets 3,997 — 3,997 Total current assets 215,815 ( 8,016 ) 207,799 Property and equipment, net 74,122 — 74,122 Intangible assets, net 21,674 — 21,674 Goodwill 25,465 — 25,465 Deferred income taxes 705 — 705 Other assets 2,918 — 2,918 Total assets $ 340,699 $ ( 8,016 ) $ 332,683 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 21,696 $ — $ 21,696 Accrued expenses 27,781 — 27,781 Other current liabilities 883 — 883 Current maturities of long-term debt 640 — 640 Income taxes payable 243 — 243 Total current liabilities 51,243 — 51,243 Long-term liabilities: Long-term debt net, less current maturities 109,799 — 109,799 Other long-term liabilities 1,048 — 1,048 Deferred income taxes 233 — 233 Income taxes payable 635 — 635 Total liabilities 162,958 — 162,958 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 83,738,974 shares issued, and 82,825,455 shares outstanding as of December 31, 2023 827 — 827 Additional paid in capital 298,394 — 298,394 Accumulated deficit ( 115,630 ) ( 8,016 ) (a) ( 123,646 ) Accumulated other comprehensive income 132 — 132 Treasury stock, at cost; 913,519 shares as of December 31, 2023 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 177,741 ( 8,016 ) 169,725 Total liabilities & stockholders’ equity $ 340,699 $ ( 8,016 ) $ 332,683 The description of the error is in the Description of Misstatement Adjustments provided herein this Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 8,016 , including a decrease to the beginning balance of Accumulated deficit of $ 340 as of December 31, 2023. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENT OF OPERATIONS AND COMPREHENSIVE LOSS Year Ended December 31, 2023 As Previously Reported Adjustments Ref As Restated Net revenue $ 216,389 $ — $ 216,389 Cost of goods sold 43,598 8,356 (a) 51,954 Gross profit 172,791 ( 8,356 ) 164,435 Operating expenses: Research and development costs 30,078 — 30,078 Selling, general, and administrative 180,022 — 180,022 Total operating expenses 210,100 — 210,100 Operating loss ( 37,309 ) ( 8,356 ) ( 45,665 ) Other income (expense): Other income (expense), net 154 ( 1,337 ) (b) ( 1,183 ) Loss on early extinguishment of debt ( 5,308 ) — ( 5,308 ) Interest expense, net ( 5,165 ) — ( 5,165 ) Total other expense ( 10,319 ) ( 1,337 ) ( 11,656 ) Loss before income taxes ( 47,628 ) ( 9,693 ) ( 57,321 ) Income tax expense 213 — 213 Net loss $ ( 47,841 ) $ ( 9,693 ) $ ( 57,534 ) Foreign currency translation adjustment 165 — 165 Comprehensive loss $ ( 47,676 ) $ ( 9,693 ) $ ( 57,369 ) Weighted average number of shares of common stock outstanding: Basic 82,087,329 — 82,087,329 Diluted 82,087,329 — 82,087,329 Net loss per share attributable to common stockholders: Basic $ ( 0.58 ) $ ( 0.12 ) $ ( 0.70 ) Diluted $ ( 0.58 ) $ ( 0.12 ) $ ( 0.70 ) The description of each error is in the Description of Misstatement Adjustments provided herein this Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $ 8,356 for the period ended December 31, 2023. (b) Interest Rate Swap - The correction of the misstatement resulted in a decrease to Other income (expense), net of $ 1,337 for the period ended December 31, 2023, and an equal impact to the beginning balance of Accumulated deficit. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SERIES EQUITY & STOCKHOLDERS’ EQUITY Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Income (Loss) Stock Equity Balance, December 31, 2022 77,770,588 $ 776 $ 213,956 $ ( 67,789 ) $ ( 33 ) $ ( 5,982 ) $ 140,928 Net loss — — — ( 47,841 ) — — ( 47,841 ) Issuance of common stock net of issuance costs of $ 827 4,312,500 43 68,410 — — — 68,453 Options exercised 668,925 7 2,399 — — — 2,406 Foreign currency translation — — — — 165 — 165 Employee stock purchase plan 73,442 1 1,265 — — — 1,266 Stock-based compensation — — 12,364 — — — 12,364 Balance, December 31, 2023 82,825,455 827 298,394 ( 115,630 ) 132 ( 5,982 ) 177,741 Adjustments Balance, December 31, 2022 — — — 1,677 — — 1,677 Net loss (a)(b) — — — ( 9,693 ) — — ( 9,693 ) Issuance of common stock net of issuance costs of $ 827 — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, December 31, 2023 — — — ( 8,016 ) — — ( 8,016 ) As Restated Balance, December 31, 2022 77,770,588 776 213,956 ( 66,112 ) ( 33 ) ( 5,982 ) 142,605 Net loss — — — ( 57,534 ) — — ( 57,534 ) Issuance of common stock net of issuance costs of $ 827 4,312,500 43 68,410 — — — 68,453 Options exercised 668,925 7 2,399 — — — 2,406 Foreign currency translation — — — — 165 — 165 Employee stock purchase plan 73,442 1 1,265 — — — 1,266 Stock-based compensation — — 12,364 — — — 12,364 Balance, December 31, 2023 82,825,455 $ 827 $ 298,394 $ ( 123,646 ) $ 132 $ ( 5,982 ) $ 169,725 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS Year Ended December 31, 2023 As Previously Reported Adjustments Ref As Restated Cash flows from operating activities Net loss $ ( 47,841 ) $ ( 9,693 ) (a)(b) $ ( 57,534 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 15,542 — 15,542 Allowance for doubtful accounts 614 — 614 Provision for excess and obsolete inventories ( 352 ) 4,389 (a) 4,037 Loss on early extinguishment of debt 1,881 — 1,881 Stock-based compensation 12,364 — 12,364 Change in fair value of financial instruments ( 791 ) 1,337 (b) 546 Other 984 — 984 Changes in other assets and liabilities, net of acquisitions: Accounts receivable ( 161 ) — ( 161 ) Inventories ( 36,595 ) 3,967 (a) ( 32,628 ) Accounts payable 6,742 — 6,742 Accrued expenses 6,428 — 6,428 Accrued legal settlement ( 22,000 ) — ( 22,000 ) Income tax receivable ( 50 ) — ( 50 ) Other assets and liabilities ( 655 ) — ( 655 ) Net cash used in operating activities ( 63,890 ) — ( 63,890 ) Cash flows from investing activities Purchases of property and equipment ( 26,716 ) — ( 26,716 ) Proceeds from sale of property and equipment 1,043 — 1,043 Purchases of intangible assets ( 1,314 ) — ( 1,314 ) Net cash used in investing activities ( 26,987 ) — ( 26,987 ) Cash flows from financing activities Proceeds from issuance of long-term debt 100,000 — 100,000 Payments on long-term debt ( 30,727 ) — ( 30,727 ) Payments of debt issuance costs ( 4,423 ) — ( 4,423 ) Proceeds from issuance of common stock, net of issuance costs 68,453 — 68,453 Proceeds from exercise of stock options 2,406 — 2,406 Proceeds from employee stock purchase plan 944 — 944 Payments on earnout liability ( 8,000 ) — ( 8,000 ) Net cash provided by financing activities 128,653 — 128,653 Effect of exchange rate changes on cash and cash equivalents ( 605 ) — ( 605 ) Net increase in cash and cash equivalents 37,171 — 37,171 Cash and cash equivalents at beginning of period 38,468 — 38,468 Cash and cash equivalents at end of period $ 75,639 $ — $ 75,639 Supplemental disclosures of cash flow information: Restricted cash $ 1,000 $ — $ 1,000 Cash paid for income taxes 908 — 908 Cash paid for interest 4,271 — 4,271 Purchase of property and equipment included in accounts payable 3,402 — 3,402 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS Year ended December 31, 2022 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash $ 38,468 $ — $ 38,468 Trade receivables, net of allowance for doubtful accounts of $ 1,688 37,687 — 37,687 Inventories, net 60,948 340 (a) 61,288 Income taxes receivable 615 — 615 Other current assets 4,658 — 4,658 Total current assets 142,376 340 142,716 Property and equipment, net 61,938 — 61,938 Intangible assets, net 22,387 — 22,387 Goodwill 25,465 — 25,465 Deferred income taxes 148 — 148 Other assets 1,795 1,337 (b) 3,132 Total assets $ 254,109 $ 1,677 $ 255,786 LIABILITIES & STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 14,939 $ — $ 14,939 Accrued expenses 26,807 — 26,807 Accrued legal settlement 22,000 — 22,000 Other current liabilities 3,844 — 3,844 Current maturities of long-term debt 728 — 728 Income taxes payable 184 — 184 Total current liabilities 68,502 — 68,502 Long-term liabilities: Long-term debt net, less current maturities 42,182 — 42,182 Other long-term liabilities 1,628 — 1,628 Deferred income taxes 342 — 342 Income taxes payable 527 — 527 Total liabilities 113,181 — 113,181 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 78,684,107 shares issued, and 77,770,588 shares outstanding as of December 31, 2022 776 — 776 Additional paid in capital 213,956 — 213,956 Accumulated deficit ( 67,789 ) 1,677 (a)(b) ( 66,112 ) Accumulated other comprehensive loss ( 33 ) — ( 33 ) Treasury stock, at cost; 913,519 shares as of December 31, 2022 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 140,928 1,677 142,605 Total liabilities & stockholders’ equity $ 254,109 $ 1,677 $ 255,786 PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Year Ended December 31, 2022 As Previously Reported Adjustments Ref As Restated Net revenue $ 181,383 $ — $ 181,383 Cost of goods sold 32,457 ( 340 ) (a) 32,117 Gross profit 148,926 340 149,266 Operating expenses: Research and development costs 24,650 — 24,650 Selling, general, and administrative 159,323 — 159,323 Legal settlement 27,000 — 27,000 Total operating expenses 210,973 — 210,973 Operating loss ( 62,047 ) 340 ( 61,707 ) Other income (expense): Other income (expense), net ( 1,214 ) 1,337 (b) 123 Interest expense, net ( 4,129 ) — ( 4,129 ) Total other expense ( 5,343 ) 1,337 ( 4,006 ) Loss before income taxes ( 67,390 ) 1,677 ( 65,713 ) Income tax benefit ( 64 ) — ( 64 ) Net loss $ ( 67,326 ) $ 1,677 $ ( 65,649 ) Foreign currency translation adjustment ( 41 ) — ( 41 ) Comprehensive loss $ ( 67,367 ) $ 1,677 $ ( 65,690 ) Weighted average number of shares of common stock outstanding: Basic 76,766,100 — 76,766,100 Diluted 76,766,100 — 76,766,100 Net loss per share attributable to common stockholders: Basic $ ( 0.88 ) $ 0.02 $ ( 0.86 ) Diluted $ ( 0.88 ) $ 0.02 $ ( 0.86 ) The description of each error is in the Description of Misstatement Adjustments provided herein this Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Cost of Sales of $ 340 for the period ended December 31, 2022. (b) Interest Rate Swap - The correction of the out of period misstatement resulted in an increase to Other income (expense), net of $ 1,337 , and impacted opening accumulated deficit, for the period ended December 31, 2022. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CONVERTIBLE PREFERRED SERIES EQUITY & STOCKHOLDERS’ EQUITY Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Income (Loss) Stock Equity Balance, December 31, 2021 76,447,287 $ 763 $ 197,868 $ ( 463 ) $ 8 $ ( 5,982 ) $ 192,194 Net loss — — — ( 67,326 ) — — ( 67,326 ) Offering costs associated with initial public offering — — ( 266 ) — — — ( 266 ) Options exercised 1,284,333 13 5,258 — — — 5,271 Foreign currency translation — — — — ( 41 ) — ( 41 ) Employee stock purchase plan 38,968 — 731 — — — 731 Stock-based compensation — — 10,365 — — — 10,365 Balance, December 31, 2022 77,770,588 776 213,956 ( 67,789 ) ( 33 ) ( 5,982 ) 140,928 Adjustments Balance, December 31, 2021 — — — — — — — Net loss (a)(b) — — — 1,677 — — 1,677 Offering costs associated with initial public offering — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, December 31, 2022 — — — 1,677 — — 1,677 As Restated Balance, December 31, 2021 76,447,287 763 197,868 ( 463 ) 8 ( 5,982 ) 192,194 Net loss — — — ( 65,649 ) — — ( 65,649 ) Offering costs associated with initial public offering — — ( 266 ) — — — ( 266 ) Options exercised 1,284,333 13 5,258 — — — 5,271 Foreign currency translation — — — — ( 41 ) — ( 41 ) Employee stock purchase plan 38,968 — 731 — — — 731 Stock-based compensation — — 10,365 — — — 10,365 Balance, December 31, 2022 77,770,588 $ 776 $ 213,956 $ ( 66,112 ) $ ( 33 ) $ ( 5,982 ) $ 142,605 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. PARAGON 28, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS Year Ended December 31, 2022 As Previously Reported Adjustments Ref As Restated Cash flows from operating activities Net loss $ ( 67,326 ) $ 1,677 (a)(b) $ ( 65,649 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 13,728 — 13,728 Allowance for doubtful accounts 155 — 155 Provision for excess and obsolete inventories 485 — 485 Stock-based compensation 10,365 — 10,365 Change in fair value of financial instruments 1,280 ( 1,337 ) (b) ( 57 ) Other 704 — 704 Changes in other assets and liabilities, net of acquisitions: Accounts receivable ( 12,013 ) — ( 12,013 ) Inventories ( 21,512 ) ( 340 ) (a) ( 21,852 ) Accounts payable 1,895 — 1,895 Accrued expenses 2,317 — 2,317 Accrued legal settlement 22,000 — 22,000 Income tax receivable/payable 391 — 391 Other assets and liabilities ( 1,650 ) — ( 1,650 ) Net cash used in operating activities ( 49,181 ) — ( 49,181 ) Cash flows from investing activities Purchase of office building ( 18,300 ) — ( 18,300 ) Purchases of property and equipment ( 22,813 ) — ( 22,813 ) Proceeds from sale of property and equipment 897 — 897 Purchases of intangible assets ( 1,973 ) — ( 1,973 ) Acquisitions, net of cash received ( 18,504 ) — ( 18,504 ) Net cash used in investing activities ( 60,693 ) — ( 60,693 ) Cash flows from financing activities Proceeds from draw on term loan 20,000 — 20,000 Proceeds from issuance of long-term debt 16,000 — 16,000 Payments on long-term debt ( 570 ) — ( 570 ) Payments of debt issuance costs ( 732 ) — ( 732 ) Proceeds from exercise of stock options 5,271 — 5,271 Proceeds from employee stock purchase plan 518 — 518 Payments on earnout liability ( 1,000 ) — ( 1,000 ) Net cash provided by financing activities 39,487 — 39,487 Effect of exchange rate changes on cash ( 497 ) — ( 497 ) Net decrease in cash ( 70,884 ) — ( 70,884 ) Cash at beginning of period 109,352 — 109,352 Cash at end of period $ 38,468 $ — $ 38,468 Supplemental disclosures of cash flow information: Cash paid for income taxes $ 1,103 $ — $ 1,103 Cash paid for interest 3,073 — 3,073 Purchase of property and equipment included in accounts payable 3,402 — 3,402

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2023
Disior LTD.
Business Acquisition [Line Items]
Summary of Purchase Consideration Transferred	The following table summarizes the purchase price: Consideration paid: Cash consideration $ 19,696 Contingent consideration 6,550 Total consideration $ 26,246
Summary of Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed as of the Disior Acquisition Date: Assets acquired: Cash and cash equivalents $ 1,192 Other current assets 410 Intangible assets 6,800 Goodwill 19,136 Total assets acquired 27,538 Liabilities assumed: Accruals and other current liabilities 615 Deferred tax liabilities, net 677 Total liabilities assumed 1,292 Net assets acquired $ 26,246
Useful Life Determination of Assets	The useful life on intangible assets was determined by management to be in line with the Company’s policy on intangible assets. Both determinations are outlined in the table below: Fair Value Estimated Useful Life Developed technology $ 6,400 12 Tradenames 400 Indefinite Total intangible assets $ 6,800
Additive Orthopaedics, LLC
Business Acquisition [Line Items]
Summary of Purchase Consideration Transferred	Consideration Paid Cash consideration $ 15,000 Contingent consideration 2,870 Total consideration $ 17,870
Summary of Fair Values of Assets Acquired and Liabilities Assumed	The following table summarizes the fair values of the assets acquired and liabilities assumed as of the Closing Date: Assets acquired: Accounts receivable $ 761 Inventory 113 Intangible assets 11,560 Goodwill 6,329 Total assets acquired 18,763 Liabilities assumed: Accounts payable 796 Accrued expenses 97 Total liabilities assumed 893 Net assets acquired $ 17,870
Useful Life Determination of Assets	below: Fair Value Estimated Useful Life Noncompete arrangements $ 30 3 Customer relationships 240 3 Developed technology 11,290 12 $ 11,560

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Summary of Property and Equipment	Property and equipment as of December 31, 2023 and 2022 consist of the following: Estimated Life December 31, (in years) 2023 2022 Surgical instrumentation 3 - 5 $ 60,100 $ 44,625 Land 3,625 3,625 Buildings 25 20,190 14,178 Leasehold improvements Various 8,307 7,961 Computer and software 3 - 5 16,546 11,562 Machinery and equipment 5 3,843 2,815 Office equipment and furniture 5 - 7 2,267 2,049 Construction in progress Various 288 5,817 Other 5 - 15 2,785 1,046 117,951 93,678 Less: accumulated depreciation ( 43,829 ) ( 31,740 ) Property and equipment, net $ 74,122 $ 61,938

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Indefinite lived and Finite Lived Intangible Assets	Intangible assets as of December 31, 2023 are as follows: Estimated Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trademarks and tradenames, indefinite-lived Indefinite $ 987 $ — $ 987 Patents, definite-lived 17.6 7,900 2,649 5,251 Customer relationships 3 - 7 1,733 567 1,166 Developed technology 12 17,690 3,424 14,266 Other intangibles 3 30 26 4 Total intangible assets, net $ 28,340 $ 6,666 $ 21,674 Intangible assets as of December 31, 2022, are as follows: Estimated Useful Life Gross Carrying Amount Accumulated Amortization Net Carrying Amount Trademarks, indefinite-lived Indefinite $ 901 $ — $ 901 Patents, definite-lived 16.5 6,671 2,370 4,301 Customer relationships 3 - 7 1,733 279 1,454 Developed technology 12 17,690 1,973 15,717 Other intangibles 3 30 16 14 Total intangible assets, net $ 27,025 $ 4,638 $ 22,387
Schedule of Expected Future Amortization Expense	Expected future amortization expense is as follows: 2024 $ 1,981 2025 1,940 2026 1,940 2027 1,940 2028 1,929

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2023
Accrued Liabilities, Current [Abstract]
Summary of Accrued Expenses	Accrued expenses consist of the following as of December 31, 2023 and 2022, respectively: December 31, 2023 2022 Accrued commissions $ 6,126 $ 6,026 Accrued compensation 10,213 8,569 Accrued purchases 1,883 204 Accrued earnout payment 2,000 6,500 Accrued interest 2,006 450 Other accrued expenses 5,553 5,058 Total accrued expenses $ 27,781 $ 26,807

Fair Value of Financial Instr_2

Fair Value of Financial Instruments (Tables)	12 Months Ended
	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Summary of Significant Financial Assets and Liabilities Measured at Fair Value	The Company ’s significant financial assets and liabilities measured at fair value as of December 31, 2023, were as follows: Level 1 Level 2 Level 3 Total Financial Assets: Interest rate swap $ — 991 — $ 991 Financial Liabilities: Contingent consideration — — 340 $ 340 The Company's significant financial assets and liabilities measured at fair value as of December 31, 2022, were as follows: Level 1 Level 2 Level 3 Total Financial Assets: Interest rate swap (As Restated) $ — 1,337 — $ 1,337 Financial Liabilities: Contingent consideration — — 3,640 $ 3,640
Schedule of Reconciliation Level 3 Earn-out Liabilities	The following table provides a reconciliation of the Level 3 earn-out liabilities for the years ended December 31, 2023 and 2022: December 31, 2023 Fair value measurement, beginning of year $ 3,640 Achieved milestones paid ( 2,500 ) Achieved milestones reclassified to accrued expenses ( 1,000 ) Change in fair value of earn-out liabilities 200 Fair value measurement, end of year $ 340

Contingent Earn-Out Considerati

Contingent Earn-Out Consideration (Tables)	12 Months Ended
	Dec. 31, 2023
Business Combinations [Abstract]
Schedule of Reconciliation Level 3 Earn-out Liabilities	The following table provides a reconciliation of the Level 3 earn-out liabilities for the years ended December 31, 2023 and 2022: December 31, 2023 Fair value measurement, beginning of year $ 3,640 Achieved milestones paid ( 2,500 ) Achieved milestones reclassified to accrued expenses ( 1,000 ) Change in fair value of earn-out liabilities 200 Fair value measurement, end of year $ 340

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2023
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Long-term debt as of December 31, 2023, and December 31, 2022, consists of the following: December 31, 2023 December 31, 2022 Ares Revolving Loan $ 25,000 $ — Ares Term Loan 75,000 — MidCap Term Loan — 30,000 Zions Term Loan 14,933 15,573 Bank of Ireland Note Payable — 86 114,933 45,659 Less: deferred issuance costs ( 4,494 ) ( 2,749 ) Total debt, net of issuance costs 110,439 42,910 Less: current portion ( 640 ) ( 728 ) Long-term debt, net, less current maturities $ 109,799 $ 42,182
Schedule of Debt Maturities	The required principal payments for the Ares Revolving Loan, Ares Term Loan and the Zions Facility following the Consolidated Balance Sheet dates are as follows: 2024 $ 640 2025 640 2026 640 2027 640 2028 100,640 Thereafter 11,733 Total $ 114,933

Loss Per Share (Tables)

Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2023
Earnings Per Share [Abstract]
Summary of Computation of Net Loss Per Share	The computation of net loss per share for the years ended December 31, 2023, 2022 and 2021, respectively was as follows: Year Ended December 31, 2023 2022 2021 (As Restated) (As Restated) Net loss $ ( 57,534 ) $ ( 65,649 ) $ ( 13,693 ) Weighted-average common stock outstanding: Basic 82,087,329 76,766,100 52,916,711 Diluted 82,087,329 76,766,100 52,916,711 Loss per share: Basic $ ( 0.70 ) $ ( 0.86 ) $ ( 0.26 ) Diluted $ ( 0.70 ) $ ( 0.86 ) $ ( 0.26 )
Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders	The following outstanding potentially dilutive securities were excluded from the calculation of diluted net loss per share attributable to common stockholders because their impact would have been antidilutive for the period presented: December 31, 2023 2022 2021 Stock options 5,943,898 6,538,536 7,953,018 Restricted stock units 1,317,402 964,054 79,886

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
	Dec. 31, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Assumptions used in Determining Fair Value of Employee Stock Purchase Plan	Below are the assumptions used for the years ended December 31, 2023 and 2022 in determining the fair value of shares under the ESPP. Year Ended December 31, 2023 2022 Expected volatility 54.64 % 70.27 % Expected dividends — — Expected term (in years) 0.50 0.50 Discount rate 15.00 % 15.00 % Risk-free rate 5.26 % 2.79 %
Assumptions used in Determining Fair Value of Stock Options	Below are the assumptions used for the years ended December 31, 2023, 2022 and 2021 in determining the fair value of each option award: Year Ended December 31, 2023 2022 2021 Expected volatility 66.20 % 55 % - 70 % 52 % - 55 % Expected dividends — — — Expected term (in years) 6.25 6.00 5.75 - 6.25 Risk-free rate 4.11 % 1.69 - 2.79 % 0.47 % - 1.20 %
2011 and 2021 Plans
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Stock Option Activity	The following table summarizes the Company’s stock option plan and the activity for the year ended December 31, 2023. Shares Weighted-Average Exercise Price Weighted-Average Remaining Contractual Term (Years) Outstanding, December 31, 2022 6,538,536 $ 10.02 7.36 Granted 225,000 18.33 Exercised or released ( 458,005 ) 6.56 Forfeited or expired ( 361,633 ) 15.29 Outstanding, December 31, 2023 5,943,898 $ 10.28 6.53 Exercisable, December 31, 2023 4,292,558 $ 8.51 6.02 Vested and expected to vest at December 31, 2023 5,938,438 $ 10.27 6.53
2021 Incentive Award Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Summary of Restricted Stock Units Activity	The following table summarizes the Company’s restricted stock units' activity for the years ended December 31, 2023. Year Ended December 31, 2023 Restricted Stock Units Weighted-Average Fair Value Outstanding, beginning of period 964,054 $ 17.74 Granted 776,359 16.56 Vested ( 273,618 ) 17.65 Forfeited or expired ( 149,393 ) 17.81 Outstanding, end of period 1,317,402 $ 17.06 Vested and expected to vest at end of period 1,305,827 $ 17.05

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Provision (Benefit) Expense for Income Taxes	Total provision (benefit) for income taxes for the years ended December 31, 2023, 2022 and 2021: December 31, 2023 2022 2021 (As Restated) (As Restated) (Loss) income before taxes Domestic $ ( 56,342 ) $ ( 64,071 ) $ ( 17,030 ) Foreign ( 979 ) ( 1,642 ) 4,050 Total loss before taxes ( 57,321 ) ( 65,713 ) ( 12,980 ) Current tax expense (benefit): Federal 105 — ( 165 ) State 58 96 ( 36 ) Foreign 730 315 744 Total current tax expense 893 411 543 Deferred tax expense (benefit): Federal ( 11,309 ) ( 15,900 ) ( 3,506 ) State ( 1,402 ) ( 1,939 ) ( 464 ) Foreign ( 1,099 ) ( 909 ) 170 Change in valuation allowance 13,129 18,273 3,970 Total deferred tax (benefit) expense ( 681 ) ( 475 ) 170 Total tax (benefit) expense: Federal ( 11,204 ) ( 15,900 ) ( 3,671 ) State ( 1,344 ) ( 1,843 ) ( 500 ) Foreign ( 368 ) ( 594 ) 914 Change in valuation allowance 13,129 18,273 3,970 Total income tax expense (benefit) $ 213 $ ( 64 ) $ 713
Schedule of Significant Components of Deferred Taxes	Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of our deferred taxes as of December 31, 2023 and 2022 were: December 31, 2023 2022 (As Restated) (As Restated) Deferred tax assets: Receivable allowances $ 253 $ 356 Accrued expenses 1,262 5,351 S263A capitalizable costs 2,923 461 Inventory reserves 4,635 3,436 Research and development credits 3,974 3,615 Net operating losses 25,176 13,505 Interest expense 2,407 906 Stock-based compensation 4,496 3,324 Lease liability 356 384 R&D IRC 174(b) capitalized costs 5,161 3,433 Other 764 651 Total deferred tax assets 51,407 35,422 Valuation allowance ( 41,671 ) ( 28,543 ) Net deferred tax assets 9,736 6,879 Deferred tax liabilities: Property and equipment ( 6,808 ) ( 5,391 ) Section 481 adjustment ( 821 ) — Patents and trademarks ( 1,343 ) ( 1,304 ) Right of use asset ( 292 ) ( 378 ) Total deferred tax liabilities ( 9,264 ) ( 7,073 ) Total net deferred tax asset (liability) $ 472 $ ( 194 )
Schedule of Reconciliation of Unrecognized Tax Benefits	A reconciliation of the beginning and ending amount of unrecognized tax benefits is as follows: 2023 2022 Gross unrecognized tax benefits - beginning of period $ 1,431 $ 1,337 Increases related to current year tax positions 92 92 Increases related to prior year tax positions — 2 Gross unrecognized tax benefits - end of period $ 1,523 $ 1,431
Schedule of Reconciliation of Provision for Income Taxes at Federal Statutory Rate	A reconciliation of the provision for income taxes at the federal statutory rate compared to the effective tax rate for the years ended December 31, 2023, 2022 and 2021 is: 2023 2022 2021 (As Restated) (As Restated) Statutory U.S. federal tax rate $ ( 12,037 ) $ ( 13,800 ) $ ( 2,726 ) State taxes net of federal benefit ( 1,356 ) ( 1,863 ) ( 492 ) Non-U.S. earnings taxed at rates different than the U.S. statutory rate 5 ( 80 ) ( 150 ) Foreign source earnings, net of associated foreign tax credits 628 486 601 Benefit of tax credits ( 501 ) ( 458 ) ( 1,569 ) Stock based compensation 27 ( 2,852 ) ( 212 ) Change in valuation allowance 13,129 18,273 3,970 Change in unrecognized tax benefits 175 92 710 Other 143 138 581 Total provision (benefit) for income taxes $ 213 $ ( 64 ) $ 713

Segment and Geographic Inform_2

Segment and Geographic Information (Tables)	12 Months Ended
	Dec. 31, 2023
Segment Reporting [Abstract]
Schedule of Total Net Revenue by Geographic Area	The following table represents total net revenue by geographic area, based on the location of the customer for the years ended December 31, 2023, 2022 and 2021, respectively. Year Ended December 31, 2023 2022 2021 United States $ 183,505 $ 158,105 $ 130,112 International 32,884 23,278 17,352 Total net revenue $ 216,389 $ 181,383 $ 147,464
Schedule of Total Non-current Assets, Excluding Deferred Taxes, by Geographic Area	The following table represents total non-current assets, excluding deferred taxes, by geographic area for the years ended December 31, 2023 and 2022, respectively. December 31, 2023 December 31, 2022 As Restated As Restated United States $ 89,531 $ 80,795 Finland 25,032 25,581 Other International 9,616 6,546 Total assets $ 124,179 $ 112,922

Quarterly Financial Data (Table

Quarterly Financial Data (Tables)	12 Months Ended
	Dec. 31, 2023
Quarterly Financial Information Disclosure [Abstract]
Schedule of effects of restatement on financial information	The net impact of the Restatement on the Consolidated Statements of Operations and Comprehensive Loss for the three-months ended December 31, 2023 and 2022 is summarized as follows: Quarter Ended December 31, 2023 2022 As Previously Reported As Restated As Previously Reported As Restated (in thousands, except per share data) Net revenue $ 60,561 $ 60,561 $ 51,508 $ 51,508 Gross profit 45,121 42,357 41,971 42,221 Operating loss ( 11,230 ) ( 13,994 ) ( 36,045 ) ( 35,795 ) Net loss $ ( 19,559 ) $ ( 22,323 ) $ ( 38,763 ) $ ( 38,479 ) Net loss per share attributable to common stockholders: Basic $ ( 0.24 ) $ ( 0.27 ) $ ( 0.50 ) $ ( 0.50 ) Diluted $ ( 0.24 ) $ ( 0.27 ) $ ( 0.50 ) $ ( 0.50 ) As of and for the Three and Nine Months Ended September 30, 2023: The effects of the restatement on the condensed consolidated balance sheet as of September 30, 2023 are summarized in the following table (in thousands, except share and per share data): September 30, 2023 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash and cash equivalents $ 34,949 $ — $ 34,949 Trade receivables, net of allowance for doubtful accounts of $ 934 33,615 — 33,615 Inventories, net 94,380 ( 5,252 ) (a) 89,128 Income taxes receivable 1,022 — 1,022 Other current assets 4,826 — 4,826 Total current assets 168,792 ( 5,252 ) 163,540 Property and equipment, net 73,530 — 73,530 Intangible assets, net 21,802 — 21,802 Goodwill 25,465 — 25,465 Deferred income taxes 132 — 132 Other assets 3,634 — 3,634 Total assets $ 293,355 $ ( 5,252 ) $ 288,103 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 27,395 $ — $ 27,395 Accrued expenses 24,966 — 24,966 Other current liabilities 1,893 — 1,893 Current maturities of long-term debt 640 — 640 Total current liabilities 54,894 — 54,894 Long-term liabilities: Long-term debt net, less current maturities 42,288 — 42,288 Other long-term liabilities 1,467 — 1,467 Deferred income taxes 327 — 327 Income taxes payable 635 — 635 Total liabilities 99,611 — 99,611 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 83,469,426 shares issued, and 82,555,907 shares outstanding as of September 30, 2023 824 — 824 Additional paid in capital 296,018 — 296,018 Accumulated deficit ( 96,071 ) ( 5,252 ) (a) ( 101,323 ) Accumulated other comprehensive loss ( 1,045 ) — ( 1,045 ) Treasury stock, at cost; 913,519 shares as of September 30, 2023 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 193,744 ( 5,252 ) 188,492 Total liabilities & stockholders’ equity $ 293,355 $ ( 5,252 ) $ 288,103 The description of the error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 5,252 , including an increase to the beginning balance of Accumulated deficit of $ 3,724 for the three months ended and a decrease to the beginning balance of Accumulated deficit of $ 340 for the nine months ended September 30, 2023. The effects of the restatement on the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2023 are summarized in the following table (in thousands except share and per share data): Three Months Ended September 30, 2023 Nine Months Ended September 30, 2023 Ref As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Net revenue $ 52,783 $ — $ 52,783 $ 155,828 $ — $ 155,828 Cost of goods sold (a) 10,394 1,528 11,922 28,158 5,592 33,750 Gross profit 42,389 ( 1,528 ) 40,861 127,670 ( 5,592 ) 122,078 Operating expenses: Research and development costs 7,244 — 7,244 21,976 — 21,976 Selling, general, and administrative 44,126 — 44,126 131,773 — 131,773 Total operating expenses 51,370 — 51,370 153,749 — 153,749 Operating loss ( 8,981 ) ( 1,528 ) ( 10,509 ) ( 26,079 ) ( 5,592 ) ( 31,671 ) Other income (expense): Other income (expenses), net (b) 1,660 ( 1,291 ) 369 1,014 ( 1,337 ) ( 323 ) Interest expense, net ( 1,119 ) — ( 1,119 ) ( 3,127 ) — ( 3,127 ) Total other income (expense) 541 ( 1,291 ) ( 750 ) ( 2,113 ) ( 1,337 ) ( 3,450 ) Loss before income taxes ( 8,440 ) ( 2,819 ) ( 11,259 ) ( 28,192 ) ( 6,929 ) ( 35,121 ) Income tax (benefit) expense ( 108 ) — ( 108 ) 90 — 90 Net loss $ ( 8,332 ) $ ( 2,819 ) $ ( 11,151 ) $ ( 28,282 ) $ ( 6,929 ) $ ( 35,211 ) Foreign currency translation adjustment ( 630 ) — ( 630 ) ( 1,012 ) — ( 1,012 ) Comprehensive loss $ ( 8,962 ) $ ( 2,819 ) $ ( 11,781 ) $ ( 29,294 ) $ ( 6,929 ) $ ( 36,223 ) Weighted average number of shares of common stock outstanding: Basic 82,548,892 — 82,548,892 81,878,814 — 81,878,814 Diluted 82,548,892 — 82,548,892 81,878,814 — 81,878,814 Net loss per share attributable to common stockholders: Basic $ ( 0.10 ) $ ( 0.04 ) $ ( 0.14 ) $ ( 0.35 ) $ ( 0.08 ) $ ( 0.43 ) Diluted $ ( 0.10 ) $ ( 0.04 ) $ ( 0.14 ) $ ( 0.35 ) $ ( 0.08 ) $ ( 0.43 ) The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $ 1,528 and $ 5,592 for the three and nine months ended September 30, 2023, respectively. (b) Interest Rate Swap - The correction of the misstatement resulted in a decrease to Other income (expense), net of $ 1,291 and $ 1,337 for the three and nine months ended September 30, 2023, respectively. The effects of the restatement on the condensed consolidated statement of cash flow for the nine months ended September 30, 2023 are summarized in the following table (in thousands): Nine Months Ended September 30, 2023 As Previously Reported Adjustments Ref Effect of Reclassification As Restated Cash flows from operating activities Net loss $ ( 28,282 ) $ ( 6,929 ) (a)(b) $ — $ ( 35,211 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 10,602 — — 10,602 Allowance for doubtful accounts 147 — — 147 Provision for excess and obsolete inventories 2,053 1,151 (a) — 3,204 Stock-based compensation 10,294 — — 10,294 Change in fair value of financial instruments — 1,337 (b) ( 1,394 ) ( 57 ) Other ( 1,428 ) — 1,394 ( 34 ) Changes in other assets and liabilities, net of acquisitions: Accounts receivable 3,706 — — 3,706 Inventories ( 35,558 ) 4,441 (a) — ( 31,117 ) Accounts payable 12,468 — — 12,468 Accrued expenses 3,718 — — 3,718 Accrued legal settlement ( 22,000 ) — — ( 22,000 ) Income tax receivable/payable ( 533 ) — — ( 533 ) Other assets and liabilities ( 2,704 ) — — ( 2,704 ) Net cash used in operating activities ( 47,517 ) — — ( 47,517 ) Cash flows from investing activities Purchases of property and equipment ( 21,893 ) — — ( 21,893 ) Proceeds from sale of property and equipment 795 — — 795 Purchases of intangible assets ( 933 ) — — ( 933 ) Net cash used in investing activities ( 22,031 ) — — ( 22,031 ) Cash flows from financing activities Payments on long-term debt ( 568 ) — — ( 568 ) Proceeds from issuance of common stock, net of issuance costs 68,453 — — 68,453 Proceeds from exercise of stock options 2,535 — — 2,535 Proceeds from employee stock purchase plan 560 — — 560 Payments on earnout liability ( 5,500 ) — — ( 5,500 ) Net cash provided by financing activities 65,480 — — 65,480 Effect of exchange rate changes on cash and cash equivalents 549 — — 549 Net decrease in cash and cash equivalents ( 3,519 ) — — ( 3,519 ) Cash and cash equivalents at beginning of period 38,468 — — 38,468 Cash and cash equivalents at end of period $ 34,949 $ — $ — $ 34,949 Supplemental disclosures of cash flow information: Restricted cash $ 1,000 $ — $ — $ 1,000 Cash paid for income taxes 610 — — 610 Cash paid for interest 3,342 — — 3,342 Purchase of property and equipment included in accounts payable 4,842 — — 4,842 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. As of and for the Three and Six Months Ended June 30, 2023: The effects of the restatement on the condensed consolidated balance sheet as of June 30, 2023 are summarized in the following table (in thousands, except share and per share data): June 30, 2023 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash and cash equivalents $ 56,747 $ — $ 56,747 Trade receivables, net of allowance for doubtful accounts of $ 1,706 34,331 — 34,331 Inventories, net 85,225 ( 3,724 ) (a) 81,501 Income taxes receivable 870 — 870 Other current assets 3,257 — 3,257 Total current assets 180,430 ( 3,724 ) 176,706 Property and equipment, net 70,936 — 70,936 Intangible assets, net 21,921 — 21,921 Goodwill 25,465 — 25,465 Deferred income taxes 319 — 319 Other assets 1,766 1,291 (b) 3,057 Total assets $ 300,837 $ ( 2,433 ) $ 298,404 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 29,681 $ — $ 29,681 Accrued expenses 24,390 — 24,390 Other current liabilities 1,700 — 1,700 Current maturities of long-term debt 652 — 652 Income taxes payable 20 — 20 Total current liabilities 56,443 — 56,443 Long-term liabilities: Long-term debt net, less current maturities 42,259 — 42,259 Other long-term liabilities 1,842 — 1,842 Deferred income taxes 620 — 620 Income taxes payable 635 — 635 Total liabilities 101,799 — 101,799 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 83,449,565 shares issued, and 82,536,046 shares outstanding as of June 30, 2023 824 — 824 Additional paid in capital 292,350 — 292,350 Accumulated deficit ( 87,739 ) ( 2,433 ) (a)(b) ( 90,172 ) Accumulated other comprehensive loss ( 415 ) — ( 415 ) Treasury stock, at cost; 913,519 shares as of June 30, 2023 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 199,038 ( 2,433 ) 196,605 Total liabilities & stockholders’ equity $ 300,837 $ ( 2,433 ) $ 298,404 The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 3,724 , including an increase to the beginning balance of Accumulated deficit of $ 983 for the three-months ended and a decrease to the beginning balance of Accumulated deficit of $ 340 for the six-months ended June 30, 2023. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other assets and a decrease to Accumulated deficit of $ 1,291 , including a decrease to the beginning balance of Accumulated deficit of $ 900 and $ 1,337 for the three- and six-months ended June 30, 2023, respectively. The effects of the restatement on the condensed consolidated statement of operations and comprehensive loss for the three and six months ended June 30, 2023 are summarized in the following table (in thousands except share and per share data): Three Months Ended June 30, 2023 Six Months Ended June 30, 2023 Ref As Previously Reported Adjustments As As Previously Reported Adjustments As Net revenue $ 51,009 $ — $ 51,009 $ 103,045 $ — $ 103,045 Cost of goods sold (a) 8,858 2,741 11,599 17,764 4,064 21,828 Gross profit 42,151 ( 2,741 ) 39,410 85,281 ( 4,064 ) 81,217 Operating expenses: Research and development costs 7,683 — 7,683 14,732 — 14,732 Selling, general, and administrative 43,827 — 43,827 87,647 — 87,647 Total operating expenses 51,510 — 51,510 102,379 — 102,379 Operating loss ( 9,359 ) ( 2,741 ) ( 12,100 ) ( 17,098 ) ( 4,064 ) ( 21,162 ) Other (expense) income: Other (expense) income, net (b) ( 467 ) 391 ( 76 ) ( 646 ) ( 46 ) ( 692 ) Interest expense, net ( 803 ) — ( 803 ) ( 2,008 ) — ( 2,008 ) Total other expense, net ( 1,270 ) 391 ( 879 ) ( 2,654 ) ( 46 ) ( 2,700 ) Loss before income taxes ( 10,629 ) ( 2,350 ) ( 12,979 ) ( 19,752 ) ( 4,110 ) ( 23,862 ) Income tax expense 269 — 269 198 — 198 Net loss $ ( 10,898 ) $ ( 2,350 ) $ ( 13,248 ) $ ( 19,950 ) $ ( 4,110 ) $ ( 24,060 ) Foreign currency translation adjustment ( 283 ) — ( 283 ) ( 382 ) — ( 382 ) Comprehensive loss $ ( 11,181 ) $ ( 2,350 ) $ ( 13,531 ) $ ( 20,332 ) $ ( 4,110 ) $ ( 24,442 ) Weighted average number of shares of common stock outstanding: Basic 82,373,441 — 82,373,441 81,536,607 — 81,536,607 Diluted 82,373,441 — 82,373,441 81,536,607 — 81,536,607 Net loss per share attributable to common stockholders: Basic $ ( 0.13 ) $ ( 0.03 ) $ ( 0.16 ) $ ( 0.24 ) $ ( 0.06 ) $ ( 0.30 ) Diluted $ ( 0.13 ) $ ( 0.03 ) $ ( 0.16 ) $ ( 0.24 ) $ ( 0.06 ) $ ( 0.30 ) The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $ 2,741 and $ 4,064 for the three and six months ended June 30, 2023, respectively. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other (expense) income, net of $ 391 and a decrease to Other (expense) income of $ 46 for the three and six months ended June 30, 2023, respectively. The effects of the restatement on the condensed consolidated statement of cash flow for the six months ended June 30, 2023 are summarized in the following table (in thousands): Six Months Ended June 30, 2023 As Previously Reported Adjustments Ref Effect of Reclassification As Restated Cash flows from operating activities Net loss $ ( 19,950 ) $ ( 4,110 ) (a)(b) $ — $ ( 24,060 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 6,414 — — 6,414 Allowance for doubtful accounts 147 — — 147 Provision for (reversal of) excess and obsolete inventories ( 205 ) 1,128 (a) — 923 Stock-based compensation 6,782 — — 6,782 Change in fair value of financial instruments — 46 (b) 320 366 Other 714 — ( 320 ) 394 Changes in other assets and liabilities, net of acquisitions: Accounts receivable 3,138 — — 3,138 Inventories ( 23,895 ) 2,936 (a) — ( 20,959 ) Accounts payable 14,745 — — 14,745 Accrued expenses 1,845 — — 1,845 Accrued legal settlement ( 22,000 ) — — ( 22,000 ) Income tax receivable/payable ( 359 ) — — ( 359 ) Other assets and liabilities ( 779 ) — — ( 779 ) Net cash used in operating activities ( 33,403 ) — — ( 33,403 ) Cash flows from investing activities Purchases of property and equipment ( 15,354 ) — — ( 15,354 ) Proceeds from sale of property and equipment 635 — — 635 Purchases of intangible assets ( 544 ) — — ( 544 ) Net cash used in investing activities ( 15,263 ) — — ( 15,263 ) Cash flows from financing activities Payments on long-term debt ( 396 ) — — ( 396 ) Proceeds from issuance of common stock, net of issuance costs 68,453 — — 68,453 Proceeds from exercise of stock options 2,464 — — 2,464 Proceeds from employee stock purchase plan 560 — — 560 Payments on earnout liability ( 4,250 ) — — ( 4,250 ) Net cash provided by financing activities 66,831 — — 66,831 Effect of exchange rate changes on cash and cash equivalents 114 — — 114 Net increase in cash and cash equivalents 18,279 — — 18,279 Cash and cash equivalents at beginning of period 38,468 — — 38,468 Cash and cash equivalents at end of period $ 56,747 $ — $ — $ 56,747 Supplemental disclosures of cash flow information: Restricted cash $ 2,250 $ — $ — $ 2,250 Cash paid for taxes 456 — — 456 Cash paid for interest 2,068 — — 2,068 Purchase of property and equipment included in accounts payable 5,617 — — 5,617 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. As of and for the Three Months Ended March 31, 2023: The effects of the restatement on the condensed consolidated balance sheet as of March 31, 2023 are summarized in the following table (in thousands, except share and per share data): March 31, 2023 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash and cash equivalents $ 85,883 $ — $ 85,883 Trade receivables, net of allowance for doubtful accounts of $ 1,816 37,262 — 37,262 Inventories, net 69,174 ( 983 ) (a) 68,191 Income taxes receivable 596 — 596 Other current assets 4,167 — 4,167 Total current assets 197,082 ( 983 ) 196,099 Property and equipment, net 66,810 — 66,810 Intangible assets, net 22,137 — 22,137 Goodwill 25,465 — 25,465 Deferred income taxes 354 — 354 Other assets 1,697 900 (b) 2,597 Total assets $ 313,545 $ ( 83 ) $ 313,462 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 20,538 $ — $ 20,538 Accrued expenses 25,446 — 25,446 Accrued legal settlement 13,000 — 13,000 Other current liabilities 3,772 — 3,772 Current maturities of long-term debt 690 — 690 Income taxes payable 208 — 208 Total current liabilities 63,654 — 63,654 Long-term liabilities: Long-term debt net, less current maturities 42,204 — 42,204 Other long-term liabilities 1,523 — 1,523 Deferred income taxes 377 — 377 Income taxes payable 635 — 635 Total liabilities 108,393 — 108,393 Commitments and contingencies Stockholders' equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 83,220,392 shares issued, and 82,306,873 shares outstanding as of March 31, 2023 821 — 821 Additional paid in capital 287,286 — 287,286 Accumulated deficit ( 76,841 ) ( 83 ) (a)(b) ( 76,924 ) Accumulated other comprehensive loss ( 132 ) — ( 132 ) Treasury stock, at cost; 913,519 shares as of June 30, 2023 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 205,152 ( 83 ) 205,069 Total liabilities & stockholders’ equity $ 313,545 $ ( 83 ) $ 313,462 The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 983 , including a decrease to the beginning balance of Accumulated deficit of $ 340 for the three months ended March 31, 2023. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other assets and an decrease to Accumulated deficit of $ 900 , including a decrease to the beginning balance of Accumulated deficit of $ 1,337 for the three months ended March 31, 2023. The effects of the restatement on the condensed consolidated statement of operations and comprehensive loss for the three months ended March 31, 2023 are summarized in the following table (in thousands, except share and per share data): Three Months Ended March 31, 2023 As Previously Reported Adjustments Ref As Restated Net revenue $ 52,036 $ — $ 52,036 Cost of goods sold 8,906 1,323 (a) 10,229 Gross profit 43,130 ( 1,323 ) 41,807 Operating expenses: Research and development costs 7,049 — 7,049 Selling, general, and administrative 43,820 — 43,820 Total operating expenses 50,869 — 50,869 Operating loss ( 7,739 ) ( 1,323 ) ( 9,062 ) Other expense: Other expense ( 179 ) ( 437 ) (b) ( 616 ) Interest expense, net ( 1,205 ) — ( 1,205 ) Total other expense ( 1,384 ) ( 437 ) ( 1,821 ) Loss before income taxes ( 9,123 ) ( 1,760 ) ( 10,883 ) Income tax benefit ( 71 ) — ( 71 ) Net loss $ ( 9,052 ) $ ( 1,760 ) $ ( 10,812 ) Foreign currency translation adjustment ( 99 ) — ( 99 ) Comprehensive loss $ ( 9,151 ) $ ( 1,760 ) $ ( 10,911 ) Weighted average number of shares of common stock outstanding: Basic 80,681,715 — 80,681,715 Diluted 80,681,715 — 80,681,715 Net loss per share attributable to common stockholders: Basic $ ( 0.11 ) $ ( 0.02 ) $ ( 0.13 ) Diluted $ ( 0.11 ) $ ( 0.02 ) $ ( 0.13 ) The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Cost of goods sold of $ 1,323 for the three months ended March 31, 2023. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other expense of $ 437 for the three months ended March 31, 2023. The effects of the restatement on the condensed consolidated statement of cash flow for the three months ended March 31, 2023 are summarized in the following table (in thousands): Three Months Ended March 31, 2023 As Previously Reported Adjustments Ref As Restated Cash flows from operating activities Net loss $ ( 9,052 ) $ ( 1,760 ) (a)(b) $ ( 10,812 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 3,117 — 3,117 Provision for excess and obsolete inventories 293 — 293 Stock-based compensation 3,182 — 3,182 Change in fair value of financial instruments 80 437 (b) 517 Other 100 — 100 Changes in other assets and liabilities, net of acquisitions: Accounts receivable 441 — 441 Inventories ( 8,435 ) 1,323 (a) ( 7,112 ) Accounts payable 5,592 — 5,592 Accrued expenses ( 877 ) — ( 877 ) Accrued legal settlement ( 9,000 ) — ( 9,000 ) Income tax payable 132 — 132 Other assets and liabilities 367 — 367 Net cash used in operating activities ( 14,060 ) — ( 14,060 ) Cash flows from investing activities Purchases of property and equipment ( 7,521 ) — ( 7,521 ) Proceeds from sale of property and equipment 223 — 223 Purchases of intangible assets ( 254 ) — ( 254 ) Net cash used in investing activities ( 7,552 ) — ( 7,552 ) Cash flows from financing activities Payments on long-term debt ( 197 ) — ( 197 ) Payments of debt issuance costs ( 7 ) — ( 7 ) Proceeds from issuance of common stock, net of issuance costs 68,449 — 68,449 Proceeds from exercise of stock options 1,622 — 1,622 Payments on earnout liability ( 500 ) — ( 500 ) Net cash provided by financing activities 69,367 — 69,367 Effect of exchange rate changes on cash ( 340 ) — ( 340 ) Net increase in cash 47,415 — 47,415 Cash at beginning of period 38,468 — 38,468 Cash at end of period $ 85,883 $ — $ 85,883 Supplemental disclosures of cash flow information: Cash paid for taxes $ — $ — $ — Cash paid for interest 601 — 601 Purchase of property and equipment included in accounts payable 4,026 — 4,026 The effects of the revision on the condensed consolidated balance sheet as of September 30, 2022 are summarized in the following table (in thousands, except share and per share data): September 30, 2022 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash $ 56,325 $ — $ 56,325 Trade receivables, net of allowance for doubtful accounts of $ 1,990 35,960 — 35,960 Inventories, net 54,771 90 (a) 54,861 Income taxes receivable 705 — 705 Other current assets 1,947 — 1,947 Total current assets 149,708 90 149,798 Property and equipment, net 58,591 — 58,591 Intangible assets, net 20,850 — 20,850 Goodwill 26,975 — 26,975 Deferred income taxes 841 — 841 Other assets — 1,303 (b) 1,303 Total assets $ 256,965 $ 1,393 $ 258,358 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 13,979 $ — $ 13,979 Accrued expenses 19,507 — 19,507 Other current liabilities 6,889 — 6,889 Current maturities of long-term debt 735 — 735 Income taxes payable 497 — 497 Total current liabilities 41,607 — 41,607 Long-term liabilities: Long-term debt net, less current maturities 42,492 — 42,492 Other long-term liabilities 907 — 907 Deferred income taxes 59 — 59 Income taxes payable 527 — 527 Total liabilities 85,592 — 85,592 Commitments and contingencies Stockholders’ equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 77,990,290 shares issued, and 77,076,771 shares outstanding as of September 30, 2022 769 — 769 Additional paid in capital 207,109 — 207,109 Accumulated deficit ( 29,026 ) 1,393 (a)(b) ( 27,633 ) Accumulated other comprehensive loss ( 1,497 ) — ( 1,497 ) Treasury stock, at cost; 913,519 shares as of September 30, 2022 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 171,373 1,393 172,766 Total liabilities & stockholders’ equity $ 256,965 $ 1,393 $ 258,358 The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in an increase to Inventories, net and a decrease to Accumulated deficit of $ 90 , including an increase to the beginning balance of Accumulated deficit of $ 198 for the three months ended September 30, 2022. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other assets and a decrease to Accumulated deficit of $ 1,303 , including a decrease to the beginning balance of Accumulated deficit of $ 414 for the three months ended September 30, 2022. The effects of the revision on the condensed consolidated statement of operations and comprehensive loss for the three and nine months ended September 30, 2022 are summarized in the following table (in thousands except share and per share data): Three Months Ended September 30, 2022 Nine Months Ended September 30, 2022 Ref As Previously Reported Adjustments As Restated As Previously Reported Adjustments As Restated Net revenue $ 46,006 $ — $ 46,006 $ 129,875 $ — $ 129,875 Cost of goods sold (a) 8,491 ( 288 ) 8,203 22,920 ( 90 ) 22,830 Gross profit 37,515 288 37,803 106,955 90 107,045 Operating expenses: Research and development costs 6,337 — 6,337 18,100 — 18,100 Selling, general, and administrative 39,667 — 39,667 114,857 — 114,857 Total operating expenses 46,004 — 46,004 132,957 — 132,957 Operating loss ( 8,489 ) 288 ( 8,201 ) ( 26,002 ) 90 ( 25,912 ) Other income (expense): Other income, net (b) 59 889 948 610 1,303 1,913 Interest expense, net ( 1,093 ) — ( 1,093 ) ( 2,865 ) — ( 2,865 ) Total other income (expense) ( 1,034 ) 889 ( 145 ) ( 2,255 ) 1,303 ( 952 ) Loss before income taxes ( 9,523 ) 1,177 ( 8,346 ) ( 28,257 ) 1,393 ( 26,864 ) Income tax expense 201 — 201 306 — 306 Net loss $ ( 9,724 ) $ 1,177 $ ( 8,547 ) $ ( 28,563 ) $ 1,393 $ ( 27,170 ) Foreign currency translation adjustment ( 588 ) — ( 588 ) ( 1,505 ) — ( 1,505 ) Comprehensive loss $ ( 10,312 ) $ 1,177 $ ( 9,135 ) $ ( 30,068 ) $ 1,393 $ ( 28,675 ) Weighted average number of shares of common stock outstanding: Basic 76,850,949 — 76,850,949 76,595,118 — 76,595,118 Diluted 76,850,949 — 76,850,949 76,595,118 — 76,595,118 Net loss per share attributable to common stockholders: Basic $ ( 0.13 ) $ 0.02 $ ( 0.11 ) $ ( 0.37 ) $ 0.02 $ ( 0.35 ) Diluted $ ( 0.13 ) $ 0.02 $ ( 0.11 ) $ ( 0.37 ) $ 0.02 $ ( 0.35 ) The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Cost of goods sold of $ 288 and $ 90 for the three and nine months ended September 30, 2022, respectively. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other income, net of $ 889 and $ 1,303 for the three- and nine-months ended September 30, 2022, respectively. The effects of the revision on the condensed consolidated statement of cash flow for the nine months ended September 30, 2022 are summarized in the following table (in thousands): Nine Months Ended September 30, 2022 As Previously Reported Adjustments Ref As Restated Cash flows from operating activities Net loss $ ( 28,563 ) $ 1,393 (a)(b) $ ( 27,170 ) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 9,624 — 9,624 Provision for excess and obsolete inventories ( 91 ) — ( 91 ) Stock-based compensation 7,052 — 7,052 Change in fair value of financial instruments — ( 1,303 ) (b) ( 1,303 ) Other ( 1,295 ) — ( 1,295 ) Changes in other assets and liabilities, net of acquisitions: Accounts receivable ( 10,227 ) — ( 10,227 ) Inventories ( 15,316 ) ( 90 ) (a) ( 15,406 ) Accounts payable 951 — 951 Accrued expenses 176 — 176 Income tax payable 297 — 297 Other assets and liabilities 1,442 — 1,442 Net cash used in operating activities ( 35,950 ) — ( 35,950 ) Cash flows from investing activities Purchase of office building ( 18,300 ) — ( 18,300 ) Purchases of property and equipment ( 15,637 ) — ( 15,637 ) Proceeds from sale of property and equipment 642 — 642 Purchases of intangible assets ( 1,720 ) — ( 1,720 ) Acquisition of Disior, net of cash received ( 18,504 ) — ( 18,504 ) Net cash used in investing activities ( 53,519 ) — ( 53,519 ) Cash flows from financing activities Proceeds from draw on term loan 20,000 — 20,000 Proceeds from issuance of long-term debt 16,000 — 16,000 Payments on long-term debt ( 367 ) — ( 367 ) Payments of debt issuance costs ( 420 ) — ( 420 ) Proceeds from exercise of stock options 2,224 — 2,224 Payments on earnout liability ( 500 ) — ( 500 ) Net cash provided by financing activities 36,937 — 36,937 Effect of exchange rate changes on cash ( 495 ) — ( 495 ) Net decrease in cash ( 53,027 ) — ( 53,027 ) Cash at beginning of period 109,352 — 109,352 Cash at end of period $ 56,325 $ — $ 56,325 Supplemental disclosures of cash flow information: Cash paid for income taxes $ 788 $ — $ 788 Cash paid for interest 2,111 — 2,111 Purchase of property and equipment included in accounts payable 2,363 — 2,363 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. As of and for the Three and Six Months Ended June 30, 2022: The effects of the revision on the condensed consolidated balance sheet as of June 30, 2022 are summarized in the following table (in thousands, except share and per share data): June 30, 2022 As Previously Reported Adjustments Ref As Restated ASSETS Current assets: Cash $ 73,002 $ — $ 73,002 Trade receivables, net of allowance for doubtful accounts of $ 1,234 32,598 — 32,598 Inventories, net 51,700 ( 198 ) (a) 51,502 Income taxes receivable 660 — 660 Other current assets 3,129 — 3,129 Total current assets 161,089 ( 198 ) 160,891 Property and equipment, net 56,066 — 56,066 Intangible assets, net 20,352 — 20,352 Goodwill 26,975 — 26,975 Deferred income taxes 563 — 563 Other assets — 414 (b) 414 Total assets $ 265,045 $ 216 $ 265,261 LIABILITIES & STOCKHOLDERS’ EQUITY Current liabilities: Accounts payable $ 14,564 $ — $ 14,564 Accrued expenses 21,407 — 21,407 Other current liabilities 6,926 — 6,926 Current maturities of long-term debt 757 — 757 Income taxes payable 305 — 305 Total current liabilities 43,959 — 43,959 Long-term liabilities: Long-term debt net, less current maturities 42,519 — 42,519 Other long-term liabilities 905 — 905 Deferred income taxes 197 — 197 Income taxes payable 527 — 527 Total liabilities 88,107 — 88,107 Commitments and contingencies Stockholders' equity: Common stock, $ 0.01 par value, 300,000,000 shares authorized; 77,451,087 shares issued, and 76,537,568 shares outstanding as of June 30, 2022 764 — 764 Additional paid in capital 202,367 — 202,367 Accumulated deficit ( 19,302 ) 216 (a)(b) ( 19,086 ) Accumulated other comprehensive loss ( 909 ) — ( 909 ) Treasury stock, at cost; 913,519 shares as of June 30, 2022 ( 5,982 ) — ( 5,982 ) Total stockholders’ equity 176,938 216 177,154 Total liabilities & stockholders’ equity $ 265,045 $ 216 $ 265,261 The description of each error is in the Description of Misstatement Adjustments provided in Note 3 Restatement of Previously Issued Consolidated Financial Statements. The impact of each error for the corresponding period in the above table is described below: (a) Inventory Treatment - The correction of the misstatement resulted in a decrease to Inventories, net and an increase to Accumulated deficit of $ 198 as of June 30, 2022. (b) Interest Rate Swap - The correction of the misstatement resulted in an increase to Other assets and a decrease to Accumulated deficit of $ 414 , including an increase to the beginning balance of Accumulat
Schedule of Effect of Restatement on the Condensed Consolidated Statement of Stockholders' Equity	2023 Effect of Restatement on the Condensed Consolidated Statement of Stockholders' Equity: The effects of the restatement on the condensed consolidated statements of stockholders' equity for each of the three periods ended March 31, 2023, June 30, 2023, and September 30, 2023, are summarized in the following table, respectively: Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, January 1, 2023 77,770,588 $ 776 $ 213,956 $ ( 67,789 ) $ ( 33 ) $ ( 5,982 ) $ 140,928 Net loss — — — ( 9,052 ) — — ( 9,052 ) Issuance of common stock 4,312,500 43 68,406 — — — 68,449 Options exercised 223,785 2 1,620 — — — 1,622 Foreign currency translation — — — — ( 99 ) — ( 99 ) Employee stock purchase plan — — 122 — — — 122 Stock-based compensation — — 3,182 — — — 3,182 Balance, March 31, 2023 82,306,873 821 287,286 ( 76,841 ) ( 132 ) ( 5,982 ) 205,152 Adjustments Balance, January 1, 2023 — — — 1,677 — — 1,677 Net loss (a)(b) — — — ( 1,760 ) — — ( 1,760 ) Issuance of common stock — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, March 31, 2023 — — — ( 83 ) — — ( 83 ) As Restated Balance, January 1, 2023 77,770,588 776 213,956 ( 66,112 ) ( 33 ) ( 5,982 ) 142,605 Net loss — — — ( 10,812 ) — — ( 10,812 ) Issuance of common stock 4,312,500 43 68,406 — — — 68,449 Options exercised 223,785 2 1,620 — — — 1,622 Foreign currency translation — — — — ( 99 ) — ( 99 ) Employee stock purchase plan — — 122 — — — 122 Stock-based compensation — — 3,182 — — — 3,182 Balance, March 31, 2023 82,306,873 $ 821 $ 287,286 $ ( 76,924 ) $ ( 132 ) $ ( 5,982 ) $ 205,069 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, March 31, 2023 82,306,873 $ 821 $ 287,286 $ ( 76,841 ) $ ( 132 ) $ ( 5,982 ) $ 205,152 Net loss — — — ( 10,898 ) — — ( 10,898 ) Offering costs associated with public offering — — 4 — — — 4 Options exercised 192,027 3 840 — — — 843 Foreign currency translation — — — — ( 283 ) — ( 283 ) Employee stock purchase plan 37,146 — 620 — — — 620 Stock-based compensation — — 3,600 — — — 3,600 Balance, June 30, 2023 82,536,046 824 292,350 ( 87,739 ) ( 415 ) ( 5,982 ) 199,038 Adjustments Balance, March 31, 2023 — — — ( 83 ) — — ( 83 ) Net loss (a)(b) — — — ( 2,350 ) — — ( 2,350 ) Offering costs associated with public offering — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, June 30, 2023 — — — ( 2,433 ) — — ( 2,433 ) As Restated Balance, March 31, 2023 82,306,873 821 287,286 ( 76,924 ) ( 132 ) ( 5,982 ) 205,069 Net loss — — — ( 13,248 ) — — ( 13,248 ) Offering costs associated with public offering — — 4 — — — 4 Options exercised 192,027 3 840 — — — 843 Foreign currency translation — — — — ( 283 ) — ( 283 ) Employee stock purchase plan 37,146 — 620 — — — 620 Stock-based compensation — — 3,600 — — — 3,600 Balance, June 30, 2023 82,536,046 $ 824 $ 292,350 $ ( 90,172 ) $ ( 415 ) $ ( 5,982 ) $ 196,605 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, June 30, 2023 82,536,046 $ 824 $ 292,350 $ ( 87,739 ) $ ( 415 ) $ ( 5,982 ) $ 199,038 Net loss — — — ( 8,332 ) — — ( 8,332 ) Options exercised 19,861 — 70 — — — 70 Foreign currency translation — — — — ( 630 ) — ( 630 ) Employee stock purchase plan — — 86 — — — 86 Stock-based compensation — — 3,512 — — — 3,512 Balance, September 30, 2023 82,555,907 824 296,018 ( 96,071 ) ( 1,045 ) ( 5,982 ) 193,744 Adjustments Balance, June 30, 2023 — — — ( 2,433 ) — — ( 2,433 ) Net loss (a)(b) — — — ( 2,819 ) — — ( 2,819 ) Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, September 30, 2023 — — — ( 5,252 ) — — ( 5,252 ) As Restated Balance, June 30, 2023 82,536,046 824 292,350 ( 90,172 ) ( 415 ) ( 5,982 ) 196,605 Net loss — — — ( 11,151 ) — — ( 11,151 ) Options exercised 19,861 — 70 — — — 70 Foreign currency translation — — — — ( 630 ) — ( 630 ) Employee stock purchase plan — — 86 — — — 86 Stock-based compensation — — 3,512 — — — 3,512 Balance, September 30, 2023 82,555,907 $ 824 $ 296,018 $ ( 101,323 ) $ ( 1,045 ) $ ( 5,982 ) $ 188,492 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. 2022 Effect of Revision on the Condensed Consolidated Statement of Stockholders' Equity: The effects of the revision on the condensed consolidated statements of stockholders' equity for each of the three periods ended March 31, 2022, June 30, 2022, and September 30, 2022, are summarized in the following table, respectively: Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, January 1, 2022 76,447,287 $ 763 $ 197,868 $ ( 463 ) $ 8 $ ( 5,982 ) $ 192,194 Net loss — — — ( 9,236 ) — — ( 9,236 ) Issuance of common stock — — — — — — — Offering costs associated with initial public offering — — ( 266 ) — — — ( 266 ) Options exercised 1,875 — 12 — — — 12 Foreign currency translation — — — — ( 324 ) — ( 324 ) Stock-based compensation — — 2,122 — — — 2,122 Balance, March 31, 2022 76,449,162 763 199,736 ( 9,699 ) ( 316 ) ( 5,982 ) 184,502 Adjustments Balance, January 1, 2022 — — — — — — — Net loss (b) — — — ( 605 ) — — ( 605 ) Issuance of common stock — — — — — — — Offering costs associated with initial public offering — — — — — — — Options exercised — — — — — — — Foreign currency translation — — — — — — — Stock-based compensation — — — — — — — Balance, March 31, 2022 — — — ( 605 ) — — ( 605 ) As Restated Balance, January 1, 2022 76,447,287 763 197,868 ( 463 ) 8 ( 5,982 ) 192,194 Net loss — — — ( 9,841 ) — — ( 9,841 ) Issuance of common stock — — — — — — — Offering costs associated with initial public offering — — ( 266 ) — — — ( 266 ) Options exercised 1,875 — 12 — — — 12 Foreign currency translation — — — — ( 324 ) — ( 324 ) Stock-based compensation — — 2,122 — — — 2,122 Balance, March 31, 2022 76,449,162 $ 763 $ 199,736 $ ( 10,304 ) $ ( 316 ) $ ( 5,982 ) $ 183,897 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, March 31, 2022 76,449,162 $ 763 $ 199,736 $ ( 9,699 ) $ ( 316 ) $ ( 5,982 ) $ 184,502 Net loss — — — ( 9,603 ) — — ( 9,603 ) Options exercised 88,406 1 288 — — — 289 Foreign currency translation — — — — ( 593 ) — ( 593 ) Stock-based compensation — — 2,343 — — — 2,343 Balance, June 30, 2022 76,537,568 764 202,367 ( 19,302 ) ( 909 ) ( 5,982 ) 176,938 Adjustments Balance, March 31, 2022 — — — ( 605 ) — — ( 605 ) Net loss (a)(b) — — — 821 — — 821 Options exercised — — — — — — — Foreign currency translation — — — — — — — Stock-based compensation — — — — — — — Balance, June 30, 2022 — — — 216 — — 216 As Restated Balance, March 31, 2022 76,449,162 763 199,736 ( 10,304 ) ( 316 ) ( 5,982 ) 183,897 Net loss — — — ( 8,782 ) — — ( 8,782 ) Options exercised 88,406 1 288 — — — 289 Foreign currency translation — — — — ( 593 ) — ( 593 ) Stock-based compensation — — 2,343 — — — 2,343 Balance, June 30, 2022 76,537,568 $ 764 $ 202,367 $ ( 19,086 ) $ ( 909 ) $ ( 5,982 ) $ 177,154 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss. Accumulated Common Additional Other Total Stock Paid-in- Accumulated Comprehensive Treasury Stockholders’ As Previously Reported Ref Shares Amount Capital Deficit Loss Stock Equity Balance, June 30, 2022 76,537,568 $ 764 $ 202,367 $ ( 19,302 ) $ ( 909 ) $ ( 5,982 ) $ 176,938 Net loss — — — ( 9,724 ) — — ( 9,724 ) Options exercised 539,203 5 2,055 — — — 2,060 Foreign currency translation — — — — ( 588 ) — ( 588 ) Employee stock purchase plan — — 100 — — — 100 Stock-based compensation — — 2,587 — — — 2,587 Balance, September 30, 2022 77,076,771 769 207,109 ( 29,026 ) ( 1,497 ) ( 5,982 ) 171,373 Adjustments Balance, June 30, 2022 — — — 216 — — 216 Net loss (a)(b) — — — 1,177 — — 1,177 Options exercised — — — — — — — Foreign currency translation — — — — — — — Employee stock purchase plan — — — — — — — Stock-based compensation — — — — — — — Balance, September 30, 2022 — — — 1,393 — — 1,393 As Restated Balance, June 30, 2022 76,537,568 764 202,367 ( 19,086 ) ( 909 ) ( 5,982 ) 177,154 Net loss — — — ( 8,547 ) — — ( 8,547 ) Options exercised 539,203 5 2,055 — — — 2,060 Foreign currency translation — — — — ( 588 ) — ( 588 ) Employee stock purchase plan — — 100 — — — 100 Stock-based compensation — — 2,587 — — — 2,587 Balance, September 30, 2022 77,076,771 $ 769 $ 207,109 $ ( 27,633 ) $ ( 1,497 ) $ ( 5,982 ) $ 172,766 See descriptions of the Net loss impacts in the Consolidated Statement of Operations and Comprehensive Loss.

Business and Basis of Present_2

Business and Basis of Presentation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 30, 2023	Oct. 19, 2021	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsidiary, Sale of Stock [Line Items]
Net proceeds after deducting underwriting discounts and commissions								$ 129,384
Net proceeds after deducting underwriting discounts and commissions	$ 68,453		$ 68,449	$ 68,453	$ 68,453	$ 68,453		$ 1,001
Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of aggregate issued	6,500,000		4,312,500			4,312,500	0	151,515
Price per share	$ 17
Initial Public Offering | Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold		8,984,375
Public offering price per share		$ 16
Net proceeds after deducting underwriting discounts and commissions		$ 133,688
Offering expenses offset against proceeds								$ 4,304
Number of shares issued upon conversion of convertible securities		20,421,200
Number of aggregate issued								8,984,375
Underwriters Option to Purchase Additional Shares | Maximum
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold	562,500
Underwriters Option to Purchase Additional Shares | Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold	412,500	1,171,875
Shares sold by Company | Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold	3,750,000
Selling securityholders
Subsidiary, Sale of Stock [Line Items]
Net proceeds after deducting underwriting discounts and commissions	$ 50,700
Selling securityholders | Common Stock
Subsidiary, Sale of Stock [Line Items]
Number of shares issued and sold	2,750,000

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details)	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2023 USD ($) Reporting	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)
Finite-Lived Intangible Assets [Line Items]
Restricted cash			$ 2,250,000		$ 1,000,000		$ 1,000,000
Impairment of property and equipment							0	$ 0	$ 0
Impairment of intangible asset, finite-lived							$ 0	0	0
Number of reporting units | Reporting							1
Income tax likelihood percentage, description							more than 50 percent
(Income) expenses for excess and obsolete inventory	$ 293,000	$ (643,000)	$ 923,000	$ (446,000)	$ 3,204,000	$ (91,000)	$ 4,037,000	485,000	$ 2,821,000
Inventory reserve							$ 20,921,000	16,804,000
Capitalized amortization period							1 year
Revenue, practical expedient [true or false]							true
Unbilled revenue							$ 5,598,000	$ 4,511,000
Additive Orthopaedics, LLC | Achievement of Milestone
Finite-Lived Intangible Assets [Line Items]
Restricted cash							$ 1,000,000
ASU 2016-13
Finite-Lived Intangible Assets [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]							true
Change in Accounting Principle, Accounting Standards Update, Adoption Date							Jan. 01, 2023
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]							true
ASU 2019-12
Finite-Lived Intangible Assets [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]							true
Change in Accounting Principle, Accounting Standards Update, Adoption Date							Jan. 01, 2023
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]							true
Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life of assets							3 years
Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life of assets							25 years
Patents
Finite-Lived Intangible Assets [Line Items]
Amortization period							17 years
Developed Technology
Finite-Lived Intangible Assets [Line Items]
Estimated useful life							12 years	12 years
Customer Relationships | Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life							3 years	3 years
Customer Relationships | Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful life							7 years	7 years
Other Intangibles
Finite-Lived Intangible Assets [Line Items]
Estimated useful life							3 years	3 years
Surgical Instrumentation | Minimum
Finite-Lived Intangible Assets [Line Items]
Useful life of assets							3 years
Surgical Instrumentation | Maximum
Finite-Lived Intangible Assets [Line Items]
Useful life of assets							5 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Schedule of Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Accounting Policies [Abstract]
Allowance for doubtful accounts, beginning of year	$ 1,688	$ 1,032
Additions charged against revenue or to expense	223	1,853
Write-offs	(572)	(1,197)
Allowance for doubtful accounts, end of year	$ 1,339	$ 1,688

Restatement of Previously Iss_3

Restatement of Previously Issued Consolidated Financial Statements - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of goods sold	$ 11,922	$ 11,599	$ 10,229	$ 8,203	$ 7,836	$ 6,791	$ 21,828	$ 14,627	$ 33,750	$ 22,830	$ 51,954	$ 32,117	$ 28,024
Accumulated deficit	(101,323)	(90,172)	(76,924)	(27,633)	(19,086)	(10,304)	(90,172)	(19,086)	(101,323)	(27,633)	(123,646)	(66,112)
Inventories, net	89,128	81,501	68,191	54,861	51,502	43,185	81,501	51,502	89,128	54,861	90,046	61,288
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of goods sold	1,528	2,741	1,323	(288)	198		4,064	198	5,592	(90)	8,356	(340)
Accumulated deficit	(5,252)	(2,433)	(83)	1,393	216	$ (605)	(2,433)	216	(5,252)	1,393	(8,016)	1,677
Inventories, net	(5,252)	(3,724)	(983)	90			(3,724)		(5,252)	90	(8,016)	340
Adjustments | Inventory Treatment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of goods sold	1,528	2,741	1,323	(288)	198		4,064	198	5,592	(90)	8,356	(340)
Accumulated deficit	(5,252)	(3,724)	(983)	90	(198)		(3,724)	(198)	(5,252)	90	(8,016)	340
Inventories, net	$ (5,252)	$ (3,724)	$ (983)	$ 90	$ (198)		$ (3,724)	$ (198)	$ (5,252)	$ 90	$ (8,016)	$ 340

Restatement of Previously Iss_4

Restatement of Previously Issued Consolidated Financial Statements - Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash					$ 38,468	$ 56,325	$ 73,002	$ 93,647
Cash and cash equivalents	$ 75,639	$ 34,949	$ 56,747	$ 85,883	38,468
Trade receivables, net of allowance for doubtful accounts	37,323	33,615	34,331	37,262	37,687	35,960	32,598	27,653
Inventories, net	90,046	89,128	81,501	68,191	61,288	54,861	51,502	43,185
Income taxes receivable	794	1,022	870	596	615	705	660	622
Other current assets	3,997	4,826	3,257	4,167	4,658	1,947	3,129	3,448
Total current assets	207,799	163,540	176,706	196,099	142,716	149,798	160,891	168,555
Property and equipment, net	74,122	73,530	70,936	66,810	61,938	58,591	56,066	51,850
Intangible assets, net	21,674	21,802	21,921	22,137	22,387	20,850	20,352	21,350
Goodwill	25,465	25,465	25,465	25,465	25,465	26,975	26,975	26,672
Deferred income taxes	705	132	319	354	148	841	563	303
Other assets	2,918	3,634	3,057	2,597	3,132	1,303	414
Total assets	332,683	288,103	298,404	313,462	255,786	258,358	265,261	268,730
Current liabilities:
Accounts payable	21,696	27,395	29,681	20,538	14,939	13,979	14,564	11,877
Accrued expenses	27,781	24,966	24,390	25,446	26,807	19,507	21,407	17,827
Accrued legal settlement				13,000	22,000
Other current liabilities	883	1,893	1,700	3,772	3,844	6,889	6,926	7,433
Current maturities of long-term debt	640	640	652	690	728	735	757	781
Income taxes payable	243		20	208	184	497	305	492
Total current liabilities	51,243	54,894	56,443	63,654	68,502	41,607	43,959	38,410
Long-term liabilities:
Long-term debt net, less current maturities	109,799	42,288	42,259	42,204	42,182	42,492	42,519	42,471
Other long-term liabilities	1,048	1,467	1,842	1,523	1,628	907	905	3,123
Deferred income taxes	233	327	620	377	342	59	197	302
Income taxes payable	635	635	635	635	527	527	527	527
Total liabilities	162,958	99,611	101,799	108,393	113,181	85,592	88,107	84,833
Commitments and contingencies
Stockholders' equity:
Common stock, $0.01 par value, 300,000,000 shares authorized; 83,738,974 and 78,684,107 shares issued, and 82,825,455 and 77,770,588 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	827	824	824	821	776	769	764	763
Additional paid in capital	298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736
Accumulated deficit	(123,646)	(101,323)	(90,172)	(76,924)	(66,112)	(27,633)	(19,086)	(10,304)
Accumulated other comprehensive income (loss)	132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)
Treasury stock, at cost; 913,519 shares as of December 31, 2023 and December 31, 2022	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
Total stockholders' equity	169,725	188,492	196,605	205,069	142,605	172,766	177,154	183,897	$ 192,194	$ 30,393
Total liabilities & stockholders' equity	332,683	288,103	298,404	313,462	255,786	258,358	265,261	268,730
As Previously Reported
Current assets:
Cash					38,468	56,325	73,002	93,647
Cash and cash equivalents	75,639	34,949	56,747	85,883
Trade receivables, net of allowance for doubtful accounts	37,323	33,615	34,331	37,262	37,687	35,960	32,598	27,653
Inventories, net	98,062	94,380	85,225	69,174	60,948	54,771	51,700	43,185
Income taxes receivable	794	1,022	870	596	615	705	660	622
Other current assets	3,997	4,826	3,257	4,167	4,658	1,947	3,129	3,448
Total current assets	215,815	168,792	180,430	197,082	142,376	149,708	161,089	168,555
Property and equipment, net	74,122	73,530	70,936	66,810	61,938	58,591	56,066	51,850
Intangible assets, net	21,674	21,802	21,921	22,137	22,387	20,850	20,352	21,350
Goodwill	25,465	25,465	25,465	25,465	25,465	26,975	26,975	26,672
Deferred income taxes	705	132	319	354	148	841	563	303
Other assets	2,918	3,634	1,766	1,697	1,795
Total assets	340,699	293,355	300,837	313,545	254,109	256,965	265,045	268,730
Current liabilities:
Accounts payable	21,696	27,395	29,681	20,538	14,939	13,979	14,564	11,877
Accrued expenses	27,781	24,966	24,390	25,446	26,807	19,507	21,407	17,827
Accrued legal settlement				13,000	22,000
Other current liabilities	883	1,893	1,700	3,772	3,844	6,889	6,926	7,433
Current maturities of long-term debt	640	640	652	690	728	735	757	781
Income taxes payable	243		20	208	184	497	305	492
Total current liabilities	51,243	54,894	56,443	63,654	68,502	41,607	43,959	38,410
Long-term liabilities:
Long-term debt net, less current maturities	109,799	42,288	42,259	42,204	42,182	42,492	42,519	42,471
Other long-term liabilities	1,048	1,467	1,842	1,523	1,628	907	905	2,518
Deferred income taxes	233	327	620	377	342	59	197	302
Income taxes payable	635	635	635	635	527	527	527	527
Total liabilities	162,958	99,611	101,799	108,393	113,181	85,592	88,107	84,228
Stockholders' equity:
Common stock, $0.01 par value, 300,000,000 shares authorized; 83,738,974 and 78,684,107 shares issued, and 82,825,455 and 77,770,588 shares outstanding as of December 31, 2023 and December 31, 2022, respectively	827	824	824	821	776	769	764	763
Additional paid in capital	298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736
Accumulated deficit	(115,630)	(96,071)	(87,739)	(76,841)	(67,789)	(29,026)	(19,302)	(9,699)
Accumulated other comprehensive income (loss)	132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)
Treasury stock, at cost; 913,519 shares as of December 31, 2023 and December 31, 2022	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
Total stockholders' equity	177,741	193,744	199,038	205,152	140,928	171,373	176,938	184,502	$ 192,194
Total liabilities & stockholders' equity	340,699	293,355	300,837	313,545	254,109	256,965	265,045	268,730
Adjustments
Current assets:
Inventories, net	(8,016)	(5,252)	(3,724)	(983)	340	90
Income taxes receivable							(198)
Total current assets	(8,016)	(5,252)	(3,724)	(983)	340	90	(198)
Other assets			1,291	900	1,337	1,303	414
Total assets	(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216
Long-term liabilities:
Other long-term liabilities								605
Total liabilities								605
Stockholders' equity:
Accumulated deficit	(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216	(605)
Total stockholders' equity	(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216	$ (605)
Total liabilities & stockholders' equity	$ (8,016)	$ (5,252)	$ (2,433)	$ (83)	$ 1,677	$ 1,393	$ 216

Restatement of Previously Iss_5

Restatement of Previously Issued Consolidated Financial Statements - Consolidated Balance Sheet (Parenthetical) (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Oct. 08, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Common stock par value	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01
Common stock share authorized	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000		300,000,000
Common stock share issued	83,738,974	83,469,426	83,449,565	83,220,392	78,684,107	77,990,290	77,451,087	77,362,681
Common stock shares, outstanding	82,825,455	82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162
Treasury stock share issued	913,519	913,519	913,519	913,519	913,519	913,519	913,519	913,519
Accumulated deficit	$ (123,646)	$ (101,323)	$ (90,172)	$ (76,924)	$ (66,112)	$ (27,633)	$ (19,086)	$ (10,304)
Allowance for doubtful accounts	1,339	934	1,706	1,816	1,688	1,990	1,234	1,310	$ 1,032
Inventories, net	90,046	89,128	81,501	68,191	61,288	54,861	51,502	43,185
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit	(115,630)	(96,071)	(87,739)	(76,841)	(67,789)	(29,026)	(19,302)	(9,699)
Inventories, net	98,062	94,380	85,225	69,174	60,948	54,771	51,700	43,185
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit	(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216	(605)
Inventories, net	(8,016)	(5,252)	(3,724)	(983)	340	90
Adjustments | Inventory Treatment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit	(8,016)	(5,252)	(3,724)	(983)	340	90	(198)
Inventories, net	$ (8,016)	$ (5,252)	(3,724)	(983)	340	90	(198)
Adjustments | Interest Rate Swap
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Accumulated deficit			1,291	900	1,337	1,303	414	$ (605)
Other assets			$ 1,291	$ 900	$ 1,337	$ 1,303	$ 414

Restatement of Previously Iss_6

Restatement of Previously Issued Consolidated Financial Statements - Consolidated Statement of Operations And Comprehensive Loss (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 60,561	$ 52,783	$ 51,009	$ 52,036	$ 51,508	$ 46,006	$ 42,498	$ 41,371	$ 103,045	$ 83,869	$ 155,828	$ 129,875	$ 216,389	$ 181,383	$ 147,464
Cost of goods sold		11,922	11,599	10,229		8,203	7,836	6,791	21,828	14,627	33,750	22,830	51,954	32,117	28,024
Gross profit	42,357	40,861	39,410	41,807	42,221	37,803	34,662	34,580	81,217	69,242	122,078	107,045	164,435	149,266	119,440
Operating expenses:
Research and development costs		7,244	7,683	7,049		6,337	5,990	5,773	14,732	11,763	21,976	18,100	30,078	24,650	16,128
Selling, general, and administrative		44,126	43,827	43,820		39,667	37,948	37,242	87,647	75,190	131,773	114,857	180,022	159,323	114,087
Legal settlement														27,000
Total operating expenses		51,370	51,510	50,869		46,004	43,938	43,015	102,379	86,953	153,749	132,957	210,100	210,973	130,215
Operating loss	(13,994)	(10,509)	(12,100)	(9,062)	(35,795)	(8,201)	(9,276)	(8,435)	(21,162)	(17,711)	(31,671)	(25,912)	(45,665)	(61,707)	(10,775)
Other income (expense):
Other income (expense)		369	(76)	(616)		948	1,671	(706)	(692)	965	(323)	1,913	(1,183)	123	(486)
Loss on early extinguishment of debt													(5,308)
Interest expense, net		(1,119)	(803)	(1,205)		(1,093)	(1,104)	(668)	(2,008)	(1,772)	(3,127)	(2,865)	(5,165)	(4,129)	(1,719)
Total other income (expense)		(750)	(879)	(1,821)		(145)	567	(1,374)	(2,700)	(807)	(3,450)	(952)	(11,656)	(4,006)	(2,205)
Loss before income taxes		(11,259)	(12,979)	(10,883)		(8,346)	(8,709)	(9,809)	(23,862)	(18,518)	(35,121)	(26,864)	(57,321)	(65,713)	(12,980)
Income Tax Expense (Benefit)		(108)	269	(71)		201	73	32	198	105	90	306	213	(64)	713
Net loss	$ (22,323)	(11,151)	(13,248)	(10,812)	$ (38,479)	(8,547)	(8,782)	(9,841)	(24,060)	(18,623)	(35,211)	(27,170)	(57,534)	(65,649)	(13,693)
Foreign currency translation adjustment		(630)	(283)	(99)		(588)	(593)	(324)	(382)	(917)	(1,012)	(1,505)	165	(41)	(815)
Comprehensive loss		$ (11,781)	$ (13,531)	$ (10,911)		$ (9,135)	$ (9,375)	$ (10,165)	$ (24,442)	$ (19,540)	$ (36,223)	$ (28,675)	$ (57,369)	$ (65,690)	$ (14,508)
Weighted average number of shares of common stock outstanding:
Basic		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100	52,916,711
Diluted		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100	52,916,711
Net loss per share attributable to common stockholders:
Basic	$ (0.27)	$ (0.14)	$ (0.16)	$ (0.13)	$ (0.5)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.3)	$ (0.24)	$ (0.43)	$ (0.35)	$ (0.7)	$ (0.86)	$ (0.26)
Diluted	$ (0.27)	$ (0.14)	$ (0.16)	$ (0.13)	$ (0.5)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.3)	$ (0.24)	$ (0.43)	$ (0.35)	$ (0.7)	$ (0.86)	$ (0.26)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net revenue	$ 60,561	$ 52,783	$ 51,009	$ 52,036	$ 51,508	$ 46,006	$ 42,498	$ 41,371	$ 103,045	$ 83,869	$ 155,828	$ 129,875	$ 216,389	$ 181,383
Cost of goods sold		10,394	8,858	8,906		8,491	7,638	6,791	17,764	14,429	28,158	22,920	43,598	32,457
Gross profit	45,121	42,389	42,151	43,130	41,971	37,515	34,860	34,580	85,281	69,440	127,670	106,955	172,791	148,926
Operating expenses:
Research and development costs		7,244	7,683	7,049		6,337	5,990	5,773	14,732	11,763	21,976	18,100	30,078	24,650
Selling, general, and administrative		44,126	43,827	43,820		39,667	37,948	37,242	87,647	75,190	131,773	114,857	180,022	159,323
Legal settlement														27,000
Total operating expenses		51,370	51,510	50,869		46,004	43,938	43,015	102,379	86,953	153,749	132,957	210,100	210,973
Operating loss	(11,230)	(8,981)	(9,359)	(7,739)	(36,045)	(8,489)	(9,078)	(8,435)	(17,098)	(17,513)	(26,079)	(26,002)	(37,309)	(62,047)
Other income (expense):
Other income (expense)		1,660	(467)	(179)		59	652	(101)	(646)	551	1,014	610	154	(1,214)
Loss on early extinguishment of debt													(5,308)
Interest expense, net		(1,119)	(803)	(1,205)		(1,093)	(1,104)	(668)	(2,008)	(1,772)	(3,127)	(2,865)	(5,165)	(4,129)
Total other income (expense)		541	(1,270)	(1,384)		(1,034)	(452)	(769)	(2,654)	(1,221)	(2,113)	(2,255)	(10,319)	(5,343)
Loss before income taxes		(8,440)	(10,629)	(9,123)		(9,523)	(9,530)	(9,204)	(19,752)	(18,734)	(28,192)	(28,257)	(47,628)	(67,390)
Income Tax Expense (Benefit)		(108)	269	(71)		201	73	32	198	105	90	306	213	(64)
Net loss	$ (19,559)	(8,332)	(10,898)	(9,052)	$ (38,763)	(9,724)	(9,603)	(9,236)	(19,950)	(18,839)	(28,282)	(28,563)	(47,841)	(67,326)
Foreign currency translation adjustment		(630)	(283)	(99)		(588)	(593)	(324)	(382)	(917)	(1,012)	(1,505)	165	(41)
Comprehensive loss		$ (8,962)	$ (11,181)	$ (9,151)		$ (10,312)	$ (10,196)	$ (9,560)	$ (20,332)	$ (19,756)	$ (29,294)	$ (30,068)	$ (47,676)	$ (67,367)
Weighted average number of shares of common stock outstanding:
Basic		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100
Diluted		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100
Net loss per share attributable to common stockholders:
Basic	$ (0.24)	$ (0.1)	$ (0.13)	$ (0.11)	$ (0.5)	$ (0.13)	$ (0.13)	$ (0.12)	$ (0.24)	$ (0.25)	$ (0.35)	$ (0.37)	$ (0.58)	$ (0.88)
Diluted	$ (0.24)	$ (0.1)	$ (0.13)	$ (0.11)	$ (0.5)	$ (0.13)	$ (0.13)	$ (0.12)	$ (0.24)	$ (0.25)	$ (0.35)	$ (0.37)	$ (0.58)	$ (0.88)
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of goods sold		$ 1,528	$ 2,741	$ 1,323		$ (288)	$ 198		$ 4,064	$ 198	$ 5,592	$ (90)	$ 8,356	$ (340)
Gross profit		(1,528)	(2,741)	(1,323)		288	(198)		(4,064)	(198)	(5,592)	90	(8,356)	340
Operating expenses:
Selling, general, and administrative									0		0		0	0
Total operating expenses									0		0		0	0
Operating loss		(1,528)	(2,741)	(1,323)		288	(198)		(4,064)	(198)	(5,592)	90	(8,356)	340
Other income (expense):
Other income (expense)		(1,291)	391	(437)		889	1,019	$ (605)	(46)	414	(1,337)	1,303	(1,337)	1,337
Total other income (expense)		(1,291)	391	(437)		889	1,019	(605)	(46)	414	(1,337)	1,303	(1,337)	1,337
Loss before income taxes		(2,819)	(2,350)	(1,760)		1,177	821	(605)	(4,110)	216	(6,929)	1,393	(9,693)	1,677
Net loss		(2,819)	(2,350)	(1,760)		1,177	821	(605)	(4,110)	216	(6,929)	1,393	(9,693)	1,677
Comprehensive loss		$ (2,819)	$ (2,350)	$ (1,760)		$ 1,177	$ 821	$ (605)	$ (4,110)	$ 216	$ (6,929)	$ 1,393	$ (9,693)	$ 1,677
Net loss per share attributable to common stockholders:
Basic		$ (0.04)	$ (0.03)	$ (0.02)		$ 0.02	$ 0.02	$ (0.01)	$ (0.06)	$ 0.01	$ (0.08)	$ 0.02	$ (0.12)	$ 0.02
Diluted		$ (0.04)	$ (0.03)	$ (0.02)		$ 0.02	$ 0.02	$ (0.01)	$ (0.06)	$ 0.01	$ (0.08)	$ 0.02	$ (0.12)	$ 0.02

Restatement of Previously Iss_7

Restatement of Previously Issued Consolidated Financial Statements - Consolidated Statement of Operations And Comprehensive Loss (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other income (expense), net	$ 369	$ (76)	$ (616)	$ 948	$ 1,671	$ (706)	$ (692)	$ 965	$ (323)	$ 1,913	$ (1,183)	$ 123	$ (486)
Cost of goods sold	11,922	11,599	10,229	8,203	7,836	6,791	21,828	14,627	33,750	22,830	51,954	32,117	$ 28,024
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other income (expense), net	(1,291)	391	(437)	889	1,019	(605)	(46)	414	(1,337)	1,303	(1,337)	1,337
Cost of goods sold	1,528	2,741	1,323	(288)	198		4,064	198	5,592	(90)	8,356	(340)
Adjustments | Inventory Treatment
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cost of goods sold	1,528	2,741	1,323	(288)	198		4,064	198	5,592	(90)	8,356	(340)
Interest Rate Swap [Member] | Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Other income (expense), net	$ (1,291)	$ 391	$ (437)	$ 889	$ 1,019	$ (605)	$ (46)	$ 414	$ (1,337)	$ 1,303	$ (1,337)	$ 1,337

Restatement of Previously Iss_8

Restatement of Previously Issued Consolidated Financial Statements - Consolidated Statements of Convertible Preferred Series Equity & Stockholders' Equity (Details) - USD ($) $ in Thousands		3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Jan. 30, 2023	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		$ 188,492	$ 196,605	$ 205,069	$ 142,605	$ 172,766	$ 177,154	$ 183,897	$ 192,194	$ 142,605	$ 192,194	$ 142,605	$ 192,194	$ 142,605	$ 192,194	$ 30,393
Net loss		(22,323)	(11,151)	(13,248)	(10,812)	(38,479)	(8,547)	(8,782)	(9,841)	(24,060)	(18,623)	(35,211)	(27,170)	(57,534)	(65,649)	(13,693)
Offering costs associated with initial public offering															(266)
Issuance of common stock					68,449									68,453		1,001
Options exercised			70	843	1,622		2,060	289	12					2,406	5,271	445
Foreign currency translation			(630)	(283)	(99)		(588)	(593)	(324)					165	(41)	(815)
Employee stock purchase plan			86	620	122		100							1,266	731
Stock-based compensation			3,512	3,600	3,182		2,587	2,343	2,122					12,364	10,365	4,948
Ending balance		$ 169,725	$ 188,492	$ 196,605	$ 205,069	$ 142,605	$ 172,766	$ 177,154	$ 183,897	$ 196,605	$ 177,154	$ 188,492	$ 172,766	$ 169,725	$ 142,605	$ 192,194
Common Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance, shares		82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162	76,447,287	77,770,588	76,447,287	77,770,588	76,447,287	77,770,588	76,447,287	46,738,540
Beginning balance		$ 824	$ 824	$ 821	$ 776	$ 769	$ 764	$ 763	$ 763	$ 776	$ 763	$ 776	$ 763	$ 776	$ 763	$ 467
Issuance of common stock, shares	6,500,000				4,312,500									4,312,500	0	151,515
Issuance of common stock					$ 43									$ 43		$ 1
Options exercised, shares			19,861	192,027	223,785		539,203	88,406	1,875					668,925	1,284,333	236,706
Options exercised				$ 3	$ 2		$ 5	$ 1						$ 7	$ 13	$ 2
Employee stock purchase plan,Shares				37,146										73,442	38,968
Employee stock purchase plan														$ 1
Ending balance, shares		82,825,455	82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162	82,536,046	76,537,568	82,555,907	77,076,771	82,825,455	77,770,588	76,447,287
Ending balance		$ 827	$ 824	$ 824	$ 821	$ 776	$ 769	$ 764	$ 763	$ 824	$ 764	$ 824	$ 769	$ 827	$ 776	$ 763
Additional Paid-in Capital [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		296,018	292,350	287,286	213,956	207,109	202,367	199,736	197,868	213,956	197,868	213,956	197,868	213,956	197,868	22,107
Offering costs associated with initial public offering															(266)
Issuance of common stock					68,406									68,410		1,000
Options exercised			70	840	1,620		2,055	288	12					2,399	5,258	443
Employee stock purchase plan			86	620	122		100							1,265	731
Stock-based compensation			3,512	3,600	3,182		2,587	2,343	2,122					12,364	10,365	4,948
Ending balance		298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736	292,350	202,367	296,018	207,109	298,394	213,956	197,868
Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		(101,323)	(90,172)	(76,924)	(66,112)	(27,633)	(19,086)	(10,304)	(463)	(66,112)	(463)	(66,112)	(463)	(66,112)	(463)	12,418
Net loss			(11,151)	(13,248)	(10,812)		(8,547)	(8,782)	(9,841)					(57,534)	(65,649)	(13,693)
Ending balance		(123,646)	(101,323)	(90,172)	(76,924)	(66,112)	(27,633)	(19,086)	(10,304)	(90,172)	(19,086)	(101,323)	(27,633)	(123,646)	(66,112)	(463)
Accumulated Other Comprehensive Income (Loss)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)	8	(33)	8	(33)	8	(33)	8	823
Foreign currency translation			(630)	(283)	(99)		(588)	(593)	(324)					165	(41)	(815)
Ending balance		132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)	(415)	(909)	(1,045)	(1,497)	132	(33)	8
Treasury stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,422)
Ending balance		(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		193,744	199,038	205,152	140,928	171,373	176,938	184,502	192,194	140,928	192,194	140,928	192,194	140,928	192,194
Net loss		(19,559)	(8,332)	(10,898)	(9,052)	(38,763)	(9,724)	(9,603)	(9,236)	(19,950)	(18,839)	(28,282)	(28,563)	(47,841)	(67,326)
Offering costs associated with initial public offering															(266)
Issuance of common stock					68,449									68,453
Options exercised			70	843	1,622		2,060	289	12					2,406	5,271
Foreign currency translation			(630)	(283)	(99)		(588)	(593)	(324)					165	(41)
Employee stock purchase plan			86	620	122		100							1,266	731
Stock-based compensation			3,512	3,600	3,182		2,587	2,343	2,122					12,364	10,365
Ending balance		$ 177,741	$ 193,744	$ 199,038	$ 205,152	$ 140,928	$ 171,373	$ 176,938	$ 184,502	$ 199,038	$ 176,938	$ 193,744	$ 171,373	$ 177,741	$ 140,928	$ 192,194
As Previously Reported | Common Stock [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance, shares		82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162	76,447,287	77,770,588	76,447,287	77,770,588	76,447,287	77,770,588	76,447,287
Beginning balance		$ 824	$ 824	$ 821	$ 776	$ 769	$ 764	$ 763	$ 763	$ 776	$ 763	$ 776	$ 763	$ 776	$ 763
Issuance of common stock, shares					4,312,500									4,312,500
Issuance of common stock					$ 43									$ 43
Options exercised, shares			19,861	192,027	223,785		539,203	88,406	1,875					668,925	1,284,333
Options exercised				$ 3	$ 2		$ 5	$ 1						$ 7	$ 13
Employee stock purchase plan,Shares				37,146										73,442	38,968
Employee stock purchase plan														$ 1
Ending balance, shares		82,825,455	82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162	82,536,046	76,537,568	82,555,907	77,076,771	82,825,455	77,770,588	76,447,287
Ending balance		$ 827	$ 824	$ 824	$ 821	$ 776	$ 769	$ 764	$ 763	$ 824	$ 764	$ 824	$ 769	$ 827	$ 776	$ 763
As Previously Reported | Additional Paid-in Capital [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		296,018	292,350	287,286	213,956	207,109	202,367	199,736	197,868	213,956	197,868	213,956	197,868	213,956	197,868
Offering costs associated with initial public offering															(266)
Issuance of common stock					68,406									68,410
Options exercised			70	840	1,620		2,055	288	12					2,399	5,258
Employee stock purchase plan			86	620	122		100							1,265	731
Stock-based compensation			3,512	3,600	3,182		2,587	2,343	2,122					12,364	10,365
Ending balance		298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736	292,350	202,367	296,018	207,109	298,394	213,956	197,868
As Previously Reported | Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		(96,071)	(87,739)	(76,841)	(67,789)	(29,026)	(19,302)	(9,699)	(463)	(67,789)	(463)	(67,789)	(463)	(67,789)	(463)
Net loss			(8,332)	(10,898)	(9,052)		(9,724)	(9,603)	(9,236)					(47,841)	(67,326)
Ending balance		(115,630)	(96,071)	(87,739)	(76,841)	(67,789)	(29,026)	(19,302)	(9,699)	(87,739)	(19,302)	(96,071)	(29,026)	(115,630)	(67,789)	(463)
As Previously Reported | Accumulated Other Comprehensive Income (Loss)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)	8	(33)	8	(33)	8	(33)	8
Foreign currency translation			(630)	(283)	(99)		(588)	(593)	(324)					165	(41)
Ending balance		132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)	(415)	(909)	(1,045)	(1,497)	132	(33)	8
As Previously Reported | Treasury stock
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
Ending balance		(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	$ (5,982)
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		(5,252)	(2,433)	(83)	1,677	1,393	216	(605)		1,677		1,677		1,677
Net loss			(2,819)	(2,350)	(1,760)		1,177	821	(605)	(4,110)	216	(6,929)	1,393	(9,693)	1,677
Ending balance		(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216	(605)	(2,433)	216	(5,252)	1,393	(8,016)	1,677
Adjustments | Accumulated Deficit
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Beginning balance		(5,252)	(2,433)	(83)	1,677	1,393	216	(605)		1,677		1,677		1,677
Net loss			(2,819)	(2,350)	(1,760)		1,177	821	(605)					(9,693)	1,677
Ending balance		$ (8,016)	$ (5,252)	$ (2,433)	$ (83)	$ 1,677	$ 1,393	$ 216	$ (605)	$ (2,433)	$ 216	$ (5,252)	$ 1,393	$ (8,016)	$ 1,677

Restatement of Previously Iss_9

Restatement of Previously Issued Consolidated Financial Statements - Consolidated Statements of Convertible Preferred Series Equity & Stockholders' Equity (Parenthetical) (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs	$ 827
Previously Reported [Member]
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs	827
Adjustments
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Issuance costs	$ 827

Restatement of Previously Is_10

Restatement of Previously Issued Consolidated Financial Statements - Consolidated Statements of Cash Flows (Details) - USD ($) $ in Thousands		3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Jan. 30, 2023	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss		$ (22,323)	$ (11,151)	$ (13,248)	$ (10,812)	$ (38,479)	$ (8,547)	$ (8,782)	$ (9,841)	$ (24,060)	$ (18,623)	$ (35,211)	$ (27,170)	$ (57,534)	$ (65,649)	$ (13,693)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization					3,117				3,030	6,414	6,566	10,602	9,624	15,542	13,728	8,961
Allowance for doubtful accounts									600	147		147		614	155	1,022
Provision for excess and obsolete inventories					293				(643)	923	(446)	3,204	(91)	4,037	485	2,821
Loss on early extinguishment of debt														1,881
Stock-based compensation					3,182				2,122	6,782	4,465	10,294	7,052	12,364	10,365	4,948
Change in fair value of financial instruments					517				605	366	(414)	(57)	(1,303)	546	(57)	440
Other					100				387	394	(1,514)	(34)	(1,295)	984	704	1,014
Changes in other assets and liabilities, net of acquisitions:
Accounts receivable					(441)				(2,240)	(3,138)	(6,825)	(3,706)	(10,227)	(161)	(12,013)	(6,461)
Inventories					(7,112)				(2,329)	(20,959)	(11,320)	(31,117)	(15,406)	(32,628)	(21,852)	(11,098)
Accounts payable					5,592				(1,178)	14,745	1,537	12,468	951	6,742	1,895	3,431
Accrued expenses					(877)					1,845	1,992	3,718	176	6,428	2,317	7,095
Accrued legal settlement					(9,000)					(22,000)		(22,000)		(22,000)	22,000
Income tax receivable/payable					132				669	(359)	454	(533)	297	(50)	391	671
Other assets and liabilities					(367)					(779)	289	(2,704)	1,442	(655)	(1,650)	(2,468)
Net cash used in operating activities					(14,060)				(9,503)	(33,403)	(23,839)	(47,517)	(35,950)	(63,890)	(49,181)	(3,317)
Cash flows from investing activities
Purchase of office building													(18,300)		(18,300)
Purchases of property and equipment					(7,521)				(23,036)	(15,354)	(29,204)	(21,893)	(15,637)	(26,716)	(22,813)	(18,296)
Proceeds from sale of property and equipment					223				305	635	519	795	642	1,043	897	799
Purchases of intangible assets					(254)				(704)	(544)	(783)	(933)	(1,720)	(1,314)	(1,973)	(2,993)
Acquisition, net of cash received									(18,201)		(18,504)		(18,504)		(18,504)	(15,000)
Net cash used in investing activities					(7,552)				(41,636)	(15,263)	(47,972)	(22,031)	(53,519)	(26,987)	(60,693)	(35,490)
Cash flows from financing activities
Proceeds from draw on term loan									20,000		20,000		20,000		20,000
Proceeds from issuance of long-term debt									16,000		16,000		16,000	100,000	16,000	10,000
Payments on long-term debt					(197)				(37)	(396)	(178)	(568)	(367)	(30,727)	(570)	(6,034)
Payments of debt issuance costs					(7)				(405)		(405)		(420)	(4,423)	(732)	(3,139)
Proceeds from issuance of common stock, net of issuance costs	$ 68,453				68,449					68,453		68,453		68,453		1,001
Proceeds from IPO, net of issuance costs																129,384
Payments for Repurchase of Common Stock																561
Proceeds from exercise of stock options					1,622				12	2,464	300	2,535	2,224	2,406	5,271	445
Proceeds from employee stock purchase plan										560		560		944	518
Payments on earnout liability					(500)					(4,250)		(5,500)	(500)	(8,000)	(1,000)
Net cash provided by financing activities					69,367				35,570	66,831	35,717	65,480	36,937	128,653	39,487	131,096
Effect of exchange rate changes on cash and cash equivalents					(340)				(136)	114	(256)	549	(495)	(605)	(497)	(438)
Net increase (decrease) in cash and cash equivalents					47,415				(15,705)	18,279	(36,350)	(3,519)	(53,027)	37,171	(70,884)	91,851
Cash and cash equivalents at beginning of period		34,949	56,747	85,883	38,468	56,325	73,002	93,647	109,352	38,468	109,352	38,468	109,352	38,468	109,352	17,501
Cash and cash equivalents at end of period		75,639	34,949	56,747	85,883	38,468	56,325	73,002	93,647	56,747	73,002	34,949	56,325	75,639	38,468	109,352
Supplemental Cash Flow Elements [Abstract]
Restricted cash		1,000	1,000	2,250						2,250		1,000		1,000
Cash paid for income taxes										456	386	610	788	908	1,103	678
Cash paid for interest					601				273	2,068	1,520	3,342	2,111	4,271	3,073	1,086
Purchase of property and equipment included in accounts payable					4,026				1,804	5,617	3,088	4,842	2,363	3,402	3,402	881
As Previously Reported
Cash flows from operating activities
Net loss		(19,559)	(8,332)	(10,898)	(9,052)	(38,763)	(9,724)	(9,603)	(9,236)	(19,950)	(18,839)	(28,282)	(28,563)	(47,841)	(67,326)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization					3,117				3,030	6,414	6,566	10,602	9,624	15,542	13,728
Allowance for doubtful accounts									600	147		147		614	155
Provision for excess and obsolete inventories					293				(643)	(205)	(446)	2,053	(91)	(352)	485
Loss on early extinguishment of debt														1,881
Stock-based compensation					3,182				2,122	6,782	4,465	10,294	7,052	12,364	10,365
Change in fair value of financial instruments					80									(791)	1,280
Other					100				387	714	(1,514)	(1,428)	(1,295)	984	704
Changes in other assets and liabilities, net of acquisitions:
Accounts receivable					(441)				(2,240)	(3,138)	(6,825)	(3,706)	(10,227)	(161)	(12,013)
Inventories					(8,435)				(2,329)	(23,895)	(11,518)	(35,558)	(15,316)	(36,595)	(21,512)
Accounts payable					5,592				(1,178)	14,745	1,537	12,468	951	6,742	1,895
Accrued expenses					(877)					1,845	1,992	3,718	176	6,428	2,317
Accrued legal settlement					(9,000)					(22,000)		(22,000)		(22,000)	22,000
Income tax receivable/payable					132				669	(359)	454	(533)	297	(50)	391
Other assets and liabilities					(367)					(779)	289	(2,704)	1,442	(655)	(1,650)
Net cash used in operating activities					(14,060)				(9,503)	(33,403)	(23,839)	(47,517)	(35,950)	(63,890)	(49,181)
Cash flows from investing activities
Purchase of office building													(18,300)		(18,300)
Purchases of property and equipment					(7,521)				(23,036)	(15,354)	(29,204)	(21,893)	(15,637)	(26,716)	(22,813)
Proceeds from sale of property and equipment					223				305	635	519	795	642	1,043	897
Purchases of intangible assets					(254)				(704)	(544)	(783)	(933)	(1,720)	(1,314)	(1,973)
Acquisition, net of cash received									(18,201)		(18,504)		(18,504)		(18,504)
Net cash used in investing activities					(7,552)				(41,636)	(15,263)	(47,972)	(22,031)	(53,519)	(26,987)	(60,693)
Cash flows from financing activities
Proceeds from draw on term loan									20,000		20,000		20,000		20,000
Proceeds from issuance of long-term debt									16,000		16,000		16,000	100,000	16,000
Payments on long-term debt					(197)				(37)	(396)	(178)	(568)	(367)	(30,727)	(570)
Payments of debt issuance costs					(7)				(405)		(405)		(420)	(4,423)	(732)
Proceeds from issuance of common stock, net of issuance costs					68,449					68,453		68,453		68,453
Proceeds from exercise of stock options					1,622				12	2,464	300	2,535	2,224	2,406	5,271
Proceeds from employee stock purchase plan										560		560		944	518
Payments on earnout liability					(500)					(4,250)		(5,500)	(500)	(8,000)	(1,000)
Net cash provided by financing activities					69,367				35,570	66,831	35,717	65,480	36,937	128,653	39,487
Effect of exchange rate changes on cash and cash equivalents					(340)				(136)	114	(256)	549	(495)	(605)	(497)
Net increase (decrease) in cash and cash equivalents					47,415				(15,705)	18,279	(36,350)	(3,519)	(53,027)	37,171	(70,884)
Cash and cash equivalents at beginning of period		34,949	56,747	85,883	38,468	56,325	73,002	93,647	109,352	38,468	109,352	38,468	109,352	38,468	109,352
Cash and cash equivalents at end of period		75,639	34,949	56,747	85,883	$ 38,468	56,325	73,002	93,647	56,747	73,002	34,949	56,325	75,639	38,468	$ 109,352
Supplemental Cash Flow Elements [Abstract]
Restricted cash		$ 1,000	1,000	2,250						2,250		1,000		1,000
Cash paid for income taxes										456	386	610	788	908	1,103
Cash paid for interest					601				273	2,068	1,520	3,342	2,111	4,271	3,073
Purchase of property and equipment included in accounts payable					4,026				1,804	5,617	3,088	4,842	2,363	3,402	3,402
Adjustments
Cash flows from operating activities
Net loss			$ (2,819)	$ (2,350)	(1,760)		$ 1,177	$ 821	(605)	(4,110)	216	(6,929)	1,393	(9,693)	1,677
Adjustments to reconcile net loss to net cash provided by operating activities:
Provision for excess and obsolete inventories										1,128		1,151		4,389
Change in fair value of financial instruments					437				605	46	(414)	1,337	(1,303)	1,337	(1,337)
Other					0				$ 0	0	0	0	0
Changes in other assets and liabilities, net of acquisitions:
Inventories					$ 1,323					$ 2,936	$ 198	$ 4,441	$ (90)	$ 3,967	$ (340)

Business Combinations - Additio

Business Combinations - Additional Information (Details) - USD ($)			3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 10, 2022	May 28, 2021	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Business Acquisition [Line Items]
Cash consideration			$ 18,201,000	$ 18,504,000	$ 18,504,000		$ 18,504,000	$ 15,000,000
Proceeds from revolving credit facility			$ 20,000,000	$ 20,000,000	$ 20,000,000		20,000,000
Disior LTD.
Business Acquisition [Line Items]
Acquired percentage	100%
Aggregate purchase price of acquisition	$ 26,246,000
Contingent earn-out consideration, estimated fair value	6,550,000
Net working capital adjustments and deferred payments, net payable	222,000
Cash consideration	19,696,000
Maximum earn out payment	8,000,000
Acquisition related costs						$ 0
Business acquisition, pro forma information, description						There is no supplemental proforma presentation of operating results of the acquisition of Disior due to the immaterial impact on the Company’s Consolidated operations for the years ended December 31, 2022 and 2021.
Net assets acquired	26,246,000
Disior LTD. | Selling, General, and Administrative Expenses
Business Acquisition [Line Items]
Acquisition related costs							761,000
Disior LTD. | Term Loan
Business Acquisition [Line Items]
Proceeds from revolving credit facility	20,000,000
Disior LTD. | Measurement Period Adjustments
Business Acquisition [Line Items]
Aggregate purchase price of acquisition	$ 26,246,000
Additive Orthopaedics, LLC
Business Acquisition [Line Items]
Aggregate purchase price of acquisition		$ 17,870,000
Contingent earn-out consideration, estimated fair value		2,870,000
Cash consideration		15,000,000
Maximum earn out payment		9,500,000
Acquisition related costs						$ 0	$ 0
Business acquisition, pro forma information, description						There is no supplemental proforma presentation of operating results of the acquisition of Additive due to the immaterial impact on the Company’s Consolidated operations for the years ended December 31, 2022 and 2021.
Net assets acquired		$ 17,870,000
Additive Orthopaedics, LLC | Selling, General, and Administrative Expenses
Business Acquisition [Line Items]
Acquisition related costs								$ 822,000

Business Combinations - Summary

Business Combinations - Summary of Purchase Consideration Transferred (Details) - USD ($) $ in Thousands			3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 10, 2022	May 28, 2021	Mar. 31, 2022	Jun. 30, 2022	Sep. 30, 2022	Dec. 31, 2022	Dec. 31, 2021
Consideration paid
Cash consideration			$ 18,201	$ 18,504	$ 18,504	$ 18,504	$ 15,000
Disior LTD.
Consideration paid
Cash consideration	$ 19,696
Contingent consideration	6,550
Total consideration	$ 26,246
Additive Orthopaedics, LLC
Consideration paid
Cash consideration		$ 15,000
Contingent consideration		2,870
Total consideration		$ 17,870

Business Combinations - Summa_2

Business Combinations - Summary of Fair Values of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jan. 10, 2022	May 28, 2021
Assets acquired:
Goodwill	$ 25,465	$ 25,465	$ 25,465	$ 25,465	$ 25,465	$ 26,975	$ 26,975	$ 26,672
Additive Orthopaedics, LLC
Assets acquired:
Accounts receivable										$ 761
Inventory										113
Intangible assets										11,560
Goodwill										6,329
Total assets acquired										18,763
Liabilities assumed:
Accounts payable										796
Accrued expenses										97
Total liabilities assumed										893
Net assets acquired										$ 17,870
Disior LTD.
Assets acquired:
Cash and cash equivalents									$ 1,192
Other current assets									410
Intangible assets									6,800
Goodwill									19,136
Total assets acquired									27,538
Liabilities assumed:
Accruals and other current liabilities									615
Deferred tax liabilities, net									677
Total liabilities assumed									1,292
Net assets acquired									$ 26,246

Business Combinations - Useful

Business Combinations - Useful Life Determination of Assets (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Disior LTD.
Business Acquisition [Line Items]
Total intangible assets, Fair Value	$ 6,800
Additive Orthopaedics, LLC
Business Acquisition [Line Items]
Total intangible assets, Fair Value	11,560
Tradenames | Disior LTD.
Business Acquisition [Line Items]
Total intangible assets, Fair Value	400
Noncompete Arrangements | Additive Orthopaedics, LLC
Business Acquisition [Line Items]
Total intangible assets, Fair Value	$ 30
Estimated Useful Life (in years)	3 years
Customer Relationships | Additive Orthopaedics, LLC
Business Acquisition [Line Items]
Total intangible assets, Fair Value	$ 240
Estimated Useful Life (in years)	3 years
Developed Technology | Disior LTD.
Business Acquisition [Line Items]
Total intangible assets, Fair Value	$ 6,400
Estimated Useful Life (in years)	12 years
Developed Technology | Additive Orthopaedics, LLC
Business Acquisition [Line Items]
Total intangible assets, Fair Value	$ 11,290
Estimated Useful Life (in years)	12 years

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 117,951				$ 93,678
Less: accumulated depreciation	(43,829)				(31,740)
Property and equipment, net	$ 74,122	$ 73,530	$ 70,936	$ 66,810	61,938	$ 58,591	$ 56,066	$ 51,850
Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	3 years
Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	25 years
Surgical instrumentation
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 60,100				44,625
Surgical instrumentation | Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	3 years
Surgical instrumentation | Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	5 years
Land
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,625				3,625
Buildings
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 20,190				14,178
Property and equipment, estimated life	25 years
Leasehold improvement
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 8,307				7,961
Property and equipment, estimated life	Various
Computer and software
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 16,546				11,562
Computer and software | Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	3 years
Computer and software | Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	5 years
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 3,843				2,815
Property and equipment, estimated life	5 years
Office equipment and furniture
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,267				2,049
Office equipment and furniture | Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	5 years
Office equipment and furniture | Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	7 years
Construction in progress
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 288				5,817
Property and equipment, estimated life	Various
Other
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 2,785				$ 1,046
Other | Minimum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	5 years
Other | Maximum
Property, Plant and Equipment [Line Items]
Property and equipment, estimated life	15 years

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 13,515	$ 10,824	$ 7,615

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Goodwill	$ 25,465,000	$ 25,465,000		$ 25,465,000	$ 25,465,000	$ 25,465,000	$ 26,975,000	$ 26,975,000	$ 26,672,000
Impairment charges related to intangible assets	0	0	$ 0
Impairment charges related to goodwill	0	0	0
Selling, General, and Administrative Expenses
Finite-Lived Intangible Assets [Line Items]
Amortization expense	$ 2,027,000	$ 2,904,000	$ 1,372,000

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Schedule of Goodwill (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
Balance, December 31, 2021	$ 25,465	$ 25,465	$ 25,465	$ 25,465	$ 26,975	$ 26,975	$ 26,672
Balance, December 31, 2022	$ 25,465	$ 25,465	$ 25,465	$ 25,465	$ 25,465	$ 26,975	$ 26,975

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Indefinite Lived Intangible Assets By Major Class [Line Items]
Gross Carrying Amount	$ 28,340	$ 27,025
Accumulated Amortization	6,666	4,638
Net Carrying Amount	21,674	22,387	$ 21,802	$ 21,921	$ 22,137	$ 20,850	$ 20,352	$ 21,350
Trademarks and Tradenames
Indefinite Lived Intangible Assets By Major Class [Line Items]
Net Carrying Amount	$ 987	$ 901
Patents
Indefinite Lived Intangible Assets By Major Class [Line Items]
Estimated Useful Life (in years)	17 years 7 months 6 days	16 years 6 months
Gross Carrying Amount	$ 7,900	$ 6,671
Accumulated Amortization	2,649	2,370
Net Carrying Amount	5,251	4,301
Customer Relationships
Indefinite Lived Intangible Assets By Major Class [Line Items]
Gross Carrying Amount	1,733	1,733
Accumulated Amortization	567	279
Net Carrying Amount	$ 1,166	$ 1,454
Customer Relationships | Minimum
Indefinite Lived Intangible Assets By Major Class [Line Items]
Estimated Useful Life (in years)	3 years	3 years
Customer Relationships | Maximum
Indefinite Lived Intangible Assets By Major Class [Line Items]
Estimated Useful Life (in years)	7 years	7 years
Developed Technology
Indefinite Lived Intangible Assets By Major Class [Line Items]
Estimated Useful Life (in years)	12 years	12 years
Gross Carrying Amount	$ 17,690	$ 17,690
Accumulated Amortization	3,424	1,973
Net Carrying Amount	$ 14,266	$ 15,717
Other Intangibles
Indefinite Lived Intangible Assets By Major Class [Line Items]
Estimated Useful Life (in years)	3 years	3 years
Gross Carrying Amount	$ 30	$ 30
Accumulated Amortization	26	16
Net Carrying Amount	$ 4	$ 14

Goodwill and Intangible Asset_5

Goodwill and Intangible Assets - Schedule of Expected Future Amortization Expense (Details) $ in Thousands	Dec. 31, 2023 USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 1,981
2025	1,940
2026	1,940
2027	1,940
2028	$ 1,929

Accrued Expenses - Summary of A

Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Accrued Liabilities, Current [Abstract]
Accrued commissions	$ 6,126				$ 6,026
Accrued compensation	10,213				8,569
Accrued purchases	1,883				204
Accrued earnout payment	2,000				6,500
Accrued interest	2,006				450
Other accrued expenses	5,553				5,058
Total accrued expenses	$ 27,781	$ 24,966	$ 24,390	$ 25,446	$ 26,807	$ 19,507	$ 21,407	$ 17,827

Fair Value of Financial Instr_3

Fair Value of Financial Instruments - Summary of Significant Financial Assets and Liabilities Measured at Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Financial Assets:
Interest rate swap (As Restated)	$ 991	$ 1,337
Derivative Asset, Statement of Financial Position [Extensible Enumeration]	Other Assets, Noncurrent	Other Assets, Noncurrent
Financial Liabilities:
Contingent consideration	$ 340	$ 3,640
Level 2
Financial Assets:
Interest rate swap (As Restated)	991	1,337
Level 3
Financial Liabilities:
Contingent consideration	$ 340	$ 3,640

Fair Value of Financial Instr_4

Fair Value of Financial Instruments - Schedule of Reconciliation of Level 3 Earn-Out Liabilities (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2023 USD ($)
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning Balance	$ 3,640
Achieved milestone paid	(2,500)
Achieved milestones reclassified to accrued expenses	(1,000)
Change in fair value of earn-out liabilities	200
Ending Balance	$ 340

Fair Value of Financial Instr_5

Fair Value of Financial Instruments - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Net increase (decrease) in estimate of earn-out liabilities	$ 517	$ 605	$ 366	$ (414)	$ (57)	$ (1,303)	$ 546	$ (57)	$ 440
Achieved milestones reclassified to accrued expenses							1,000
Payments on earnout liability in cash	$ 500		$ 4,250		$ 5,500	$ 500	8,000	1,000
Other (expense) income
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Net increase (decrease) in estimate of earn-out liabilities							200
Additive Orthopaedics, LLC
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payments on earnout liability in cash							500
Disior LTD.
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Payments on earnout liability in cash							5,000
Accrued Expenses | Additive Orthopaedics, LLC
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Achieved milestones reclassified to accrued expenses							1,000	1,500
Accrued Expenses | Disior LTD.
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Achieved milestones reclassified to accrued expenses								$ 5,000
Accrued Expenses | Disior LTD. | Remaining Project Milestone
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Achieved milestones reclassified to accrued expenses							1,000
Level 2 | Other (expense) income
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Change in fair value of interest rate swap							$ 300

Debt - Schedule of Long-term De

Debt - Schedule of Long-term Debt Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Debt Instrument [Line Items]
Debt, gross amount	$ 114,933				$ 45,659
Less: deferred issuance costs	(4,494)				(2,749)
Total debt, net of issuance costs	110,439				42,910
Less: current portion	(640)	$ (640)	$ (652)	$ (690)	(728)	$ (735)	$ (757)	$ (781)
Long-term debt net, less current maturities	109,799	$ 42,288	$ 42,259	$ 42,204	42,182	$ 42,492	$ 42,519	$ 42,471
Ares Revolving Loan
Debt Instrument [Line Items]
Debt, gross amount	25,000				0
Ares Term Loan
Debt Instrument [Line Items]
Debt, gross amount	75,000				0
MidCap Term Loan
Debt Instrument [Line Items]
Debt, gross amount	0				30,000
Zions Term Loan Facility
Debt Instrument [Line Items]
Debt, gross amount	14,933				15,573
Bank of Ireland Note Payable
Debt Instrument [Line Items]
Debt, gross amount	$ 0				$ 86

Debt - Ares Credit Agreement -

Debt - Ares Credit Agreement - Additional Information (Details) - USD ($)		12 Months Ended
	Nov. 02, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt, gross amount		$ 114,933,000	$ 45,659,000
Ares Credit Agreements [Member]
Debt Instrument [Line Items]
Expiration date	Nov. 02, 2028
indebtedness principal or stated amount	$ 12,500,000
Debt issuance cost before amortization		4,275,000
Ares Credit Agreements [Member] | Interest Expense
Debt Instrument [Line Items]
Amortization expense		$ 147,000	$ 0	$ 0
Ares Credit Agreements [Member] | Ares Term Loan
Debt Instrument [Line Items]
Total borrowing capacity	100,000,000
Drew down value	$ 75,000,000
Ares Credit Agreements [Member] | Ares Term Loan | SOFR
Debt Instrument [Line Items]
Variable interest rate	6.75%
Ares Credit Agreements [Member] | Ares Revolving Loan
Debt Instrument [Line Items]
Drew down value	$ 25,000,000
Ares Credit Agreements [Member] | Ares Revolving Loan | Maximum
Debt Instrument [Line Items]
Total borrowing capacity	$ 50,000,000
Ares Credit Agreements [Member] | Ares Revolving Loan | SOFR
Debt Instrument [Line Items]
Variable interest rate	4%
Ares Credit Agreements [Member] | Revolving Loan | Secured Debt
Debt Instrument [Line Items]
Total borrowing capacity	$ 150,000,000

Debt - MidCap Credit Agreements

Debt - MidCap Credit Agreements - Additional Information (Details) - USD ($)			12 Months Ended
	Nov. 09, 2022	May 06, 2021	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Debt, gross amount			$ 114,933,000	$ 45,659,000
Loss on early extinguishment of debt			5,308,000
Total debt issuance costs			4,494,000	2,749,000
MidCap Credit Agreements
Debt Instrument [Line Items]
Debt, gross amount		$ 70,000,000
Loss on early extinguishment of debt			(5,308,000)
Unamortized debt issuance costs			1,881,000
Fees incurred to early exit of debt			3,427,000
MidCap Credit Agreements | Interest Expense
Debt Instrument [Line Items]
Amortization expense			$ 613,000	$ 586,000	$ 576,000
MidCap Credit Agreements | Term Loan
Debt Instrument [Line Items]
Debt, gross amount		$ 40,000,000
MidCap Credit Agreements | Term Loan | LIBOR
Debt Instrument [Line Items]
Variable interest rate		6%
MidCap Credit Agreements | Term Loan | SOFR
Debt Instrument [Line Items]
Variable interest rate	6%
MidCap Credit Agreements | Term Loan, First Commitment
Debt Instrument [Line Items]
Debt, gross amount		$ 10,000,000
MidCap Credit Agreements | Term Loan, Second Commitment
Debt Instrument [Line Items]
Debt, gross amount		30,000,000
MidCap Credit Agreements | Revolving Loan
Debt Instrument [Line Items]
Total borrowing capacity	$ 50,000,000	$ 30,000,000
Expiration date		May 01, 2026
MidCap Credit Agreements | Revolving Loan | LIBOR
Debt Instrument [Line Items]
Variable interest rate	3%	3%
MidCap Credit Agreements | Revolving Loan | SOFR
Debt Instrument [Line Items]
Variable interest rate	3.75%

Debt - Vectra Bank Colorado Loa

Debt - Vectra Bank Colorado Loan Agreements - Additional Information (Details) - USD ($)			12 Months Ended
	Nov. 10, 2022	Mar. 24, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Line Of Credit Facility [Line Items]
Total debt issuance costs			$ 4,494,000	$ 2,749,000
Secured Term Loan Facility
Line Of Credit Facility [Line Items]
Principal amount		$ 16,000,000
Maturity date		Mar. 24, 2037
Debt, frequency of payment		monthly
Amortization of debt issuance costs			16,000	$ 13,000	$ 0
Threshold amount of operating cash flow to calculate liquidity ratio	$ 0
Threshold Amount of Operating Cash Flow to Calculate Fixed Charge Coverage Ratio	$ 0
Secured Term Loan Facility | SOFR
Line Of Credit Facility [Line Items]
Variable interest rate		1.75%
Zions Facility
Line Of Credit Facility [Line Items]
Total debt issuance costs			$ 219,000

Debt - Bank of Ireland Note Pay

Debt - Bank of Ireland Note Payable - Additional Information (Details) - Bank of Ireland Note Payable - USD ($)		12 Months Ended
	Jun. 12, 2020	Dec. 31, 2023
Debt Instrument [Line Items]
Principal amount	$ 474,000
Interest rate	4%
Debt payment terms		The Bank of Ireland Note Payable bore an annual interest rate of 4% and was due in equal monthly installments over a 36-month period, including interest.
Debt, frequency of payment	monthly
Debt instrument term	36 months

Debt - Schedule of Debt Maturit

Debt - Schedule of Debt Maturities (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Total debt, net of issuance costs	$ 110,439	$ 42,910
Total	114,933	$ 45,659
Ares Revolving Loan, Ares Term Loan and Zions Facility
Debt Instrument [Line Items]
2024	640
2025	640
2026	640
2027	640
2028	100,640
Thereafter	11,733
Total	$ 114,933

Convertible Preferred Series _2

Convertible Preferred Series Equity and Stockholders Equity - Additional Information (Details) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended				3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 30, 2023	Oct. 19, 2021	Jul. 31, 2020	Nov. 30, 2012	Feb. 29, 2012	Dec. 31, 2011	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Oct. 31, 2021	Oct. 08, 2021
Class of Stock [Line Items]
Options reserved for future grants																	310,000,000
Common stock share authorized							300,000,000	300,000,000	300,000,000	300,000,000	300,000,000		300,000,000	300,000,000	300,000,000		300,000,000
Common stock par value							$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01	$ 0.01	$ 0.01		$ 0.01
Convertible preferred stock, authorized																	10,000,000
Convertible preferred stock, par value																	$ 0.01
Common stock, voting rights, description										Each holder of common stock is entitled to one vote for each share owned on all matters voted upon by the stockholders, and a majority vote is required for all actions taken by stockholders.
Issuance costs										$ 827
Treasury stock repurchase shares										0	0	85,049
Treasury stock repurchase value												$ 561
Average cost per share												$ 6.60
Net proceeds after deducting underwriting discounts and commissions	$ 68,453						$ 68,449	$ 68,453	$ 68,453	$ 68,453		$ 1,001
Common Stock
Class of Stock [Line Items]
Number of aggregate issued	6,500,000						4,312,500			4,312,500	0	151,515
Price per share	$ 17
Initial Public Offering
Class of Stock [Line Items]
Issuance costs												$ 4,304
Initial Public Offering | Common Stock
Class of Stock [Line Items]
Number of aggregate issued												8,984,375
Conversion of shares		20,421,200
Number of shares issued and sold		8,984,375
Shares sold by Company | Common Stock
Class of Stock [Line Items]
Number of shares issued and sold	3,750,000
Selling securityholders
Class of Stock [Line Items]
Net proceeds after deducting underwriting discounts and commissions	$ 50,700
Selling securityholders | Common Stock
Class of Stock [Line Items]
Number of shares issued and sold	2,750,000
Underwriters Option to Purchase Additional Shares | Maximum
Class of Stock [Line Items]
Number of shares issued and sold	562,500
Underwriters Option to Purchase Additional Shares | Common Stock
Class of Stock [Line Items]
Number of shares issued and sold	412,500	1,171,875
Series A Convertible Preferred Stock
Class of Stock [Line Items]
Number of aggregate issued				10,562,495	10,562,495	3,250,005
Proceeds from issuance of convertible preferred stock				$ 3,250	$ 3,250	$ 1,000
Price per share				$ 0.30769	$ 0.30769	$ 0.30769
Series A Convertible Preferred Stock | Initial Public Offering | Common Stock
Class of Stock [Line Items]
Conversion of shares																13,812,500
Series B Convertible Preferred Stock
Class of Stock [Line Items]
Number of aggregate issued			6,608,700
Proceeds from issuance of convertible preferred stock			$ 36,030
Cash dividends accrued		$ 2,328
Issuance costs			$ 1,970
Price per share			$ 5.75
Series B Convertible Preferred Stock | Initial Public Offering | Common Stock
Class of Stock [Line Items]
Conversion of shares		6,608,700

Loss Per Share - Summary of Com

Loss Per Share - Summary of Computation of Net Loss Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net loss attributable to common stockholders
Net loss	$ (22,323)	$ (11,151)	$ (13,248)	$ (10,812)	$ (38,479)	$ (8,547)	$ (8,782)	$ (9,841)	$ (24,060)	$ (18,623)	$ (35,211)	$ (27,170)	$ (57,534)	$ (65,649)	$ (13,693)
Weighted-average common stock outstanding:
Basic		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100	52,916,711
Diluted		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100	52,916,711
Loss per share, Basic:
Basic	$ (0.27)	$ (0.14)	$ (0.16)	$ (0.13)	$ (0.5)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.3)	$ (0.24)	$ (0.43)	$ (0.35)	$ (0.7)	$ (0.86)	$ (0.26)
Loss per share, Diluted:
Diluted	$ (0.27)	$ (0.14)	$ (0.16)	$ (0.13)	$ (0.5)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.3)	$ (0.24)	$ (0.43)	$ (0.35)	$ (0.7)	$ (0.86)	$ (0.26)

Loss Per Share - Summary of Pot

Loss Per Share - Summary of Potentially Dilutive Securities Excluded from Calculation of Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of dilutive net loss per share	5,943,898	6,538,536	7,953,018
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities excluded from computation of dilutive net loss per share	1,317,402	964,054	79,886

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Details) - USD ($)		3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Oct. 19, 2021	Mar. 31, 2023	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted								225,000	359,054	3,467,069
Cash received from exercise of stock options		$ 1,622,000	$ 12,000	$ 2,464,000	$ 300,000	$ 2,535,000	$ 2,224,000	$ 2,406,000	$ 5,271,000	$ 445,000
Employee contribution percentage								100%
Weighted average strike price								$ 18.33	$ 16.08	$ 14.63
2021 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options reserved for future grant								13,510,971
Percentage of shares issued from outstanding number of shares	5%
2021 Incentive Award Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options permitted to grant	7,641,979
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Market price of shares authorized percentage	85%
Shares issued								73,442	38,968	0
Shares available for issuance								2,758,808
Employee contribution percentage								15%
Maximum purchase value of shares available for each employee								$ 25,000,000
Compensation expense								322,000	$ 213,000	$ 0
Percentage of shares issued from outstanding number of shares	1%
Employee Stock Purchase Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options permitted to grant	1,329,040
Employee Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Cash received from exercise of stock options								2,406,000	5,271,000	445,000
Tax benefit from equity options exercised								560,000	1,223,000	93,000
Compensation expense								5,542,000	8,500,000	4,863,000
Aggregate intrinsic value of options outstanding								22,900,000
Aggregate intrinsic value of vested and exercisable options								21,530,000
Aggregate intrinsic value of options exercised								4,742,000	18,764,000	3,743,000
Total unrecognized compensation cost related to non-vested stock awards								$ 5,634,000
Total unrecognized compensation cost related to non-vested stock awards, weighted average recognition period								1 year 9 months 10 days
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense								$ 6,822,000	$ 1,865,000	$ 85,000
Total unrecognized compensation cost related to non-vested stock awards								$ 18,689,000
Total unrecognized compensation cost related to non-vested stock awards, weighted average recognition period								2 years 10 months 17 days
Restricted Stock Units | 2021 Incentive Award Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual term								10 years
Vesting, description								RSUs granted under the 2021 Plan have a ten-year contractual term and typically vest over a three or four-year period, contingent upon continued service with the Company.
Number of shares granted								776,359	929,090	79,886
Number of days grant date fair value for RSUs is trailing average market price of the common stock								30 days
Vested								273,618
Forfeited								149,393
Restricted Stock Units | 2021 Incentive Award Plan | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								3 years
Restricted Stock Units | 2021 Incentive Award Plan | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period								4 years

Stock-Based Compensation - Assu

Stock-Based Compensation - Assumptions used in Determining Fair Value (Details)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Employee Stock Option
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility	66.20%
Expected volatility, minimum		55%	52%
Expected volatility, maximum		70%	55%
Expected dividends	0%	0%	0%
Expected term (in years)	6 years 3 months
Risk-free rate	4.11%
Risk-free rate, minimum		1.69%	0.47%
Risk-free rate, maximum		2.79%	1.20%
Employee Stock Option | Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)		6 years	5 years 9 months
Employee Stock Option | Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected term (in years)			6 years 3 months
Employee Stock Purchase Plan
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expected volatility	54.64%	70.27%
Expected dividends	0%	0%
Expected term (in years)	6 months	6 months
Discount rate	15%	15%
Risk-free rate	5.26%	2.79%

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares, Granted	225,000	359,054	3,467,069
Weighted-Average Exercise Price, Beginning Balance	$ 16.08	$ 14.63
Weighted-Average Exercise Price, Ending Balance	$ 18.33	$ 16.08	$ 14.63
2011 and 2021 Plans
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Shares Outstanding, Beginning Balance	6,538,536
Shares, Granted	225,000
Shares, Exercised or Released	(458,005)
Shares, Forfeited or Expired	(361,633)
Shares Outstanding, Ending Balance	5,943,898	6,538,536
Shares, Exercisable	4,292,558
Shares, Vested and Expected To Vest	5,938,438
Weighted-Average Exercise Price, Beginning Balance	$ 10.02
Weighted-Average Exercise Price, Granted	18.33
Weighted-Average Exercise Price, Exercised or Released	6.56
Weighted-Average Exercise Price, Forfeited or Expired	15.29
Weighted-Average Exercise Price, Ending Balance	10.28	$ 10.02
Weighted-Average Exercise Price, Exercisable	8.51
Weighted-Average Exercise Price, Vested and Expected To Vest	$ 10.27
Weighted-Average Remaining Contractual Term (Years)	6 years 6 months 10 days	7 years 4 months 9 days
Weighted-Average Remaining Contractual Term (Years), Exercisable	6 years 7 days
Weighted-Average Remaining Contractual Term (Years), Vested and expected to vest	6 years 6 months 10 days

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of RSU Activity (Details) - Restricted Stock Units - 2021 Plans - $ / shares	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Outstanding, Beginning balance	964,054
Granted	776,359	929,090	79,886
Vested	(273,618)
Forfeited or expired	(149,393)
Outstanding, Ending balance	1,317,402	964,054
Vested and expected to vest	1,305,827
Weighted Average Fair Value, Beginning balance	$ 17.74
Weighted Average Fair Value, Granted	16.56
Weighted Average Fair Value, Vested	17.65
Weighted Average Fair Value, Forfeited or expired	17.81
Weighted Average Fair Value, Ending balance	17.06	$ 17.74
Weighted Average Fair Value, Vested and expected to vest	$ 17.05

Employee Benefit Plan - Additio

Employee Benefit Plan - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Retirement Benefits [Abstract]
Defined contribution plan, description	The Company sponsors a defined contribution plan for eligible employees who are 21 years of age with three months of service can voluntarily contribute up to 100% of their eligible compensation.
Defined contribution plan minimum annual contributions per employee percent	3%
Defined benefit plan, plan assets, contributions by employer	$ 1,190	$ 992	$ 633
Defined contribution plan, maximum percentage of eligible compensation for voluntary contribution	100%

Income Taxes - Schedule of Prov

Income Taxes - Schedule of Provision (Benefit) Expense for Income Taxes (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Pre-tax (loss) / income
Domestic											$ (56,342)	$ (64,071)	$ (17,030)
Foreign											(979)	(1,642)	4,050
Loss before income taxes	$ (11,259)	$ (12,979)	$ (10,883)	$ (8,346)	$ (8,709)	$ (9,809)	$ (23,862)	$ (18,518)	$ (35,121)	$ (26,864)	(57,321)	(65,713)	(12,980)
Current tax expense / (benefit):
Federal											105		(165)
State											58	96	(36)
Foreign											730	315	744
Total current tax expense											893	411	543
Deferred tax expense / (benefit):
Federal											(11,309)	(15,900)	(3,506)
State											(1,402)	(1,939)	(464)
Foreign											(1,099)	(909)	170
Change in valuation allowance											13,129	18,273	3,970
Total deferred tax (benefit) expense											(681)	(475)	170
Total tax expense (benefit):
Federal											(11,204)	(15,900)	(3,671)
State											(1,344)	(1,843)	(500)
Foreign											(368)	(594)	914
Change in valuation allowance											13,129	18,273	3,970
Total income tax expense (benefit)	$ (108)	$ 269	$ (71)	$ 201	$ 73	$ 32	$ 198	$ 105	$ 90	$ 306	$ 213	$ (64)	$ 713

Income Taxes - Schedule of Sign

Income Taxes - Schedule of Significant Components of Deferred Taxes (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Deferred tax assets:
Receivable allowances	$ 253	$ 356
Accrued expenses	1,262	5,351
S263A capitalizable costs	2,923	461
Inventory reserves	4,635	3,436
Research and development credits	3,974	3,615
Net operating losses	25,176	13,505
Interest expense	2,407	906
Stock-based compensation	4,496	3,324
Lease liability	356	384
R&D IRC 174(b) capitalized costs	5,161	3,433
Other	764	651
Total deferred tax assets	51,407	35,422
Valuation allowance	(41,671)	(28,543)
Net deferred tax assets	9,736	6,879
Deferred tax liabilities:
Property and equipment	(6,808)	(5,391)
Section 481 adjustment	(821)
Patents and trademarks	(1,343)	(1,304)
Right of use asset	(292)	(378)
Total deferred tax liabilities	(9,264)	(7,073)
Total net deferred tax asset (liability)	$ 472
Total net deferred tax asset (liability)		$ (194)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ 41,671	$ 28,543
Unrecognized tax benefits	1,523
Unrecognized tax benefits, income tax penalties and interest expense	106
Cash		38,468	$ 56,325	$ 73,002	$ 93,647
U.S Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 97,490	$ 52,009
Net operating loss carryforwards, expiration description	indefinite	indefinite
U.S State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 52,211
Net operating loss carryforwards, expiration year	2033
Foreign
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 10,368
Net operating loss carryforwards, expiration year	2034
Cash	$ 10,293

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Provision for Income Taxes at Federal Statutory Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Gross unrecognized tax benefits - beginning of period	$ 1,431	$ 1,337
Increases related to current year tax positions	92	92
Increases related to prior year tax positions		2
Gross unrecognized tax benefits - end of period	$ 1,523	$ 1,431

Income Taxes - Schedule of Re_2

Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Statutory U.S. federal tax rate											$ (12,037)	$ (13,800)	$ (2,726)
State taxes net of federal benefit											(1,356)	(1,863)	(492)
Non-U.S. earnings taxed at rates different than the U.S. statutory rate											5	(80)	(150)
Foreign source earnings, net of associated foreign tax credits											628	486	601
Benefit of tax credits											(501)	(458)	(1,569)
Stock based compensation											27	(2,852)	(212)
Change in valuation allowance											13,129	18,273	3,970
Change in unrecognized tax benefits											175	92	710
Other											143	138	581
Total income tax expense (benefit)	$ (108)	$ 269	$ (71)	$ 201	$ 73	$ 32	$ 198	$ 105	$ 90	$ 306	$ 213	$ (64)	$ 713

Commitments And Contigencies -

Commitments And Contigencies - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended
	Nov. 28, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Lease liability			$ 1,821
Operating Lease, Liability, Statement of Financial Position [Extensible Enumeration]			Other Liabilities
Right-of-use asset		$ 1,533	$ 1,795
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]		Other Assets, Noncurrent	Other Assets, Noncurrent
Short-term lease liabilities			$ 447
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]		Other Liabilities, Current	Other Liabilities, Current
Long-term lease liabilities		$ 1,048	$ 1,374
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]		Other Liabilities, Noncurrent	Other Liabilities, Noncurrent
Lease expense		$ 574	$ 408
Lease expiration year		2029
Rent expense under operating leases				$ 1,369
Settlement Agreement | Stryker Corp.
Loss Contingencies [Line Items]
Settlement amount	$ 26,000
Legal fees	1,000
Settlement Agreement | Stryker Corp. | First Installment to be Paid, On or by December 16, 2022
Loss Contingencies [Line Items]
Settlement amount	5,000
Settlement Agreement | Stryker Corp. | Second Installment to be Paid, January 1, 2023 - January 16, 2023
Loss Contingencies [Line Items]
Settlement amount	8,000
Settlement Agreement | Stryker Corp. | Third Installment to be Paid, April 1, 2023 - April 17, 2023
Loss Contingencies [Line Items]
Settlement amount	$ 13,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Related Party Transaction [Line Items]
Payments to related party	$ 11,922	$ 11,599	$ 10,229	$ 8,203	$ 7,836	$ 6,791	$ 21,828	$ 14,627	$ 33,750	$ 22,830	$ 51,954	$ 32,117	$ 28,024
Due to related parties	1,893	1,700	3,772	6,889	6,926	7,433	1,700	6,926	1,893	6,889	883	3,844
Selling, general and administrative expenses from transactions with related party	$ 44,126	$ 43,827	$ 43,820	$ 39,667	$ 37,948	$ 37,242	$ 87,647	$ 75,190	$ 131,773	$ 114,857	$ 180,022	159,323	114,087
Director | License Agreement
Related Party Transaction [Line Items]
Percentage of revenue paid as royalty											4%
Royalty estimated useful life											15 years
Related party transaction term of agreement											20 years
Related party transaction, agreement renewal term											5 years
Director | Related Party | License Agreement
Related Party Transaction [Line Items]
Due to related parties											$ 16	0
Payments to related party											269	249	87
Due to related parties											155	164
Selling, general and administrative expenses from transactions with related party											327	$ 405	$ 542
Annual Payment Threshold | Minimum | Director | Related Party | License Agreement
Related Party Transaction [Line Items]
Due to related parties											$ 250

Segment and Geographic Inform_3

Segment and Geographic Information - Additional Information - (Details)	12 Months Ended
	Dec. 31, 2023 Country Customer	Dec. 31, 2022 Country Customer	Dec. 31, 2021 Country
Segment Reporting Information [Line Items]
Number of customers accounted for more than ten percent of total product sales	0	0
Number of customers accounted for more than ten percent of consolidated accounts receivable	0	0
International
Segment Reporting Information [Line Items]
Number of countries accounted more than ten percent of net revenue | Country	0	0	0

Segment and Geographic Inform_4

Segment and Geographic Information - Schedule of Total Net Revenue by Geographic Area (Details) - USD ($) $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Segment Reporting Information [Line Items]
Total net revenue	$ 60,561	$ 52,783	$ 51,009	$ 52,036	$ 51,508	$ 46,006	$ 42,498	$ 41,371	$ 103,045	$ 83,869	$ 155,828	$ 129,875	$ 216,389	$ 181,383	$ 147,464
United States
Segment Reporting Information [Line Items]
Total net revenue													183,505	158,105	130,112
International
Segment Reporting Information [Line Items]
Total net revenue													$ 32,884	$ 23,278	$ 17,352

Segment and Geographic Inform_5

Segment and Geographic Information - Schedule of Total Non-current Assets, Excluding Deferred Taxes, by Geographic Area (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Segment Reporting Information [Line Items]
Total assets	$ 124,179	$ 112,922
United States
Segment Reporting Information [Line Items]
Total assets	89,531	80,795
Finland
Segment Reporting Information [Line Items]
Total assets	25,032	25,581
Other International
Segment Reporting Information [Line Items]
Total assets	$ 9,616	$ 6,546

Quarterly Financial Data - Effe

Quarterly Financial Data - Effects of the Restatement on the Condensed Consolidated Balance Sheet (Details) - USD ($) $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash					$ 38,468	$ 56,325	$ 73,002	$ 93,647
Cash and cash equivalents	$ 75,639	$ 34,949	$ 56,747	$ 85,883	38,468
Trade receivables, net of allowance for doubtful accounts	37,323	33,615	34,331	37,262	37,687	35,960	32,598	27,653
Inventories, net	90,046	89,128	81,501	68,191	61,288	54,861	51,502	43,185
Income taxes receivable	794	1,022	870	596	615	705	660	622
Other current assets	3,997	4,826	3,257	4,167	4,658	1,947	3,129	3,448
Total current assets	207,799	163,540	176,706	196,099	142,716	149,798	160,891	168,555
Property and equipment, net	74,122	73,530	70,936	66,810	61,938	58,591	56,066	51,850
Intangible assets, net	21,674	21,802	21,921	22,137	22,387	20,850	20,352	21,350
Goodwill	25,465	25,465	25,465	25,465	25,465	26,975	26,975	26,672
Deferred income taxes	705	132	319	354	148	841	563	303
Other assets	2,918	3,634	3,057	2,597	3,132	1,303	414
Total assets	332,683	288,103	298,404	313,462	255,786	258,358	265,261	268,730
Current liabilities:
Accounts payable	21,696	27,395	29,681	20,538	14,939	13,979	14,564	11,877
Accrued expenses	27,781	24,966	24,390	25,446	26,807	19,507	21,407	17,827
Accrued legal settlement				13,000	22,000
Other current liabilities	883	1,893	1,700	3,772	3,844	6,889	6,926	7,433
Current maturities of long-term debt	640	640	652	690	728	735	757	781
Income taxes payable	243		20	208	184	497	305	492
Total current liabilities	51,243	54,894	56,443	63,654	68,502	41,607	43,959	38,410
Long-term liabilities:
Long-term debt net, less current maturities	109,799	42,288	42,259	42,204	42,182	42,492	42,519	42,471
Other long-term liabilities	1,048	1,467	1,842	1,523	1,628	907	905	3,123
Deferred income taxes	233	327	620	377	342	59	197	302
Income taxes payable	635	635	635	635	527	527	527	527
Total liabilities	162,958	99,611	101,799	108,393	113,181	85,592	88,107	84,833
Commitments and contingencies
Stockholders' equity:
Common stock	827	824	824	821	776	769	764	763
Additional paid in capital	298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736
Accumulated deficit	(123,646)	(101,323)	(90,172)	(76,924)	(66,112)	(27,633)	(19,086)	(10,304)
Accumulated other comprehensive income (loss)	132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)
Treasury stock	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
Total stockholders' equity	169,725	188,492	196,605	205,069	142,605	172,766	177,154	183,897	$ 192,194	$ 30,393
Total liabilities & stockholders' equity	332,683	288,103	298,404	313,462	255,786	258,358	265,261	268,730
As Previously Reported
Current assets:
Cash					38,468	56,325	73,002	93,647
Cash and cash equivalents	75,639	34,949	56,747	85,883
Trade receivables, net of allowance for doubtful accounts	37,323	33,615	34,331	37,262	37,687	35,960	32,598	27,653
Inventories, net	98,062	94,380	85,225	69,174	60,948	54,771	51,700	43,185
Income taxes receivable	794	1,022	870	596	615	705	660	622
Other current assets	3,997	4,826	3,257	4,167	4,658	1,947	3,129	3,448
Total current assets	215,815	168,792	180,430	197,082	142,376	149,708	161,089	168,555
Property and equipment, net	74,122	73,530	70,936	66,810	61,938	58,591	56,066	51,850
Intangible assets, net	21,674	21,802	21,921	22,137	22,387	20,850	20,352	21,350
Goodwill	25,465	25,465	25,465	25,465	25,465	26,975	26,975	26,672
Deferred income taxes	705	132	319	354	148	841	563	303
Other assets	2,918	3,634	1,766	1,697	1,795
Total assets	340,699	293,355	300,837	313,545	254,109	256,965	265,045	268,730
Current liabilities:
Accounts payable	21,696	27,395	29,681	20,538	14,939	13,979	14,564	11,877
Accrued expenses	27,781	24,966	24,390	25,446	26,807	19,507	21,407	17,827
Accrued legal settlement				13,000	22,000
Other current liabilities	883	1,893	1,700	3,772	3,844	6,889	6,926	7,433
Current maturities of long-term debt	640	640	652	690	728	735	757	781
Income taxes payable	243		20	208	184	497	305	492
Total current liabilities	51,243	54,894	56,443	63,654	68,502	41,607	43,959	38,410
Long-term liabilities:
Long-term debt net, less current maturities	109,799	42,288	42,259	42,204	42,182	42,492	42,519	42,471
Other long-term liabilities	1,048	1,467	1,842	1,523	1,628	907	905	2,518
Deferred income taxes	233	327	620	377	342	59	197	302
Income taxes payable	635	635	635	635	527	527	527	527
Total liabilities	162,958	99,611	101,799	108,393	113,181	85,592	88,107	84,228
Stockholders' equity:
Common stock	827	824	824	821	776	769	764	763
Additional paid in capital	298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736
Accumulated deficit	(115,630)	(96,071)	(87,739)	(76,841)	(67,789)	(29,026)	(19,302)	(9,699)
Accumulated other comprehensive income (loss)	132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)
Treasury stock	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
Total stockholders' equity	177,741	193,744	199,038	205,152	140,928	171,373	176,938	184,502	$ 192,194
Total liabilities & stockholders' equity	340,699	293,355	300,837	313,545	254,109	256,965	265,045	268,730
Adjustments
Current assets:
Inventories, net	(8,016)	(5,252)	(3,724)	(983)	340	90
Income taxes receivable							(198)
Total current assets	(8,016)	(5,252)	(3,724)	(983)	340	90	(198)
Other assets			1,291	900	1,337	1,303	414
Total assets	(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216
Long-term liabilities:
Other long-term liabilities								605
Total liabilities								605
Stockholders' equity:
Accumulated deficit	(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216	(605)
Total stockholders' equity	(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216	$ (605)
Total liabilities & stockholders' equity	$ (8,016)	$ (5,252)	$ (2,433)	$ (83)	$ 1,677	$ 1,393	$ 216

Quarterly Financial Data - Ef_2

Quarterly Financial Data - Effects of the Restatement on the Condensed Consolidated Balance Sheet (Parenthetical) (Details) - USD ($) $ / shares in Units, $ in Thousands	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Dec. 31, 2021	Oct. 08, 2021
Common stock par value	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01	$ 0.01		$ 0.01
Common stock share authorized	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000	300,000,000		300,000,000
Common stock share issued	83,738,974	83,469,426	83,449,565	83,220,392	78,684,107	77,990,290	77,451,087	77,362,681
Common stock shares, outstanding	82,825,455	82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162
Treasury stock share issued	913,519	913,519	913,519	913,519	913,519	913,519	913,519	913,519
Allowance for doubtful accounts	$ 1,339	$ 934	$ 1,706	$ 1,816	$ 1,688	$ 1,990	$ 1,234	$ 1,310	$ 1,032
Other long-term liabilities	1,048	1,467	1,842	1,523	1,628	907	905	3,123
Accumulated deficit	(123,646)	(101,323)	(90,172)	(76,924)	(66,112)	(27,633)	(19,086)	(10,304)
Inventories, net	90,046	89,128	81,501	68,191	61,288	54,861	51,502	43,185
Adjustments
Other long-term liabilities								605
Accumulated deficit	(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216	(605)
Inventories, net	(8,016)	(5,252)	(3,724)	(983)	340	90
Adjustments | Interest Rate Swap
Other assets			1,291	900	1,337	1,303	414
Other long-term liabilities								605
Accumulated deficit			1,291	900	1,337	1,303	414	$ (605)
Adjustments | Inventory Treatment
Accumulated deficit	(8,016)	(5,252)	(3,724)	(983)	340	90	(198)
Inventories, net	$ (8,016)	$ (5,252)	$ (3,724)	$ (983)	$ 340	$ 90	$ (198)

Quarterly Financial Data - Ef_3

Quarterly Financial Data - Effects of the Restatement on the Condensed Consolidated Statement of Operations And Comprehensive (Loss) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Net revenue	$ 60,561	$ 52,783	$ 51,009	$ 52,036	$ 51,508	$ 46,006	$ 42,498	$ 41,371	$ 103,045	$ 83,869	$ 155,828	$ 129,875	$ 216,389	$ 181,383	$ 147,464
Cost of goods sold		11,922	11,599	10,229		8,203	7,836	6,791	21,828	14,627	33,750	22,830	51,954	32,117	28,024
Gross profit	42,357	40,861	39,410	41,807	42,221	37,803	34,662	34,580	81,217	69,242	122,078	107,045	164,435	149,266	119,440
Operating expenses:
Research and development costs		7,244	7,683	7,049		6,337	5,990	5,773	14,732	11,763	21,976	18,100	30,078	24,650	16,128
Selling, general, and administrative		44,126	43,827	43,820		39,667	37,948	37,242	87,647	75,190	131,773	114,857	180,022	159,323	114,087
Total operating expenses		51,370	51,510	50,869		46,004	43,938	43,015	102,379	86,953	153,749	132,957	210,100	210,973	130,215
Operating loss	(13,994)	(10,509)	(12,100)	(9,062)	(35,795)	(8,201)	(9,276)	(8,435)	(21,162)	(17,711)	(31,671)	(25,912)	(45,665)	(61,707)	(10,775)
Other income (expense):
Other income (expense), net		369	(76)	(616)		948	1,671	(706)	(692)	965	(323)	1,913	(1,183)	123	(486)
Interest expense, net		(1,119)	(803)	(1,205)		(1,093)	(1,104)	(668)	(2,008)	(1,772)	(3,127)	(2,865)	(5,165)	(4,129)	(1,719)
Total other income (expense)		(750)	(879)	(1,821)		(145)	567	(1,374)	(2,700)	(807)	(3,450)	(952)	(11,656)	(4,006)	(2,205)
Loss before income taxes		(11,259)	(12,979)	(10,883)		(8,346)	(8,709)	(9,809)	(23,862)	(18,518)	(35,121)	(26,864)	(57,321)	(65,713)	(12,980)
Income tax (benefit) expense		(108)	269	(71)		201	73	32	198	105	90	306	213	(64)	713
Net loss	$ (22,323)	(11,151)	(13,248)	(10,812)	$ (38,479)	(8,547)	(8,782)	(9,841)	(24,060)	(18,623)	(35,211)	(27,170)	(57,534)	(65,649)	(13,693)
Foreign currency translation adjustment		(630)	(283)	(99)		(588)	(593)	(324)	(382)	(917)	(1,012)	(1,505)	165	(41)	(815)
Comprehensive loss		$ (11,781)	$ (13,531)	$ (10,911)		$ (9,135)	$ (9,375)	$ (10,165)	$ (24,442)	$ (19,540)	$ (36,223)	$ (28,675)	$ (57,369)	$ (65,690)	$ (14,508)
Weighted average number of shares of common stock outstanding:
Basic		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100	52,916,711
Diluted		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100	52,916,711
Net loss per share attributable to common stockholders:
Basic	$ (0.27)	$ (0.14)	$ (0.16)	$ (0.13)	$ (0.5)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.3)	$ (0.24)	$ (0.43)	$ (0.35)	$ (0.7)	$ (0.86)	$ (0.26)
Diluted	$ (0.27)	$ (0.14)	$ (0.16)	$ (0.13)	$ (0.5)	$ (0.11)	$ (0.11)	$ (0.13)	$ (0.3)	$ (0.24)	$ (0.43)	$ (0.35)	$ (0.7)	$ (0.86)	$ (0.26)
As Previously Reported
Net revenue	$ 60,561	$ 52,783	$ 51,009	$ 52,036	$ 51,508	$ 46,006	$ 42,498	$ 41,371	$ 103,045	$ 83,869	$ 155,828	$ 129,875	$ 216,389	$ 181,383
Cost of goods sold		10,394	8,858	8,906		8,491	7,638	6,791	17,764	14,429	28,158	22,920	43,598	32,457
Gross profit	45,121	42,389	42,151	43,130	41,971	37,515	34,860	34,580	85,281	69,440	127,670	106,955	172,791	148,926
Operating expenses:
Research and development costs		7,244	7,683	7,049		6,337	5,990	5,773	14,732	11,763	21,976	18,100	30,078	24,650
Selling, general, and administrative		44,126	43,827	43,820		39,667	37,948	37,242	87,647	75,190	131,773	114,857	180,022	159,323
Total operating expenses		51,370	51,510	50,869		46,004	43,938	43,015	102,379	86,953	153,749	132,957	210,100	210,973
Operating loss	(11,230)	(8,981)	(9,359)	(7,739)	(36,045)	(8,489)	(9,078)	(8,435)	(17,098)	(17,513)	(26,079)	(26,002)	(37,309)	(62,047)
Other income (expense):
Other income (expense), net		1,660	(467)	(179)		59	652	(101)	(646)	551	1,014	610	154	(1,214)
Interest expense, net		(1,119)	(803)	(1,205)		(1,093)	(1,104)	(668)	(2,008)	(1,772)	(3,127)	(2,865)	(5,165)	(4,129)
Total other income (expense)		541	(1,270)	(1,384)		(1,034)	(452)	(769)	(2,654)	(1,221)	(2,113)	(2,255)	(10,319)	(5,343)
Loss before income taxes		(8,440)	(10,629)	(9,123)		(9,523)	(9,530)	(9,204)	(19,752)	(18,734)	(28,192)	(28,257)	(47,628)	(67,390)
Income tax (benefit) expense		(108)	269	(71)		201	73	32	198	105	90	306	213	(64)
Net loss	$ (19,559)	(8,332)	(10,898)	(9,052)	$ (38,763)	(9,724)	(9,603)	(9,236)	(19,950)	(18,839)	(28,282)	(28,563)	(47,841)	(67,326)
Foreign currency translation adjustment		(630)	(283)	(99)		(588)	(593)	(324)	(382)	(917)	(1,012)	(1,505)	165	(41)
Comprehensive loss		$ (8,962)	$ (11,181)	$ (9,151)		$ (10,312)	$ (10,196)	$ (9,560)	$ (20,332)	$ (19,756)	$ (29,294)	$ (30,068)	$ (47,676)	$ (67,367)
Weighted average number of shares of common stock outstanding:
Basic		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100
Diluted		82,548,892	82,373,441	80,681,715		76,850,949	76,481,709	76,447,454	81,536,607	76,465,082	81,878,814	76,595,118	82,087,329	76,766,100
Net loss per share attributable to common stockholders:
Basic	$ (0.24)	$ (0.1)	$ (0.13)	$ (0.11)	$ (0.5)	$ (0.13)	$ (0.13)	$ (0.12)	$ (0.24)	$ (0.25)	$ (0.35)	$ (0.37)	$ (0.58)	$ (0.88)
Diluted	$ (0.24)	$ (0.1)	$ (0.13)	$ (0.11)	$ (0.5)	$ (0.13)	$ (0.13)	$ (0.12)	$ (0.24)	$ (0.25)	$ (0.35)	$ (0.37)	$ (0.58)	$ (0.88)
Adjustments
Cost of goods sold		$ 1,528	$ 2,741	$ 1,323		$ (288)	$ 198		$ 4,064	$ 198	$ 5,592	$ (90)	$ 8,356	$ (340)
Gross profit		(1,528)	(2,741)	(1,323)		288	(198)		(4,064)	(198)	(5,592)	90	(8,356)	340
Operating expenses:
Selling, general, and administrative									0		0		0	0
Total operating expenses									0		0		0	0
Operating loss		(1,528)	(2,741)	(1,323)		288	(198)		(4,064)	(198)	(5,592)	90	(8,356)	340
Other income (expense):
Other income (expense), net		(1,291)	391	(437)		889	1,019	$ (605)	(46)	414	(1,337)	1,303	(1,337)	1,337
Total other income (expense)		(1,291)	391	(437)		889	1,019	(605)	(46)	414	(1,337)	1,303	(1,337)	1,337
Loss before income taxes		(2,819)	(2,350)	(1,760)		1,177	821	(605)	(4,110)	216	(6,929)	1,393	(9,693)	1,677
Net loss		(2,819)	(2,350)	(1,760)		1,177	821	(605)	(4,110)	216	(6,929)	1,393	(9,693)	1,677
Comprehensive loss		$ (2,819)	$ (2,350)	$ (1,760)		$ 1,177	$ 821	$ (605)	$ (4,110)	$ 216	$ (6,929)	$ 1,393	$ (9,693)	$ 1,677
Net loss per share attributable to common stockholders:
Basic		$ (0.04)	$ (0.03)	$ (0.02)		$ 0.02	$ 0.02	$ (0.01)	$ (0.06)	$ 0.01	$ (0.08)	$ 0.02	$ (0.12)	$ 0.02
Diluted		$ (0.04)	$ (0.03)	$ (0.02)		$ 0.02	$ 0.02	$ (0.01)	$ (0.06)	$ 0.01	$ (0.08)	$ 0.02	$ (0.12)	$ 0.02

Quarterly Financial Data - Ef_4

Quarterly Financial Data - Effects of the Restatement on the Condensed Consolidated Statement of Operations And Comprehensive (Loss) (Parenthetical) (Details) - USD ($) $ in Thousands	3 Months Ended						6 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Other income (expense), net	$ 369	$ (76)	$ (616)	$ 948	$ 1,671	$ (706)	$ (692)	$ 965	$ (323)	$ 1,913	$ (1,183)	$ 123	$ (486)
Cost of goods sold	11,922	11,599	10,229	8,203	7,836	6,791	21,828	14,627	33,750	22,830	51,954	32,117	$ 28,024
Adjustments
Other income (expense), net	(1,291)	391	(437)	889	1,019	(605)	(46)	414	(1,337)	1,303	(1,337)	1,337
Cost of goods sold	1,528	2,741	1,323	(288)	198		4,064	198	5,592	(90)	8,356	(340)
Adjustments | Interest Rate Swap
Other income (expense), net	(1,291)	391	(437)	889	1,019	$ (605)	(46)	414	(1,337)	1,303	(1,337)	1,337
Adjustments | Inventory Treatment
Cost of goods sold	$ 1,528	$ 2,741	$ 1,323	$ (288)	$ 198		$ 4,064	$ 198	$ 5,592	$ (90)	$ 8,356	$ (340)

Quarterly Financial Data - Ef_5

Quarterly Financial Data - Effects of the Restatement on the Condensed Consolidated Statement of Cash Flow (Details) - USD ($) $ in Thousands		3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Jan. 30, 2023	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities
Net loss		$ (22,323)	$ (11,151)	$ (13,248)	$ (10,812)	$ (38,479)	$ (8,547)	$ (8,782)	$ (9,841)	$ (24,060)	$ (18,623)	$ (35,211)	$ (27,170)	$ (57,534)	$ (65,649)	$ (13,693)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization					3,117				3,030	6,414	6,566	10,602	9,624	15,542	13,728	8,961
Allowance for doubtful accounts									600	147		147		614	155	1,022
Provision for (reversal of) excess and obsolete inventories					293				(643)	923	(446)	3,204	(91)	4,037	485	2,821
Stock-based compensation					3,182				2,122	6,782	4,465	10,294	7,052	12,364	10,365	4,948
Change in fair value of financial instruments					517				605	366	(414)	(57)	(1,303)	546	(57)	440
Other					100				387	394	(1,514)	(34)	(1,295)	984	704	1,014
Changes in other assets and liabilities, net of acquisitions:
Accounts receivable					(441)				(2,240)	(3,138)	(6,825)	(3,706)	(10,227)	(161)	(12,013)	(6,461)
Inventories					(7,112)				(2,329)	(20,959)	(11,320)	(31,117)	(15,406)	(32,628)	(21,852)	(11,098)
Other current assets									(3)
Accounts payable					5,592				(1,178)	14,745	1,537	12,468	951	6,742	1,895	3,431
Accrued expenses and other current liabilities									(682)
Accrued expenses					(877)					1,845	1,992	3,718	176	6,428	2,317	7,095
Accrued legal settlement					(9,000)					(22,000)		(22,000)		(22,000)	22,000
Income tax receivable/payable					132				669	(359)	454	(533)	297	(50)	391	671
Other assets and liabilities					(367)					(779)	289	(2,704)	1,442	(655)	(1,650)	(2,468)
Net cash used in operating activities					(14,060)				(9,503)	(33,403)	(23,839)	(47,517)	(35,950)	(63,890)	(49,181)	(3,317)
Cash flows from investing activities
Purchase of office building													(18,300)		(18,300)
Purchases of property and equipment					(7,521)				(23,036)	(15,354)	(29,204)	(21,893)	(15,637)	(26,716)	(22,813)	(18,296)
Proceeds from sale of property and equipment					223				305	635	519	795	642	1,043	897	799
Purchases of intangible assets					(254)				(704)	(544)	(783)	(933)	(1,720)	(1,314)	(1,973)	(2,993)
Acquisition, net of cash received									(18,201)		(18,504)		(18,504)		(18,504)	(15,000)
Net cash used in investing activities					(7,552)				(41,636)	(15,263)	(47,972)	(22,031)	(53,519)	(26,987)	(60,693)	(35,490)
Cash flows from financing activities
Proceeds from draw on term loan									20,000		20,000		20,000		20,000
Proceeds from issuance of long-term debt									16,000		16,000		16,000	100,000	16,000	10,000
Payments on long-term debt					(197)				(37)	(396)	(178)	(568)	(367)	(30,727)	(570)	(6,034)
Payments of debt issuance costs					(7)				(405)		(405)		(420)	(4,423)	(732)	(3,139)
Proceeds from issuance of common stock, net of issuance costs	$ 68,453				68,449					68,453		68,453		68,453		1,001
Payments on treasury stock repurchased																(561)
Proceeds from exercise of stock options					1,622				12	2,464	300	2,535	2,224	2,406	5,271	445
Proceeds from employee stock purchase plan										560		560		944	518
Payments on earnout liability					(500)					(4,250)		(5,500)	(500)	(8,000)	(1,000)
Net cash provided by financing activities					69,367				35,570	66,831	35,717	65,480	36,937	128,653	39,487	131,096
Effect of exchange rate changes on cash and cash equivalents					(340)				(136)	114	(256)	549	(495)	(605)	(497)	(438)
Net increase (decrease) in cash and cash equivalents					47,415				(15,705)	18,279	(36,350)	(3,519)	(53,027)	37,171	(70,884)	91,851
Cash and cash equivalents at beginning of period		34,949	56,747	85,883	38,468	56,325	73,002	93,647	109,352	38,468	109,352	38,468	109,352	38,468	109,352	17,501
Cash and cash equivalents at end of period		75,639	34,949	56,747	85,883	38,468	56,325	73,002	93,647	56,747	73,002	34,949	56,325	75,639	38,468	109,352
Supplemental disclosures of cash flow information:
Restricted cash		1,000	1,000	2,250						2,250		1,000		1,000
Cash paid for income taxes										456	386	610	788	908	1,103	678
Cash paid for interest					601				273	2,068	1,520	3,342	2,111	4,271	3,073	1,086
Purchase of property and equipment included in accounts payable					4,026				1,804	5,617	3,088	4,842	2,363	3,402	3,402	881
As Previously Reported
Cash flows from operating activities
Net loss		(19,559)	(8,332)	(10,898)	(9,052)	(38,763)	(9,724)	(9,603)	(9,236)	(19,950)	(18,839)	(28,282)	(28,563)	(47,841)	(67,326)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization					3,117				3,030	6,414	6,566	10,602	9,624	15,542	13,728
Allowance for doubtful accounts									600	147		147		614	155
Provision for (reversal of) excess and obsolete inventories					293				(643)	(205)	(446)	2,053	(91)	(352)	485
Stock-based compensation					3,182				2,122	6,782	4,465	10,294	7,052	12,364	10,365
Change in fair value of financial instruments					80									(791)	1,280
Other					100				387	714	(1,514)	(1,428)	(1,295)	984	704
Changes in other assets and liabilities, net of acquisitions:
Accounts receivable					(441)				(2,240)	(3,138)	(6,825)	(3,706)	(10,227)	(161)	(12,013)
Inventories					(8,435)				(2,329)	(23,895)	(11,518)	(35,558)	(15,316)	(36,595)	(21,512)
Other current assets									(3)
Accounts payable					5,592				(1,178)	14,745	1,537	12,468	951	6,742	1,895
Accrued expenses and other current liabilities									(682)
Accrued expenses					(877)					1,845	1,992	3,718	176	6,428	2,317
Accrued legal settlement					(9,000)					(22,000)		(22,000)		(22,000)	22,000
Income tax receivable/payable					132				669	(359)	454	(533)	297	(50)	391
Other assets and liabilities					(367)					(779)	289	(2,704)	1,442	(655)	(1,650)
Net cash used in operating activities					(14,060)				(9,503)	(33,403)	(23,839)	(47,517)	(35,950)	(63,890)	(49,181)
Cash flows from investing activities
Purchase of office building													(18,300)		(18,300)
Purchases of property and equipment					(7,521)				(23,036)	(15,354)	(29,204)	(21,893)	(15,637)	(26,716)	(22,813)
Proceeds from sale of property and equipment					223				305	635	519	795	642	1,043	897
Purchases of intangible assets					(254)				(704)	(544)	(783)	(933)	(1,720)	(1,314)	(1,973)
Acquisition, net of cash received									(18,201)		(18,504)		(18,504)		(18,504)
Net cash used in investing activities					(7,552)				(41,636)	(15,263)	(47,972)	(22,031)	(53,519)	(26,987)	(60,693)
Cash flows from financing activities
Proceeds from draw on term loan									20,000		20,000		20,000		20,000
Proceeds from issuance of long-term debt									16,000		16,000		16,000	100,000	16,000
Payments on long-term debt					(197)				(37)	(396)	(178)	(568)	(367)	(30,727)	(570)
Payments of debt issuance costs					(7)				(405)		(405)		(420)	(4,423)	(732)
Proceeds from issuance of common stock, net of issuance costs					68,449					68,453		68,453		68,453
Proceeds from exercise of stock options					1,622				12	2,464	300	2,535	2,224	2,406	5,271
Proceeds from employee stock purchase plan										560		560		944	518
Payments on earnout liability					(500)					(4,250)		(5,500)	(500)	(8,000)	(1,000)
Net cash provided by financing activities					69,367				35,570	66,831	35,717	65,480	36,937	128,653	39,487
Effect of exchange rate changes on cash and cash equivalents					(340)				(136)	114	(256)	549	(495)	(605)	(497)
Net increase (decrease) in cash and cash equivalents					47,415				(15,705)	18,279	(36,350)	(3,519)	(53,027)	37,171	(70,884)
Cash and cash equivalents at beginning of period		34,949	56,747	85,883	38,468	56,325	73,002	93,647	109,352	38,468	109,352	38,468	109,352	38,468	109,352
Cash and cash equivalents at end of period		75,639	34,949	56,747	85,883	$ 38,468	56,325	73,002	93,647	56,747	73,002	34,949	56,325	75,639	38,468	$ 109,352
Supplemental disclosures of cash flow information:
Restricted cash		$ 1,000	1,000	2,250						2,250		1,000		1,000
Cash paid for income taxes										456	386	610	788	908	1,103
Cash paid for interest					601				273	2,068	1,520	3,342	2,111	4,271	3,073
Purchase of property and equipment included in accounts payable					4,026				1,804	5,617	3,088	4,842	2,363	3,402	3,402
Adjustments
Cash flows from operating activities
Net loss			$ (2,819)	$ (2,350)	(1,760)		$ 1,177	$ 821	(605)	(4,110)	216	(6,929)	1,393	(9,693)	1,677
Adjustments to reconcile net loss to net cash provided by operating activities:
Provision for (reversal of) excess and obsolete inventories										1,128		1,151		4,389
Change in fair value of financial instruments					437				605	46	(414)	1,337	(1,303)	1,337	(1,337)
Other					0				$ 0	0	0	0	0
Changes in other assets and liabilities, net of acquisitions:
Inventories					$ 1,323					2,936	$ 198	4,441	$ (90)	$ 3,967	$ (340)
Effect of Reclassification
Adjustments to reconcile net loss to net cash provided by operating activities:
Change in fair value of financial instruments										320		(1,394)
Other										$ (320)		$ 1,394

Quarterly Financial Data - Ef_6

Quarterly Financial Data - Effect of the Restatement on the Condensed Consolidated Statement of Stockholders' Equity (Details) - USD ($) $ in Thousands		3 Months Ended								6 Months Ended		9 Months Ended		12 Months Ended
	Jan. 30, 2023	Dec. 31, 2023	Sep. 30, 2023	Jun. 30, 2023	Mar. 31, 2023	Dec. 31, 2022	Sep. 30, 2022	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2023	Jun. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Beginning balance		$ 188,492	$ 196,605	$ 205,069	$ 142,605	$ 172,766	$ 177,154	$ 183,897	$ 192,194	$ 142,605	$ 192,194	$ 142,605	$ 192,194	$ 142,605	$ 192,194	$ 30,393
Net loss		(22,323)	(11,151)	(13,248)	(10,812)	(38,479)	(8,547)	(8,782)	(9,841)	(24,060)	(18,623)	(35,211)	(27,170)	(57,534)	(65,649)	(13,693)
Issuance of common stock					68,449									68,453		1,001
Offering costs associated with initial public offering				4					(266)
Options exercised			70	843	1,622		2,060	289	12					2,406	5,271	445
Foreign currency translation			(630)	(283)	(99)		(588)	(593)	(324)					165	(41)	(815)
Employee stock purchase plan			86	620	122		100							1,266	731
Stock-based compensation			3,512	3,600	3,182		2,587	2,343	2,122					12,364	10,365	4,948
Ending balance		169,725	188,492	196,605	205,069	142,605	172,766	177,154	183,897	196,605	177,154	188,492	172,766	169,725	142,605	192,194
As Previously Reported
Beginning balance		193,744	199,038	205,152	140,928	171,373	176,938	184,502	192,194	140,928	192,194	140,928	192,194	140,928	192,194
Net loss		(19,559)	(8,332)	(10,898)	(9,052)	(38,763)	(9,724)	(9,603)	(9,236)	(19,950)	(18,839)	(28,282)	(28,563)	(47,841)	(67,326)
Issuance of common stock					68,449									68,453
Offering costs associated with initial public offering				4					(266)
Options exercised			70	843	1,622		2,060	289	12					2,406	5,271
Foreign currency translation			(630)	(283)	(99)		(588)	(593)	(324)					165	(41)
Employee stock purchase plan			86	620	122		100							1,266	731
Stock-based compensation			3,512	3,600	3,182		2,587	2,343	2,122					12,364	10,365
Ending balance		177,741	193,744	199,038	205,152	140,928	171,373	176,938	184,502	199,038	176,938	193,744	171,373	177,741	140,928	$ 192,194
Adjustments
Beginning balance		(5,252)	(2,433)	(83)	1,677	1,393	216	(605)		1,677		1,677		1,677
Net loss			(2,819)	(2,350)	(1,760)		1,177	821	(605)	(4,110)	216	(6,929)	1,393	(9,693)	1,677
Ending balance		$ (8,016)	$ (5,252)	$ (2,433)	$ (83)	$ 1,677	$ 1,393	$ 216	$ (605)	$ (2,433)	$ 216	$ (5,252)	$ 1,393	$ (8,016)	$ 1,677
Common Stock
Beginning balance, shares		82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162	76,447,287	77,770,588	76,447,287	77,770,588	76,447,287	77,770,588	76,447,287	46,738,540
Beginning balance		$ 824	$ 824	$ 821	$ 776	$ 769	$ 764	$ 763	$ 763	$ 776	$ 763	$ 776	$ 763	$ 776	$ 763	$ 467
Issuance of common stock, shares	6,500,000				4,312,500									4,312,500	0	151,515
Issuance of common stock					$ 43									$ 43		$ 1
Options exercised, shares			19,861	192,027	223,785		539,203	88,406	1,875					668,925	1,284,333	236,706
Options exercised				$ 3	$ 2		$ 5	$ 1						$ 7	$ 13	$ 2
Employee stock purchase plan,Shares				37,146										73,442	38,968
Employee stock purchase plan														$ 1
Ending balance, shares		82,825,455	82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162	82,536,046	76,537,568	82,555,907	77,076,771	82,825,455	77,770,588	76,447,287
Ending balance		$ 827	$ 824	$ 824	$ 821	$ 776	$ 769	$ 764	$ 763	$ 824	$ 764	$ 824	$ 769	$ 827	$ 776	$ 763
Common Stock | As Previously Reported
Beginning balance, shares		82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162	76,447,287	77,770,588	76,447,287	77,770,588	76,447,287	77,770,588	76,447,287
Beginning balance		$ 824	$ 824	$ 821	$ 776	$ 769	$ 764	$ 763	$ 763	$ 776	$ 763	$ 776	$ 763	$ 776	$ 763
Issuance of common stock, shares					4,312,500									4,312,500
Issuance of common stock					$ 43									$ 43
Options exercised, shares			19,861	192,027	223,785		539,203	88,406	1,875					668,925	1,284,333
Options exercised				$ 3	$ 2		$ 5	$ 1						$ 7	$ 13
Employee stock purchase plan,Shares				37,146										73,442	38,968
Employee stock purchase plan														$ 1
Ending balance, shares		82,825,455	82,555,907	82,536,046	82,306,873	77,770,588	77,076,771	76,537,568	76,449,162	82,536,046	76,537,568	82,555,907	77,076,771	82,825,455	77,770,588	76,447,287
Ending balance		$ 827	$ 824	$ 824	$ 821	$ 776	$ 769	$ 764	$ 763	$ 824	$ 764	$ 824	$ 769	$ 827	$ 776	$ 763
Additional Paid-in-Capital
Beginning balance		296,018	292,350	287,286	213,956	207,109	202,367	199,736	197,868	213,956	197,868	213,956	197,868	213,956	197,868	22,107
Issuance of common stock					68,406									68,410		1,000
Offering costs associated with initial public offering				4					(266)
Options exercised			70	840	1,620		2,055	288	12					2,399	5,258	443
Employee stock purchase plan			86	620	122		100							1,265	731
Stock-based compensation			3,512	3,600	3,182		2,587	2,343	2,122					12,364	10,365	4,948
Ending balance		298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736	292,350	202,367	296,018	207,109	298,394	213,956	197,868
Additional Paid-in-Capital | As Previously Reported
Beginning balance		296,018	292,350	287,286	213,956	207,109	202,367	199,736	197,868	213,956	197,868	213,956	197,868	213,956	197,868
Issuance of common stock					68,406									68,410
Offering costs associated with initial public offering				4					(266)
Options exercised			70	840	1,620		2,055	288	12					2,399	5,258
Employee stock purchase plan			86	620	122		100							1,265	731
Stock-based compensation			3,512	3,600	3,182		2,587	2,343	2,122					12,364	10,365
Ending balance		298,394	296,018	292,350	287,286	213,956	207,109	202,367	199,736	292,350	202,367	296,018	207,109	298,394	213,956	197,868
Accumulated Deficit
Beginning balance		(101,323)	(90,172)	(76,924)	(66,112)	(27,633)	(19,086)	(10,304)	(463)	(66,112)	(463)	(66,112)	(463)	(66,112)	(463)	12,418
Net loss			(11,151)	(13,248)	(10,812)		(8,547)	(8,782)	(9,841)					(57,534)	(65,649)	(13,693)
Ending balance		(123,646)	(101,323)	(90,172)	(76,924)	(66,112)	(27,633)	(19,086)	(10,304)	(90,172)	(19,086)	(101,323)	(27,633)	(123,646)	(66,112)	(463)
Accumulated Deficit | As Previously Reported
Beginning balance		(96,071)	(87,739)	(76,841)	(67,789)	(29,026)	(19,302)	(9,699)	(463)	(67,789)	(463)	(67,789)	(463)	(67,789)	(463)
Net loss			(8,332)	(10,898)	(9,052)		(9,724)	(9,603)	(9,236)					(47,841)	(67,326)
Ending balance		(115,630)	(96,071)	(87,739)	(76,841)	(67,789)	(29,026)	(19,302)	(9,699)	(87,739)	(19,302)	(96,071)	(29,026)	(115,630)	(67,789)	(463)
Accumulated Deficit | Adjustments
Beginning balance		(5,252)	(2,433)	(83)	1,677	1,393	216	(605)		1,677		1,677		1,677
Net loss			(2,819)	(2,350)	(1,760)		1,177	821	(605)					(9,693)	1,677
Ending balance		(8,016)	(5,252)	(2,433)	(83)	1,677	1,393	216	(605)	(2,433)	216	(5,252)	1,393	(8,016)	1,677
Accumulated Other Comprehensive Loss
Beginning balance		(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)	8	(33)	8	(33)	8	(33)	8	823
Foreign currency translation			(630)	(283)	(99)		(588)	(593)	(324)					165	(41)	(815)
Ending balance		132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)	(415)	(909)	(1,045)	(1,497)	132	(33)	8
Accumulated Other Comprehensive Loss | As Previously Reported
Beginning balance		(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)	8	(33)	8	(33)	8	(33)	8
Foreign currency translation			(630)	(283)	(99)		(588)	(593)	(324)					165	(41)
Ending balance		132	(1,045)	(415)	(132)	(33)	(1,497)	(909)	(316)	(415)	(909)	(1,045)	(1,497)	132	(33)	8
Treasury stock
Beginning balance		(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,422)
Ending balance		(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
Treasury stock | As Previously Reported
Beginning balance		(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)	(5,982)
Ending balance		$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)	$ (5,982)

Subsequent Events - Additional

Subsequent Events - Additional Information - (Details) - USD ($) $ / shares in Units, $ in Thousands			3 Months Ended	6 Months Ended	9 Months Ended	12 Months Ended
	Jan. 30, 2023	Oct. 19, 2021	Mar. 31, 2023	Jun. 30, 2023	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Subsequent Event [Line Items]
Net proceeds after deducting underwriting discounts and commissions	$ 68,453		$ 68,449	$ 68,453	$ 68,453	$ 68,453		$ 1,001
Common Stock
Subsequent Event [Line Items]
Number of aggregate issued	6,500,000		4,312,500			4,312,500	0	151,515
Price per share	$ 17
Underwriters Option to Purchase Additional Shares | Maximum
Subsequent Event [Line Items]
Number of shares issued and sold	562,500
Underwriters Option to Purchase Additional Shares | Common Stock
Subsequent Event [Line Items]
Number of shares issued and sold	412,500	1,171,875